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des-Formylflustrabromine (dFBr), isolated from the marine organism Flustra foliacea, is the first 
selective, positive allosteric modulator (PAM) of α4β2 nicotinic acetylcholine receptors that 
potentiates the action of the neurotransmitter acetylcholine (ACh). Most agonists for this 
receptor population are not selective and can activate other nACh receptors. A selective PAM, 
which activates α4β2 nACh receptors only in the presence of ACh, might find application in the 
xxii 
 
treatment of of various neurological diseases such as Alzheimer’s disease or autism.  dFBr was 
examined and found to produce a biphasic dose-response curve over a wide concentration range 
(i.e., potentiation at low concentration, but inhibition of the ACh-induced response at high 
concentrations). Our goal was to examine various structural features of dFBr required for 
potentiation; a secondary goal was to examine the same for inhibition. To understand the 
structural requirements of dFBr, a systematic ‘deconstruction-reconstruction-elaboration’ 
approach was employed to determine the contribution of various structrual components of dFBr 
to its activity at α4β2 nACh receptors. Novel compounds were synthesized and characterized. 
Human α4β2 nACh  receptors were expressed in Xenopus oocytes and the actions of dFBr and its 
analogs were measured using a two-electrode voltage clamp technique. Dose-response curves 
were obtained for the compounds in the absence and presence of 100 μM ACh. Structural 
features of dFBr optimal and/or required for PAM action at 42 nACh receptors were 
identified. A novel reconstructed analog with all the essential features for PAM action was 
synthesized and submitted for biological testing. Elaborated analogs of dFBr further helped in 
identification of various structural features important for PAM action and the  inhibition of 
action of ACh. The ‘deconstruction-reconstructio-elaboration’ approach identified important 
structural features of dFBr that modify its actions as a PAM or an antagonist (NAM? or channel 
blocker?) at α4β2 nACh receptors. This information should be useful for the subsequent design 
of novel analogs to evaluate their potential for the treatment of neurological disorders associated 
with ACh. 
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1. Introduction 
 
Homeostasis is essential to the day-to-day biological functions of all living organisms. For 
example simple ions (e.g., Na
+
, K
+
, Ca
2+
, Cl

) play a vital role in the regulation of water inside 
and outside a cell. The phenomenon of transfer of ions across the cell membrane occurs through 
ion channels. The concept of ion channels evolved because of the discovery of two natural 
phenomena: the discovery of the Torpedo fish and its electrofiring capabilities, and the discovery 
of -bungarotoxin, a venom (found in the Taiwanese krait snake).1 These two spectacular 
discoveries were the events that attracted the attention of the scientific community to ion channel 
research. Ion channels are essential for the survival of all organisms including mammals. 
Malfunction occurs when the normal flow of ions is disrupted which can directly affect the 
reaction time of the organism to its environment. 
Nicotinic acetylcholine receptors are the oldest known ion channels and have been a model for 
the study of other ligand-gated ion channels.
2
 The nicotinic acetylcholine receptors are 
pentameric in nature with varying subunits (1-10, 1-4, ,  and ) located both in the central 
nervous system and the peripheral nervous system.
3
 The neuronal acetylcholine (nACh) 
receptors are found to play a modulatory role in the brain where 42 and 7 nACh receptors 
predominate, and have been implicated in various neurological disorders.
4
 On binding of the 
neurotransmitter acetylcholine to the extracellular surface of the ion channel a conformational 
change in the receptor protein occurs and enables the opening of the channel pore through which 
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ions pass.
2
 The long exposure of the neurotransmitter or agonist causes desensitization of the  
nACh receptor.
5
 The desensitized receptor is the state where the affinity of the neurotransmitter 
is high but the channels are closed. Problems of desensitization of the receptors and the non-
selectivity of various agents across various subtypes of the nACh receptors still pose a 
considerable challenge to develop agents that can modulate ACh action.
6
 
Allosteric agents are compounds that bind to the protein/receptor and stabilize the protein in a 
given conformation. Monod, Wyman and Changeux proposed the allosteric model in 1965 and 
the concept has been widely investigated since then.
7
 Allosteric molecules can be positive 
allosteric modulators (PAMs) or negative allosteric modulators (NAMs) depending on whether 
they activate or inhibit neurotransmitter action.
8
  
desFormlyflustrabromine (dFBr) was one of 22 alkaloids isolated from the marine bryozoan 
Flustra foliacea and was found to be a selective PAM at the 42 nACh receptors; that is, it was 
inactive alone, but potentiated the effect of ACh.
9
 Thus, dFBr serves as a unique lead for 
structure-activity relationship studies to understand what structural features are important for its 
potentiation and/or inhibition of ACh action.  
The present investigation is aimed at understanding why dFBr is a PAM of ACh action at 42 
nACh receptors. 
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II. Background 
 
 
A. RECEPTORS 
 
1. Definition 
John Newport Langley, a Cambridge physiologist, was a pioneer in the field of ‘receptor 
research’ and was the first to conceptualize the idea of receptors in 1905.10 He defined the 
‘receptor’ (a receptive substance) as a site where an agonist or antagonist competes with the 
vehicle for the transmission of a stimulus (transduction) which brings about a physiologic 
response.
10
 Until the 1960s the concept of drug-receptor interactions was a hypothetical scenario. 
The 1965 development of the receptor-subtype specific -adrenergic receptor antagonist 
propranolol established the acceptance of receptors in the pharmacological community.
11
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2. General classification 
Now, according to the International Union of Pharmacology (IUPHAR) Committee on Receptor 
Nomenclature and Drug Classification, a receptor is defined as “a cellular macromolecule, or an 
assembly of macromolecules, that is concerned directly and specifically in chemical signaling 
between and within cells”.12 A change in cell function is initiated upon interaction of a hormone, 
neurotransmitter, drug, or intracellular messenger, with its receptor(s).
12
  
The IUPHAR database classifies receptors as: 
1. G protein-coupled receptors (GPCRs) 
2. Ligand-gated ion channels (LGICs) 
3. Voltage-gated ion channels (VGICs) 
4. Nuclear hormone receptors (NHRs) 
5. Enzymes 
 
3. Classification of ligand-gated ion channels 
The concept of ion channels can be dated back to the late 1800s and the early 1900s. Prof. 
Langley first observed a twitch in the muscle of a dead frog on the application of nicotine and 
referred to this as fibrillar twitching.
13
 Hodgkin and Huxley,
14,15
 independently, were the first to 
study nerve impulses on the neuron of the giant squid (Loligo) which is approximately 100 to 
1000 times larger than the human neuron in diameter. Later, they also showed that nerve 
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conductance depends on specific ions outside and inside the nerve cell. They showed that during 
nerve impulse, or the spike phase, Na
+
 ion inflow increases the positive potential in the cell and 
causes a response while the falling phase involves K
+
 ions outflow.
15
 LGICs are transmembrane 
proteins that carry out a physiological response by an ion channel which opens on binding of a 
ligand.
16
 These are termed ‘ionotropic’ which refers to the ion-channel nature of the receptors. 
The whole process of channel opening and ion-flow is a display of speed and size. The channel is 
open for a few milliseconds in which thousands of ions flow through. The channel is a dynamic 
pore that allows passage of ions. The pore can be a few atoms thick at its narrowest point but still 
functions as a speedway for ions to go through.
17
 LGICs mediate action at the synapse and in a 
matter of microseconds the neurotransmitter released from the nerve terminal interacts with the 
target protein, and binds and triggers a physiologic response. LGIC receptors are comprised of 
the following superfamilies:
17,18
 
1. The superfamily that resembles the nicotinic receptors. 
2. The ionotropic glutamate receptor superfamily (GluR). 
3. Adenosine triphosphate (ATP)-gated purine receptors (P2X). 
The classification of LGIC receptor superfamilies is based on molecular architecture, functional 
behavior, and sequence homology.
19
 All of the LGIC receptors share common features, such as 
their location in the cell membrane, and the three key structural domains that each of them 
possesses.
19
 The superfamily that resembles the nicotinic receptor is distinct because of the 
presence of a cysteine-loop (Cys-loop) in the extracellular domain of the receptor conserved 
across all the receptor populations and includes the: 
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1. Glycine receptors (GlyRs) 
2. -Amino butyric acid receptors (GABAA and GABAC) 
3. Serotonin type 3 receptors (5-HT3 Rs) 
4. Nicotinic acetylcholine receptors (AChRs) 
 
B. ACETYLCHOLINE AND ITS RECEPTORS 
 
1. Acetylcholine 
In 1865 Oscar Liebreich (according to Gamgee) isolated and identified a mixture of chemicals 
from animal brain that was characterized for its elemental content and referred to it as 
‘protagon’.20 This finding had a major impact for the next couple of decades and researchers 
around the world were intrigued and started to study it more closely so as to figure out more 
about this mystery chemical composite.
20
 Later Liebreich
21,22
 was able to identify neurin/choline 
by treating the protagon with a barium hydroxide solution. The finding of Liebreich was 
consistent with those of Baeyer who had independently synthesized choline.
22
 In 1914, Ewins
23,24
 
synthesized acetylcholine which was also isolated and found to be the major component in the 
extract of ergot fungus which produced an inhibitory effect on heart muscle and a stimulating 
effect on intestinal muscle; both responses were abolished by atropine.
24
 Henry Dale
25
 was 
responsible for identifying acetylcholine (ACh) in ergot fungus extract. Later, an extensive study 
was carried out with various ethers and ester of choline and it was found that ACh was the most 
  
7 
 
active chemical entity that produced the effect.
26
 Thus, from this initial literature, it can be seen 
that ACh was studied and investigated long before it was known to be a neurotransmitter. It was 
only in the early 1900s that Otto Loewi identified ACh as the first neurotransmitter.
26
 Both 
Henry Dale and Otto Loewi received the Nobel Prize in the field of Physiology or Medicine in 
1936.
23,25-27
 Acetylcholine is, chemically, 2-acetoxy-N,N,N-trimethylethanamanium (1), which is 
an acetyl derivative of choline. 
 
 
 Acetylcholine (1) 
The cholinergic system is, phylogenetically, one of the oldest nervous pathways. The neurons 
that synthesize, store, and release ACh as a neurotransmitter are called cholinergic neurons.
28
 
 
2. Biosynthesis and Metabolism of ACh 
In the peripheral nervous system, ACh is involved in smooth and cardiac muscle regulation as 
well as skeletal muscle movement. In the central nervous system ACh is involved in chemo-
electrical transduction in cholinergic synapses. ACh is synthesized (Figure 1) in the cytosol of 
nerve terminals and stored in synaptic vesicles prior to exocytotic release.
28
 Choline 
acetyltransferase is an enzyme involved in the synthesis of ACh. Choline is taken up from the 
synapse by the Na
+
-dependent choline transporter.
28
 Acetyl-CoA, which is present in the nerve 
terminal, along with choline, forms ACh in the presence of choline acetyltransferase. CoA is 
taken up in the mitochondria and is acetylated to acetyl-CoA which is available for ACh 
synthesis and the cycle continues.
29
 The ACh is taken up to the synaptic vesicles by the vesicular 
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ACh transporter, where it is stored.
29
 Upon excitation of the neuron, vesicular fusion occurs and 
ACh is released into the synapse.
29
 The concentration of ACh in the synaptic cleft rises to around 
0.1 to 1 mM for less than 1 msec.
28
 The released ACh interacts with postsynaptic cholinergic 
receptors and triggers the relevant physiological response. ACh is metabolized in the synaptic 
cleft.
29
 Acetylcholine esterase (AChE) is the enzyme present in the synapse that metabolizes 
ACh to choline and acetate.
29
 Choline is taken up by the choline transporter present at the 
presynaptic nerve terminal which is utilized to synthesize ACh.
28
 Metabolism, along with 
reuptake of ACh by diffusion, rapidly allows normal physiological levels of around 10
-9
 M to be 
attained.
28,29
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Figure 1. Synthesis and metabolism of ACh adapted from a review by Niewiadomska et al.
30
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3. Classification of ACh receptors 
It was in the early 1900s that physiologists were able to identify that not all responses to the ACh 
stimulus were identical. They then hypothesized that ACh interacts differently with the so-called 
muscarinic receptors on some receptors and nicotinic receptors on others.
31
 These two receptor 
classes were perceived to have different pharmacological properties along with different 
interactions with ACh and associated postsynaptic properties.
31
 The early classification of ACh 
receptors involved what ACh imitated, namely, the actions of muscarine and nicotine. This 
finding was further confirmed with the discovery of selective agents for the two subtypes of ACh 
receptors. These included nicotinic receptor-selective agents (e.g. tetramethylammonium (TMA), 
dimethyl-4-phenylpiperazinium (DMPP), phenyltrimethylammonium (PTMA), suxamethonium, 
and decamethonium) and muscarinic receptor-selective agents (e.g. acetyl-β-methylcholine, 
oxotremorine, pilocarpine and arecoline).
32
 Later, it was found that nicotinic receptors could be 
classified further as autonomic, which show a preferential affinity towards DMPP, and skeletal 
muscle, which are more responsive to PTMA. Antagonists for ACh receptors were also 
investigated to confirm the presence of three different receptor populations.
32 
Atropine 
selectively blocked the effect of muscarinic receptors, whereas hexamethonium and 
decamethonium differentiated between the autonomic and the skeletal nicotinic receptors.
32
 
Currently, several receptor subtypes of classical ACh receptor populations have been identified. 
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The ACh receptors now are classified as shown in Figure 2. 
 
Figure 2. Classification of the ACh receptors.
33,34
 
 
Muscarinic receptors are present in the central nervous system (CNS) and the peripheral nervous 
system (PNS).
33
 The natural ligand that activates these receptor subtypes is muscarine (2) which 
is a plant alkaloid found in various species of mushrooms.
33
 The classification of the muscarinic 
receptors is based on their location and their pharmacological effect.
33
 All the subtypes consist of 
7 transmembrane-spanning -helices and are G-protein coupled.33 The CNS effects associated 
with muscarinic receptors include motor control, temperature regulation, cardiovascular 
regulation, and memory.
33
 Peripheral effects include smooth muscle contraction, glandular 
secretion, and modulation of cardiac rate and force.
33
 Nicotinic receptors belong to the LGIC 
receptor superfamily and are ionotropic in nature.
34
 The natural ligand that mimics ACh is 
nicotine (3) which is a plant alkaloid found in the tobacco plant,
34
 Nicotiana tabacum. Nicotinic 
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receptors are broadly classified on the basis of their location.
34
 Nicotinic receptors are present 
throughout the body and are found, for example, in the PNS, CNS, skeletal muscle, lymphocytes, 
and fibroblasts.
34
 Based on their location, they are broadly classified into neuronal and skeletal 
subtypes.
34
 Nicotinic receptors play a vital role in mediating excitatory neurotransmission at the 
neuromuscular junction, and modulation of neurotransmitter release.
34
 
      
Muscarine (2)      (-)Nicotine (3) 
 
In general, nicotinic receptors (Figure 3) are pentameric in nature consisting of 5 subunits 
arranged in a bundle that forms a channel in the center.
34
 Upon activation by the neurotransmitter 
ACh, the channel opens to allow ions to flow through. The common feature across all nicotinic 
receptor subtypes is the extensive N-terminal region of around 200 amino acid residues in the 
extracellular region.
34
 They are all comprised of four transmembrane domains (M1–M4), with 
the M2 domain lining the ion pore.
34
 The M2 domain consists of amino acids lining the pore 
which is essential for ion transport.
34
 A unique intracellular loop between the M3 and M4 
subunits consists of 100-200 amino acids, and an extracellular C-terminus.
34
 The most prominent 
feature of all the nicotinic receptors is a loop of 13 amino acids between two cysteine residues 
forming a disulfide bridge in the N-terminal domain; thus, the name cys-loop LGIC receptors.
34
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Figure 3. Schematic representation of a subunit of the nicotinic receptor adapted from Lukas et 
al.
34
 
 
4. Nicotinic ACh receptors 
Nicotinic ACh receptors were the first neurotransmitter receptors to be characterized, purified, 
and cloned.
35
 Elliott
36
 observed that a hormone present in the motor nerve ending in cross-
striated muscle can activate nerve impulses in a manner comparable to adrenaline’s action on 
non-striated muscle. Herring
37
 was able to support Elliott’s findings in the electric fish, Torpedo 
mormorata, that had a high concentrations of motor nerve endings in their electrical organs that 
caused an electrical firing caused by ACh due to its depolarizing action at the motor end plates.
38
 
Also, a very high concentration of AChE was observed at the site of the electrical organ 
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implicating the presence of ACh.
38
 It was found that the fish contain a very high concentration of 
ACh, around 40-100 g/g of fresh tissue.38 
     
a. Types and sub-types 
Unwin reported the first-ever crystal structure of a nicotinic receptor in a closed conformation at 
9 Å-resolution using electron microscopy of a tubular crystal from the postsynaptic membrane of 
Torpedo mormorata.
39
 Initially, four different skeletal muscle type subunits of nicotinic 
receptors were identified, namely: 1, 1,  and  based on increasing molecular weights of the 
various subunits.
40
 The  subunit is converted to the  subunit from the fetal to the adult 
subtype.
40
 Cloning and purification of various nicotinic receptors have revealed many additional 
subtypes.
40
 Neuronal ACh receptors can consist of 2-10 and 2-4 subtypes with varying 
combinations possible between  and  subunits.40 The  subunit consists of Cys 192 and 193, 
which is a characteristic and has been shown to be important for ACh binding in all  subunits, a 
feature not observed in the  subunit.41 Thus, the  subunit was not able to bind ACh or various 
agents. To date nine other  subunits have been identified; 2-10 along with four other  
subunits; 2-4.41 
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C. Neuronal ACh (nACh) receptors 
nACh receptors consist of various combinations of 1-10 and 2-4 subunits arranged in a 
pentameric structure (Figure 2).
42
 Functional receptors are a result of the assembly of 5-subunits 
around a pseudosymmetric axis.
42
 Various combinatorial associations of different  and  
subunits are possible, and these form functional nACh receptor subtypes of a large variety.
43
 It is 
known that the principal component of the nACh receptor is associated with the 2, 3, 4, 6, 
7, 8 or 9 subunits.42 The principal component consists of two adjacent Cys residues, and 
contributes towards the binding of ligands with three loops from discontinuous sections.
41,44
 The 
complementary component of the nACh receptor consists of 2, 4, 7, 8, or 9 subunits. 
The complementary component provides an additional three discontinuous loops for binding of 
the ligands.
44
 The 10 subunit, although classified as an -type subunit, can only function as a 
principal component at the binding site in nACh receptors in conjunction with the 9 subunit.45 
The stoichiometry of (x)2(y)3 is, in general, seen with most of the subunits except the 7, 8, 
10 subunits that form homopentameric functional receptors when studied by expressing the 
subunits in Xenopus laevis oocytes.
46
 The ACh binding site, and the transmembrane (TM) 
spanning regions, are highly conserved across the various subtypes of nACh receptors, whereas 
the intra-cellular loop between M3 and M4 (Figure 3) is conserved across various species.
46
 The 
various subunits of the nACh receptors share a very high homology (91-99%) amongst 
themselves.
46
 Thus, a single amino acid change in the extra-cellular amino terminal (Figure 3) 
may affect the property of the nACh receptors.   
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1. Distribution of nACh receptors 
Various techniques, such as in situ hybridization using a subunit mRNA probe, ligand binding 
studies by means of autoradiography, immunohistochemistry, immunoprecipitation, radioligand 
binding assays using various ligands such as nicotine, -bungarotoxin to name a few, and nACh 
receptor gene knock-out studies, have been performed to map the tissue distribution of nACh 
receptors.
47
  
 
a. Peripheral Tissues 
It is accepted that nACh receptors are located in the ganglionic synapse of the PNS along with 
broader locations in peripheral tissues.
42
 The 3, 5, 7, 2 and 4 subunits are the major 
subunits identified in peripheral tissue.
48
 Chick ganglia and cromaffin cells have 3-, 7-, and 
4-containing subtypes of nACh receptors.48,49 Developing muscles show the presence of the 7-
containing subtype.
50
 Various subunits, such as 3, 5, 7, 2 and 4, are expressed in 
keratinocytes,
51
 bronchial epithelial cells,
52
 and arterial endothelium.
43
 Nicotinic receptors have 
also been found on lymphocytes and polymorphonuclear cells of human blood, and very little is 
known about their function.
53
 Functional nACh receptors containing 3, 5, 2 and 4 subunits 
are found in endothelial cells lining blood vessels and are quite similar in their channel-open 
time and, in general, functioning, found in the CNS.
43
 6-Containing nACh receptors are present 
in the optic pathway which oligomerizes with 4, 2, 3, and 3 subunits to form functional 
nACh receptors.
54
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b. Central nervous system 
The distribution of nACh receptors in primates is less well known when compared to rodents, 
which have been far more extensively studied to map the distribution of the nACh receptors and 
the subunits involved.
47
 In rodents the most abundant subunits expressed in whole brain are the 
4, 7, and 2 subunits (Figure 4). 2-Containing nACh receptors are highly expressed in the 
caudate, putamen, and the hippocampal regions of the CNS.
55
 The 4 subunit is highly expressed 
in the cortex, whereas the 7 is expressed in the lateral and medial geniculate nucleus along with 
the reticular thalamic nucleus.
56
 In rodents, as well in humans, 42 nACh receptors are the 
most abundant and widespread in the human brain all along the hippocampus, basal ganglia, and 
cerebellum.
47
 Recent studies have suggested that there is an incorporation of the 5 or 6 
subunit in some 42 nACh receptors.47 In rodents, 34 nACh receptors are present in the 
autonomic ganglia, pineal gland, medial habenula, and interpeduncular nucleus,
57
 to name a few. 
6-Containing nACh receptors are present in the locus coereuleus along with the dopaminergic 
neurons of the mesolimbic system which control dopamine release.
57
 The homopentameric 7 
nACh receptors are particularly found in the hippocampus, hypothalamus, cortex, and motor 
nucleus of the vagus.
47
 nACh receptors are anatomically and functionally located in pre- and 
post-synaptic sites in the CNS where they perform various functions such as, pre-synaptically, 
regulating the release of various neurotransmitters such as norepinephrine, glutamate and 
GABA, while post-synaptically, bringing about various voltage-dependent downstream 
responses.
47,57
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Figure 4. Regional distribution of various receptor subtypes in a rodent CNS adapted from Gotti 
et al.
57
 
  
2. Importance of 7 and 42 nACh receptors in the brain 
The two main classes of nACh receptors widely distributed in the brain are the 7 and the 42 
subtypes.
4
 They are thought to be involved in various pathophysiological states such as 
schizophrenia, Alzheimer’s disease (AD), autism, nicotine addiction, attention deficit 
hyperactivity disorder (ADHD), depression, Parkinson’s disease (PD), and pain. Also, non-
neuronal nACh receptors present in certain tissues and cells are implicated in various disease 
states such as lung cell carcinoma, blood pressure, and, inflammatory bowel disease. Due to the 
vastness of the various disease states, only neuronal disorders are considered here. 
 
  
19 
 
a. Schizophrenia 
Schizophrenia is a neuropsychiatric disorder associated or characterized by delusions, 
hallucinations, disorganized speech, and catatonic behavior.
58
 A high prevalence of an almost 3-
fold increase of smoking in schizophrenic patients led to investigations of the possible 
involvement of nACh receptors in schizophrenia.
59
 Also, the fact that neuroleptic neuronal side 
effects were fewer among smokers, and a negative correlation between smoking and the 
symptoms of schizophrenia, established definite involvement of nACh receptors in the 
pathophysiology of schizophrenia.
60,61
 Sensory gating, which is an involuntary process to 
selectively sense a stimulus, is impaired in schizophrenic patients, was restored to some extent in 
heavy smokers.
62
 It was found that heteromeric nACh receptors are not involved in the 
pathophysiology of schizophrenia.
63
 Experimental studies were unable to show a difference 
between controls and schizophrenic patients in terms of [
3
H]-nicotine binding and the levels of 
4, 3, and 2 subunits in the hippocampus, thalamus, cortex and caudate putamen where most 
heteromeric nACh receptors are located.
63,64
 The homomeric 7 nACh receptors, on the other 
hand, were significantly involved in the pathophysiology of schizophrenia, which was shown by 
-bungarotoxin administration to induce sensory gating defects in mice.65 -Bungarotoxin was 
also seen to have reduced binding in temporal lobes along with 7 nACh receptor 
immunoreactivity in the hippocampus,
66,67
 reticular nucleus of the thalamus and cingulated 
frontal cortex of the schizophrenic patients, where 7 nACh receptors predominate.63 Agents 
approved by the FDA for the treatment of schizophrenia include various atypical antipsychotics 
such as clozapine, olanzapine and others. Clozapine has been shown to improve gating deficits, 
and, thus, improve sensory stimulus.
68
 The improvement can also be attributed to clozapine-
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induced increased levels of ACh in the hippocampus.
68
 This observation was experimentally 
demonstrated when -bungarotoxin was shown to block clozapine’s effects.69 Clozapine is not a 
preferred choice for the treatment of schizophrenia due to its severe toxicity profile.
68
 Thus, 
various 7 nACh receptor agonists have been examined as potential therapeutic candidates for 
the treatment of schizophrenia.
68
  
 
b. Alzheimer’s disease (AD) 
AD is the most common form of dementia in the elderly population.
70
 It is characterized by 
neuronal cell loss due to the presence of β amyloid (Aβ1-42) and progressive accumulation of 
neurofibrillary tangles caused by aggregates of hyperphosphorylated tau proteins in the neurons 
and amyloid fibers in senile plaques and in the walls of the blood vessels.
70
 To test the 
neurotoxicity of Aβ, Jay et al.71 were able to demonstrate that the mortality rates of transgenic 
animals that overexpressed Aβ were doubled compared to control so as to determine that 
overexpression of Aβ is sufficient to induce neurotoxicity. This degeneration affects many types 
of neurons and may account for the numerous neurobiological deficiencies that patients 
experience with the disease onset. The most notable degeneration occurs in the hippocampus, 
cerebral cortex, and amygdala.
71
 These are the regions that play a major role in memory, 
cognition and behavior.
71
 The vast majority of the people with AD have a late-onset form of the 
disease in which memory loss occurs at the age of 60 years or more.
70
 There are few cases where 
people are diagnosed with an inherited form of AD at an age as early as 30 or 40 years.
70
 In AD 
patients it has been found that 4 nACh subunits are decreased in the hippocampus and the 
cortical areas of the brain.
72
 Also since the 2 nACh subunit, together with 4, forms the most 
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abundant heteromeric nACh receptors, a relationship was established between nACh receptors 
and AD.
73
 This relationship was further supported by genetic polymorphism studies of the 4 
and 2 subunits in AD patients.73 The Aβ1-42 is seen to inhibit the 42 and 7 nACh receptor 
subtypes acutely at nM and pM concentrations, respectively, which could contribute to the 
memory and cognitive impairments associated with AD patients.
74
 It has been shown that Aβ1-42 
is a non-competitive antagonist of the 42 subtype of nACh receptors. It has been 
experimentally shown that the β2 subunit isn’t affected, suggesting an alternate site of action for 
the Aβ1-42.
75
 The Aβ1-42 inhibition is not mediated through an open channel block and 
pretreatment with Aβ1-42 is necessary to induce convincing inhibition.
54,75
 To combat AD there 
are two strategies that can help increase cholinergic transmission in the brain: firstly by 
increasing the amount of ACh at the synapse that could be achieved by blocking acetylcholine 
esterase (AChE) activity, and secondly by potentiating the action of ACh at nACh receptors. 
Galantamine, tacrine, memantine, donepezil and rivastigmine are commonly used AChE 
inhibitors for the treatment of mild to moderate cognitive symptoms of AD of which 
galantamine, in addition, allosterically potentiates 42 and 7 nACh receptors present in the 
brain.
76
 Thus, drugs selectively targeting the nACh receptor subtypes can increase cholinergic 
tone in the diseased brain and, hence, provide therapeutic potential for the treatment of AD. 
 
c. Autism 
Autism is characterized by impaired social and communications skills along with odd and 
stereotypical behavior. It is also associated with impaired planning and attention. Autism is also 
considered as a spectral disorder with severe developmental defects that are apparent beginning 
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in early childhood.
77
 A decreased level of 4 mRNA in the parietal cortex and cerebellum as 
well as decreased levels of 42 nACh receptors with unchanged levels of 7 nACh subtypes 
can be seen in autistic patients.
78
 ‘Nicotinic tone’ which refers to the overall activation of 
synapses by nicotine is considered as a factor that could be contributing towards the changes in 
the etiology of autism.
78
 Thus agents that can restore the ‘nicotinic tone’ and potentiate the 42 
nACh receptors might play a crucial role in providing therapeutic options for autism. Selective 
42 nACh receptor potentiators can provide important insight into some of the cellular and 
molecular mechanisms that can help understand the etiology and pharmacology of autism, which 
is still unclear. 
 
d. Attention deficit hyperactivity disorder (ADHD) 
ADHD is a psychiatric disorder characterized by hyperactivity, inattentiveness and impulsivity 
symptoms.
79
 Factors such as academic, employment and marital difficulties, psychiatric 
disorders, substance abuse, depression, anxiety and personality disorders can be a result from 
ADHD in adults.
80
 nACh receptors have been implicated and studied for their role in the disease 
state; and it was found that nicotine and its analogs were efficient in treating ADHD symptoms.
79
 
42 nACh receptor activation by ABT-089 (4), a selective weak agonist, was found to alleviate 
the symptoms of ADHD in rodents and primates and humans by improving attention, learning 
and memory.
81
 Drugs targeting selectively at the 42 nACh receptors subtypes can tackle 
cognitive disturbances and hence provide therapeutic potential for the treatment of ADHD. 
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 ABT-089 (4)       (-)Nicotine (3) 
 
e. Nicotine addiction 
Nicotine (3), a plant alkaloid, is an active constituent of the leaves of nicotiana tabacum that 
interacts with all the nACh receptor subtypes distributed in the CNS as well as the PNS.
82
 
Nicotine is the chief component of tobacco, which is widely abused by smoking and chewing of 
the dried and cured leaf. There is an immediate need in understanding the mechanism of nicotine 
addiction due to the extreme health risk associated with nicotine abuse.
83
 Prolonged exposure to 
nicotine causes a gradual decrease of the ionic responses called as the high affinity, super-open 
desensitized state of nACh receptors that is of key importance to understanding nicotine 
addiction.
84
 The brain areas involved in addiction are the dopaminergic neurons in the ventral 
tegmental area (VTA), the prefrontal cortex, the nucleus accumbens (NA), extended amygdala, 
hippocampus, and the habenulo-interpeduncular system.
82
 Activation followed by desensitization 
by nicotine causes an alteration in the synaptic response that, in turn, alters synaptic signaling.
82
 
The dopaminergic system in the VTA and its projections in the NA reinforce the nicotine reward 
function and nicotine addiction.
85
 Presynaptic 42 nACh receptors on the dopaminergic 
neurons cause the release of dopamine which is strongly attributed to the addictive properties on 
nicotine.
86
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f. Depression   
A direct correlation exists between smoking and depression with an almost 3-fold increase in 
nicotine dependence in depressed patients verses nondepressed.
87
 Similar ratios can be found for 
the population who attempts to quit nicotine consumption, where depressed individuals are 2-3 
times less prone to quit versus the nondepressed. This clearly indicates a nicotine component 
involved in depression and mood.
87,88
 The 42 nACh receptor subtype has been considered as 
an important therapeutic target for the potential treatment of depression due to its widespread 
presence in the brain.
89
 42 nACh receptors have been implicated to modulate the levels of 
dopamine which is an important neurotransmitter involved in reward and reinforcement 
regulation in the brain through direct actions as well as indirectly through the excitatory 
glutamatergic and the inhibitory GABAergic neurons.
1,57
 The neuronal component of nACh 
receptors is involved in depression, and not the peripheral nACh receptor subtypes.
90
  Smoking 
has been known to decrease depression through desensitization of nACh receptors; thus, an 
antagonist at nACh receptors could have antidepressant effects.
90,91
  This correlation was 
observed in studies involving mecamylamine (5), a non-selective, non-competitive antagonist at 
nACh receptors that showed antidepressant-like effects in behavioral tests performed in mice.
92
 
Cytisine (6), a partial agonist at nACh receptors with low efficacy at 42 nACh receptors and 
full agonist action at ganglionic 34 ACh receptor and 7 nACh receptors, is used as a 
smoking cessation agent and was also tested for its antidepressant effect.
93
 A partial agonist at 
the nACh receptor will increase the activity of the nACh receptor but limits the ability of ACh to 
activate receptors.
94
 Hence, if high levels of ACh lead to depression-like effect, a partial agonist 
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might provide therapeutic benefit towards depression. Studies with cytisine (6) in mice have 
supported this theory.
95
  
        
Mecamylamine (5)       Cytisine (6) 
      
Veranicline (7)       Sezetidine-A (8) 
 
Similar studies were performed with veranicline (7), which is also a partial agonist at nACh 
receptors with low efficacy at 42 nACh receptors, with higher efficacy than cytisine and is a 
full agonist at ganglionic 34 ACh receptors and 7 nACh receptors. Veranicline (7) has a 
similar profile as that of cytisine.
96
 The 7 nACh receptor agonist effect in the above drugs could 
be a possible reason for the antidepressant like effect. This theory was eliminated when 
sezetidine-A (8), a selective 42 nACh receptor partial agonist, was able to cause 
antidepressant-like effect in mice.
97-99
 Future directions towards depression and nicotinic 
receptors as potential targets requires a bidirectional approach where various factors including 
different receptor subtypes, different brain areas where the ligands might act, and different 
neurotransmitters that could be influenced by ACh along with different levels of mood, stress 
and depression levels in patients. Drugs selectively targeting the 42 nACh receptor subtype 
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can potentially target the depressed state of the patient and hence provide therapeutic treatment 
for depression. 
 
g. Parkinson’s disease (PD) 
PD is a neurodegenerative disorder marked by tremor, rigidity, postural instability and 
bradykinesia.
100
 The pharmacology involves the degeneration of the nigrostriatal dopaminergic 
pathway (NDP) which involves neuronal loss in the CNS and PNS. Various neurotransmitters 
are thought to be affected, but to a lesser extent compared to the NDP. Collectively there is 
impairment of motor function, cognition/memory and autonomic functions.
100
 Currently, 
dopamine replacement therapy is the preferred treatment for PD with L-DOPA along with other 
dopamine agonists. These agents are effective for the motor function deficit for the disease state, 
while ineffective for the nonmotor symptoms in PD.
101
 This led to other therapeutic avenues 
being explored and it was found that nicotine was able to protect the NDP pathway, thus 
encouraging researchers to explore the cholinergic systems. It has been shown that 46(2)23 
and 42 nACh receptors are predominantly present in the corpus striatum with their projections 
in the substantia nigra region controlling dopaminergic firing.
101
 The 62*-containing nACh 
receptors are almost exclusively expressed on the presynaptic dopaminergic neuronal terminals, 
whereas 42*-containing nACh receptors are widely distributed on presynaptic dopaminergic 
and postsynaptic glutamatergic, GABAergic and serotonergic neurons.
44,102,103
 Researchers were 
able to show that the 42* and 62* nACh receptors present on dopaminergic neurons 
modulate dopamine release and are important for NDP functioning, thus posing as attractive 
targets for development of selective agents for the treatment of PD.
101
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3. Agents of nACh and other receptors in disease state 
nACh receptor subtypes have been validated as critical drug targets due to their roles in the 
muscle and ganglionic functions. This has stimulated a wide interest in the research for 
generation of synthetic analogs for the various nACh receptor subtypes. However there is still a 
major void in subtype selective agents. Listed below in Table 1 are a few examples of analogs 
which have been implicated and approved for the use of the various disease states. 
 
Table 1. List of agents implicated in various disease state. 
Agents Targets Disease state 
Additional 
information 
 
ABT-418 (9) 
42, 7 
agonist 
AD,
104
 ADHD
81
 
Phase trials; 
discontinued 
for AD 
 
AZD-3480/Ispronicline/ 
TC-1734 (10) 
 
42, 7 
partial 
agonist 
AD
105
 
Phase IIb; 
discontinued 
ADHD Phase II
106
 
 
AZD-1446 (11) 
42 
agonist 
AD Phase II
107
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Galantamine (12) 
AChE 
inhibitor, 
42 and 7 
agonist 
AD
108
 
FDA 
approved 
 
Tacrine (13) 
AChE 
inhibitor 
AD
109
 
FDA 
approved 
 
Rivastigmine (14) 
AChE 
inhibitor 
AD
110
, dementia 
related to PD
111
 
FDA 
approved 
 
Memantine (15) 
NMDA 
antagonist, 
7 non-
competitive 
antagonist 
AD
112,113
 
FDA 
approved 
 
Donepezil (16) 
AChE 
inhibitor 
AD
114
 
FDA 
approved 
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A-85380 (17) 
42 
7, 11 
agonist 
Pharmacological 
probe
115
 
 
 
Bupropion (18) 
nicotinic 
receptor 
antagonist 
Antidepressant,
116
 
smoking 
cessation
117
 
FDA 
approved 
 
TC-2429 (19) 
62 
agonist 
PD
118
 
Preclinical 
development 
 
ABT-107 (20) 
7 agonist 
AD, 
schizophrenia
119,120
 
Phase trials; 
discontinued 
 
DMXB-A/GTS-21 (21) 
7 partial 
agonist 
schizophrenia Phase II
121
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TC-5619 (22) 
7 partial 
agonist 
ADHD, 
schizophrenia
122
 
Phase II;
123
 
discontinued 
 
 
4. Desensitization of nACh receptors 
Desensitization means decrease of the response in the presence of a stimulus. Katz and Thesleff
5
 
first noted that continuous application of ACh on frog muscle end-plate resulted in a decreased 
cell response and almost abolished the response that was quickly recovered upon removal of 
ACh from the system.
124,125
 This phenomenon was thus termed as ‘desensitization’ and was 
hypothesized to have resulted from the transition of the receptor into a refractory state.
125
 It was 
also shown that animals exposed to nicotine resulted in an increased density of nACh receptors. 
This phenomenon allowed scientists to propose a two-state model of nACh receptor 
desensitization which involved activation and desensitization by nicotine (or any agonist) at the 
same time.
126
 Various factors together provide the net effect of nicotine on nACh receptors such 
as drug concentration, exposure length, and the state of the receptor.
127
 nACh receptors have a 
complex pharmacology and this can be mostly attributed to the activation and desensitization of 
the nACh receptors over a short time course of nicotine exposure.
127
 The various biological 
events associated with nACh receptor are initiated by the binding of the ACh, which brings about 
a conformational change in the receptor shape.
128
 As previously discussed the nACh receptors 
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exist in four states; the closed, the open, the intermediate transition state and the high-affinity 
channel-inactive desensitized state (Figure 5).
128,129
  
 
 
Figure 5. Multiple conformation states of nACh receptors and their transition from one state to 
the other in the presence of ACh (adapted from Arias
128
). 
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The closed state is the low-affinity resting state of the receptor and, in the absence of the 
agonist/ACh, consists of around 80% of the receptor population while the remaining 20% exists 
in the desensitized state.
130,131
 Desensitization of the nACh receptors has been found to be 
modulated by the activation of protein kinases and receptor phosphorylation.
132
 It can be noted 
that the agonist-induced desensitization of the nACh receptor occurs rapidly. Experiments were 
performed on the membrane of Torpedo species and intrinsic fluorescence measurements 
showed that the t1/2 was 1.9 sec for agonist induced desensitization.
133
 The time frame for the 
activation cycle of the nACh receptor consists of sec to msec for the fast activation of the 
receptor from the closed to the open state upon ACh binding. Prolonged presence of agonist/ACh 
causes the receptor to convert to the intermediate transition state which takes around msec and 
finally inducing into a high-affinity channel-inactive desensitized state which occurs in a sec to 
min time frame.
128
 Desensitization of the homomeric 7 nACh receptor is associated with a 
structural change of the binding sites at the orthosteric site and the ion pore.
134,135
 Also, mutation 
of Leu247 in the pore-lining M2 domain of the TM region of the nACh receptor was shown to 
destabilize the conformation of the desensitized receptor making it conducive to channel 
opening, thus causing ions to flow through and considerably slow the rate of desensitization of 
the rapidly fast-desensitizing 7 nACh receptor.134,136 Desensitization experiments of various 
heteromeric nACh receptors have shown that the rate of desensitization is faster for the 2 
containing than the 4 containing subtypes.135 The N-terminal region of the  subunit has been 
shown to confer the different rate of desensitization of the -containing heteromeric nACh 
receptors.
134
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D. Allosterism 
Receptors are proteins that can adopt multiple tertiary conformations. Receptors can also interact 
with other cellular proteins that can function as downstream messengers of the signal 
transduction pathway. The origin of allosterism is in the Greek literature where allos means 
‘other’ and stereos mean ‘solid shapes’. The concept of allosterism was first proposed by Monod 
and Jacob in 1961
7,137
 when it was found that certain bacterial enzymes were feedback inhibited 
by the end product or regulatory ligand of the biosynthesis pathway, even though they had no 
structural similarity with the starting material or the substrate.
138
 Further experiments were able 
to demonstrate that the interaction between the substrate and the regulatory ligand were the result 
of distinct binding sites at which the molecules bind. The binding of the regulatory ligand brings 
about a change in the conformation of the protein that reversibly modifies the conformation of 
the active site indirectly.
138
 The concept was studied and adopted by Monod, Wyman and 
Changeux (MWC) in 1965
139
 where they showed that allosteric effects do not fit general 
enzymatic theories, and that a molecular transition, also called the allosteric transition, occurs 
when an allosteric ligand binds to stabilize the protein.
137
  Henceforth, the allosteric model of 
ligand interaction was also called the MWC model. 
 
1. Theory 
In an allosteric modulation various factors play a role such as the dynamic conformational 
change of the protein in the absence of the ligand, and stabilization of the protein upon ligand 
binding in a preferred conformation. Thus, in theory, a nACh receptor agonist will preferentially 
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stabilize the active open state conformation and a nACh receptor competitive antagonist will 
stabilize the resting or the closed state conformation. As mentioned earlier, different states of the 
receptor possess different affinity for a ligand (Figure 5). Transition between the different states 
can be brought about either by ligand binding or a free energy change between the states (L0-L2) 
(Figure 5) that involves transition from one state to another. A three-state model for the allosteric 
properties of the nACh receptor has been proposed that involves the resting state, open state, and 
the desensitized state of the receptor. Generally the allosteric system involves quaternary protein 
structures that can cause alteration in the bonding of the subunits of the receptor. Allosteric 
effects can be broadly classified into two types; homotropic and heterotropic.
137
 A homotropic 
effect occurs when the second molecule of the endogenous ligand (ACh) can bring about an 
allosteric modulation for ACh binding at the orthosteric site. In the case of the heterotropic 
effect, the allosteric modulator binds at a site distinct from the orthosteric site and modulates the 
binding of the orthosteric ligand. Agents that stabilize the open state of the receptor, thus 
potentiating the effect of the endogenous ligand and further shifting the equilibrium towards the 
open state, are called as positive allosteric modulators (PAMs) (Figure 6).
139
 Whereas, on the 
other hand, ligands that bind at an allosteric site and increase the energy barrier along with 
shifting the equilibrium to the resting state are called negative allosteric modulators (NAMs). 
PAMs on their own are inactive and don’t activate the ion channel. A ligand that binds at an 
allosteric site and activates the receptor on its own is called an allosteric potentiating ligand or 
allosteric non-competitive agonist.
140
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Figure 6. Schematic representation of positive allosteric modulation where the pentameric nACh 
receptor is depicted in blue (adapted from Bertrand and Gopalakrishnan
139
). 
 
Cooperativity is an important phenomenon where binding of two or more ligands on the same 
protein at distinct sites generally increases or decreases the rate of binding of the second ligand 
onto the protein and is termed positive or negative cooperativity, respectively. Cooperativity is 
measured using a Hill coefficient (n) which provides a quantifiable measure of the same. A 
coefficient of n >1 indicates a positive cooperativity while n < 1 indicates negative cooperativity. 
Kinetic models of the ACh response show that two molecules of ACh are required for the 
activation of the receptor and that n = 1.5 to 2.2, which suggests a homotropic effect.
141
 The 
unbinding of the ACh from the receptor is slow enough to allow the receptor to activate the 
channel opening more than once, thus suggesting that the channel opens and closes with ACh 
remaining bound to the receptor.
142
 Thus, the allosteric model of ACh binding should include the 
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unliganded, single liganded and double liganded state of the receptor. The model (Figure 7) 
shows the complexity of the transition of the ACh receptor from one state to the other. At resting 
state, the closed conformation (R) of the receptor is predominant. The closed channel (R) has 
low affinity for the ligand but possesses a fast rate constant to go to the open state (AR) of the 
receptor.
143
 Once the receptor is bound by 2 molecules of ACh (A2R), the probability of channel 
opening is almost a million times more when compared to the closed unliganded state (R) of the 
receptor. Once in the activated state, the receptor desensitizes (A2RD) rapidly; thus, eventually, 
the burst fades away. Thermodynamically, the desensitized state of the receptor is the high-
affinity state with a 100-fold higher affinity for the ACh. With equilibrium favoring the closed 
state (R) of the receptor, the desensitized receptor (A2RD and ARD) and the receptor reverts to the 
closed state and the cycle is ready to repeat.
142
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Figure 7. Allosteric model of the various transition states of the nACh receptors. R= Receptor in 
the open state, AR= 1 molecule of ACh bound to the receptor, A2R= 2 molecules of ACh bound 
to the receptor, *= open state of the receptor, D= desensitized state of the receptor.
142
 
 
2. Advantage of allosteric modulators over traditional orthosteric ligands 
There are various advantages of allosteric modulators over orthosteric ligands for receptor 
activation. First, the orthosteric ligand binds to the orthosteric site and activates the receptor; on 
the other hand, the allosteric modulator doesn’t have any intrinsic activation, thus the natural 
state of the receptor along with the physiological stimulus produced by the endogenous ligand 
can be maintained. This phenomenon could possibly reduce the likelihood of receptor 
desensitization even when an allosteric modulator is continuously present, thus providing a tool 
to escape tolerance.
144
 A second major problem associated with the orthosteric ligands is the 
overdose/toxicity aspect. The allosteric modulators are saturable; thus once all the binding sites 
for the allosteric modulators are occupied it cannot produce any additional effect and, thus, can 
be a safer alternative in cases of overdose.
145
 The third advantage tries to tackle the most 
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problematic aspect of drug discovery, i.e., selectivity of the ligands across various receptor 
subtypes. In the case of nACh receptors the orthosteric site is highly conserved providing very 
little room for designing selective agents for various nACh receptor subtypes. An allosteric site 
could be found anywhere on the receptor surface and thus can be specific for a particular 
receptor subtype population and provide selectivity.
144
 
 
3. Allosteric modulators of nACh receptors 
Due to the broad implication of nACh receptors in various neurodegenerative disorders, PAMs 
can play crucial role in restoration of nicotinic tone.
54
 Ivermectin, an anthelminthic agent, was 
the first agent to be identified as a PAM at 7 nACh receptors. The compound was able to 
decrease the EC50 and increase the slope of the dose response curve, thus potentiating the effect 
of ACh.
146
 Since then, various other agents have come to light as potential PAMs at the 7 nACh 
receptor subtype.
139
 Galantamine, which is an AChE inhibitor, was shown to activate 7 and 
42 nACh receptors along with other subtype populations, through binding at a site distinct 
from the orthosteric site for ACh.
147
 Thus, co-application of galantamine with ACh in Xenopus 
oocytes expressed with 42 nACh receptors was shown to potentiate the effect of ACh.147 The 
neuro-steroid 17-estradiol was shown to potentiate ACh-induced responses by increasing 
channel opening probability at 42 nACh receptors.148 It was found that the C-terminal region 
of the 4 subunit was involved in 17-estradiol binding and that the site was different from other 
progesterone inhibitions.
148
 Various cations, such as zinc (Zn
2+
)
149
 and calcium (Ca
2+
),
150
 seem to 
play a crucial role in the modulation of the various nACh receptor subtype populations in the 
brain. Zinc co-application (50 M) with a saturating ACh concentration was shown to potentiate 
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ACh-evoked currents by 260%. Also, it was observed that zinc potentiates at low concentrations 
(EC50=16 M) and inhibits at high concentrations (IC50=440 M).
151
 Through mutagenesis 
studies it was observed that the Zn
2+
 potentiates low-affinity (4)3(2)2 receptors that have a 
4+/4- phase while inhibiting both the low- and high-affinity stoichiometry of 42 nACh 
receptor that have a 2+/4- phase that is required for Zn2+ binding.149,152  
PAMs have different qualitative effects on the ACh response.
153
 They are classified into two 
types namely, Type I and Type II PAMs. Type I PAMs are agents that increase the receptor 
sensitivity by increasing the magnitude of the current produced by ACh without affecting the 
decay rates of the current.
153
 Type I PAMs do not affect the onset and the basic decay kinetics of 
the response. On the other hand Type II PAMs increased the apparent peak current by rapid 
onset of action and weak current decay kinetics.
154
 In the case of 7 nACh receptors Type II 
PAMs were able to reactivate the desensitized receptors which are considered to be the reason of 
the prolonged decay rates for the ACh currents.
153
 Table 2 summarizes various agents that have 
been shown to be PAMs at the two major nACh receptor populations in the human brain: the 7 
and 42 subtypes.  
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Table 2. A list of agents and their selectivity profile at various nACh receptor subtypes. 
Agent Target Type 
 
Genistein (23) 
7 nACh receptor,153 
tyrosine kinase inhibitor 
PAM type I 
 
NS-1738 (24) 
Non-specific at nACh 
receptors
155
 
PAM type I 
 
PNU-120596 (25) 
7 nACh receptor156-158 PAM type II 
 
TQS (26) 
7 nACh receptor153 PAM type II 
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Galantamine (27) 
AChE inhibitor,
140
 
7 and 42 nACh 
receptor 
159
 
PAM type II 
 
17-Estradiol (28) 
42 nACh receptor148 
and various nuclear 
receptors 
PAM type II 
 
5-Hydroxyindole (29) 
7 nACh receptor,160 
endogenous ligand 
PAM type I 
 
A-998679 (30) 
42 nACh receptor161 PAM type II 
 
LY-2087101 (31) 
7 and 42 nACh 
receptor
162
 
PAM type I 
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4. des-Formylflustrabromine (dFBr) 
Marine biology has been for years a great source of novel creatures and a part of the research to 
identify novel agents for drug discovery. Flustra foliacea is a marine bryozoan species found 
commonly in the North Sea and is now known to biosynthesize a variety of indole-containing 
natural products as metabolites.
163
 To date, about 22 alkaloids and monoterpenes have been 
isolated from the bryozoan species.
163,164
 One of the indolic compounds is dFBr (32). Peters et 
al.
165
 performed binding experiments with dFBr (32) at 42 and 7 nACh receptors and it 
showed low (Ki = 3,400 nM and >50,000 nM, respectively) affinity compared to (-)nicotine (3) 
(Ki = <1 nM).
165
 Some of the metabolites were shown to possess muscle relaxant properties.
166
 
Several of the Flustra metabolites were tested for their biological activity against 32, 34, 
42, 44 and 7 nACh receptors expressed in oocytes and only dFBr (32) showed any 
significant activity at the 42 nACh receptor subtype.166 dFBr (32) was shown to potentiate 
ACh-induced responses in Xenopus oocytes expressed with 42 nACh receptors, while a 
statistically insignificant inhibitory response was measured at the 7 nACh receptor subtype.166 
Various experiments were conducted by Sala et al.
166
 and dFBr (32) was found to potentiate 
ACh’s effects through a mechanism that does not involve direct activation of α4β2 nicotinic 
receptors at the orthosteric site. Rather than behaving as an orthosteric agonist, dFBr is a positive 
allosteric modulator that can potentiate the actions of ACh at 42 nACh receptors.166 It was 
shown that the action of dFBr (32) was not on the pore properties but kept the channel open for a 
longer time following ACh binding, along with reopening the channel faster, hence increasing 
the potency and efficacy of the ACh-induced response.
166
 The potentiation caused by dFBr on 
ACh-induced currents was also found to be reversible and concentration-dependent. dFBr was 
  
43 
 
the first compound shown to possess selectivity for 42 receptors as a PAM and could 
potentially be of great benefit for further understanding the importance of 42 nACh receptors 
in various disease states. Biological testing was performed using the various Flustra metabolites 
as their free bases, which required using DMSO for solubilizing the compounds.
166
 Joshi et al.
167
 
were able to modify the conventional oocyte electrophysiological experiments and incorporated 
a vertical flow system that was shown to have extended oocyte stability, drug exposure to the 
complete oocyte surface, and that can be attached to an HPLC autosampler for high throughput 
style assays. The vertical oocyte chamber was also able to provide a faster exposure thus 
providing more accurate determination of the results compared to the conventional flow oocyte 
chamber.
167
  
  
des-Formylflustrabromine (dFBr) (32) 
  
  
44 
 
 
III. Specific aims 
 
 
With the advent of allosteric modulation as a novel route for activation of nACh receptors it is 
important to identify agents that act selectively so that nACh receptors and their subtypes can be 
studied in greater detail. The major limiting factor with allosteric modulators is that they are 
impossible to design a priori. Thus, the only way to identify such compounds is through 
serendipity or through high-throughput screening methodology. Sala et al.
166
 were fortunate to 
find dFBr as a novel agent that was able to potentiate 42 nACh receptors allosterically and it, 
thus, provided a novel lead for further drug development. The previous studies of dFBr (32) 
involved the use of DMSO solutions of the water-insoluble free base for all the biological studies 
employed. Also, researchers relied on the natural source for obtaining dFBr (32) and, hence, its 
availability was limited. Our laboratory (i.e., Kim et al.)
9
 and Lindel et al.
168
 independently 
identified convenient synthetic routes for the synthesis of dFBr (32), which was synthesized as a 
water-soluble HCl salt. The water-soluble HCl salt was tested for its action at the 42 and 7 
nACh receptor subtypes. It was shown that the potentiating effects of the HCl salt of dFBr was 
greatly improved over that of its free base.
9
 This could be because of better water solubility 
while performing the biological testing, or due to the non-necessity of using DMSO as solvent. 
Interestingly, it was observed that contrary to results published by Sala et al.
166
 the HCl salt of 
dFBr (32) produced a biphasic response at the 42 nACh receptor (Figure 8) with an EC50 of 
120 nM for the potentiation component and an IC50 of 150,000 nM for the inhibitory component 
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of the dose-response curve when co-applied with 100 M ACh.9 dFBr (32) potentiated the 
maximal ACh response to almost 300%.
9
 The inhibition profile at relatively higher 
concentrations was hypothesized to be due to an open channel blockade mechanism with further 
studies required to prove it. At 7 nACh receptors, dFBr (32) produced only an inhibitory 
response with an IC50 of 44,000 nM (Figure 9).
9
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Figure 8. Potentiation and response curve for dFBr at 42 nACh receptors. (A) A typical trace 
of the potentiation of the ACh-evoked response for dFBr (32) from a single oocyte expressing 
human 42 nACh receptors. (B) A biphasic dose-response curve for dFBr (32) co-applied with 
100 M ACh on human 42 nACh receptors.9  
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Figure 9. Potentiation and response curve for dFBr at 7 nACh receptors. (A) A typical trace of 
potentiation of the ACh-evoked response by dFBr (32) from a single oocyte expressing human 
7 nACh receptors. (B) An inhibitory dose-response curve for dFBr (32) co-applied with 100 
M ACh on human 7 nACh receptors.9  
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Few, if any, allosteric ligands show selectivity for 42 nACh receptors. dFBr (32) is the first 
selective allosteric modulator that potentiates the actions of ACh at 42 nACh receptors. 
Unfortunately, dFBr (32), at high concentrations, will eventually behave (possibly as a channel 
blocking agent) to reverse its effects on the ACh receptor activation profile at 42 nACh 
receptors.
9
 Thus, it would be important to determine what structural requirements are responsible 
for: a) allosteric activation of 42 nACh receptors, and b) antagonism. A study will be 
undertaken to understand structure-activity relationships (SAR) with dFBr (32) as a starting 
point.  
 
To perform the SAR studies that might lead to identification of a possible pharmacophore for 
PAM action at the 42 nACh receptor subtype a ‘deconstruction-reconstruction-elaboration’ 
approach will be employed. This approach involves single structural changes being made to a 
compound and the subsequent evaluation of the new compounds for biological activity.
169
 Thus, 
any change in activity can be associated with a single change in the structure of a molecule, and 
a rational SAR can be established. The process involves three phases to determine the necessity 
or contribution to activity of various structural components of the parent molecule. The first 
phase is the ‘deconstruction’ phase where the key structural features in the parent molecule are 
removed one at a time and the new compounds are biologically evaluated to measure the 
importance of that particular functional group. Also, this might identify the minimum structural 
features that are required to retain the activity of the parent compound, providing a 
pharmacophore for designing future analogs. The process of ‘deconstruction’ is also beneficial in 
identifying analogs that retain action and simultaneously provide a simpler synthetic procedure 
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which might ease the scale-up synthesis of a desired final ligand. Once a thorough understanding 
of the importance of various structural features of the parent molecule is established, the process 
can move to a ‘reconstruction’ phase where an analog with all essential structural features is 
synthesized and biologically evaluated to compare to the parent molecule. The third phase is the 
‘elaboration’ phase where the important structural features are further elaborated to understand 
their role in producing the action. In this phase, principles of classical medicinal chemistry are 
applied and an SAR is developed where various substituent parameters, such as electronic, steric, 
and lipophilic can be studied. A rational approach using the Topliss decision-tree
170
 or the Craig 
Plot
171
 can be implemented to minimize the vast number of possible substituents that might be 
introduced, and the total number of compounds that will be required for synthesis and evaluation. 
The ‘elaboration’ phase generally involves lead optimization and allows an understanding of 
‘why’ a particular substituent is important. It also might provide a drug-like molecule with novel 
structural features. 
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The specific aims of the current investigation are:  
1. Elucidation of critical structural features of dFBr (32) required for potentiation of ACh at 
42 nACh receptors. 
2. Determination of what structural features of dFBr (32) contribute to the potentiation and 
inhibition profile of the biphasic dose-response curve of dFBr (32) (Figure 8) which will 
eventually help better understand the true potentiation potential of dFBr (32) analogs at 42 
nACh receptors. 
3. Identification of structurally-simpler PAMs that might result in greater ease of synthesis for 
scale-up (e.g. for purpose of in vivo studies). 
4. Synthesis of a radiolabeled ligand as a selective PAM at 42 nACh receptors that might 
facilitate binding experiments to determine binding profiles along with efficacy studies.  
The general goal of this work is to prepare dFBr (32) analogs that can help provide an 
understanding of various structural features and their effects towards 42 nACh receptor 
action. Specifically, the compounds considered for synthesis and evaluation are shown in Figure 
10. 
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Figure 10. Deconstructed analogs of dFBr (32) proposed for synthesis and evaluation. For 
example, compound 33 can provide information on the necessity of the 6-bromo group of 32, 
whereas 34 can provide information on the need for unsaturation. Each structure can provide 
important information on the contribution of specific substituents.  
 
It might be noted that one of the first studies conducted in our laboratory showed that the 6-
bromo substituent of dFBr was an important, but not necessary, contributor to activity (see 
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discussion to follow). Consequently, compounds 41-45 (Figure 11) will be prepared and 
evaluated, to determine the contribution of the 2-position chain substituents to 42 PAM 
action. The reason for this is because of the difficulty in preparing 2-alkyl-6-bromotryptamines. 
The intent is to identify an optimal 2-position substituent, and to then prepare the 6-bromo 
analog of this compound (i.e., reconstruction). 
 
 
Figure 11. Deconstructed analogs of 6-desbromo dFBr (33) proposed for synthesis and 
evaluation. 
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IV. Results and discussion of deconstruction of dFBr 
 
 
A. Drug-like properties of dFBr (32) 
The drug-like properties of a compound are related to its structure which, in turn, is essential for 
absorption, distribution, metabolism and elimination (ADME) in humans. The physicochemical 
properties of a compound, such as its lipophilicity and solubility, might be related to various 
ADME properties. Medicinal chemists generally engage in the process of structure-activity 
relationship (SAR) and/or structure-property relationship (SPR) studies to increase the potency 
and selectivity towards a drug target, to reduce the undesirable effects, and to improve the drug-
like properties of a compound. During SAR studies the molecular properties of the compound, 
such as molecular weight and logP, along with solubility and molecular volume, to name a few, 
are considered and a multi-dimensional optimization approach is carried out. Lipinski’s rule of 5 
is a widely accepted guide for understanding the drug’s bioavailability, generally for an orally 
active drug. The rule states that an orally active drug should consist of: 1) no more than 5 
hydrogen bond donors; 2) no more than 10 hydrogen bond acceptors; 3) molecular weight under 
500 Daltons; and 4) a logP not greater than 5.
172
 There are exceptions to these rules and various 
other parameters such as the polar surface area and number of rotatable bonds in a compound are 
considered to better predict the oral bioavailability of a drug.
173
 Table 3 summarizes the various 
physical properties of dFBr (32) which were calculated using the OSIRIS property explorer (a 
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web-based molecule editor predicting various drug-relevant properties) and MOLSOFT 
molecular property calculator. 
 
Table 3. Physicochemical properties of dFBr (32) versus ideal values   
Physicochemical properties Predicted values Ideal values 
logP 4.24  5 
solubility -4.36  -4.0 
Molecular weight (MW) 320  500 
Hydrogen bond acceptors 0  10 
Hydrogen bond donors 3  5 
Drug likeness -6.18 High positive value 
Drug score 0.26 High positive value 
 
According to the Lipinksi’s rule of 5, the molecular weight, logP, hydrogen bond acceptor and 
hydrogen bond donor are within the requirements, thus dFBr (32) can qualify as a potential drug. 
The drug likeness and the drug score is determined by comparing various marketed drugs.
174
 
These scores also consider the various fragments in the compound that can be problematic and 
potentially toxic. A positive value for the drug likeness would mean that the fragments of the 
compound are what are generally present in commercial drugs. Thus, drug likeness, along with 
lipophilicity, molecular weight and potential toxicity, can determine the relative drug-like 
attributes of a compound. From Table 3 it can be observed that the drug likeness and the overall 
drug score of dFBr (32) is poor which suggest that dFBr (32) is not an ideal drug candidate. Use 
  
55 
 
of such tools along with other computational models can help in performing SAR and/or SPR 
studies on dFBr which can help in determining the structural features which can improve the 
drug-like property of dFBr (32). For example, secondary amines are less lipophilic and more 
prone to metabolism than, for example, tertiary amine or -alkyl amines. Hence, such factors 
should be investigated.  
 
B. Chemistry 
Analogs of dFBr (32) were synthesized in collaboration with others in our laboratory concurrent 
with the present investigation. For example the synthesis of compounds 33-36, 38, 41, and 42 
were synthesized by German et al.
175
 and have now been reported. Compound 35 (Figure 10) 
was a useful intermediate for analogs where 2-position substitution was introduced as a separate 
step. Compound 40 (Scheme 1) was synthesized by performing a modified Henry reaction on an 
indole nucleus instead of the Speeter-Anthony glyoxylamide synthesis because the reaction and 
the yield of primary glyoxylamide was poor compared to the secondary glyoxylamide. 6-
Bromoindole (46) (Scheme 1) was allowed to react with 1-dimethylamino-2-nitroethylene in the 
presence of TFA to yield 3-[(E)-2-nitroethenyl]-6-bromo-1H-indole (47), which, upon reduction 
with NaBH4 in the presence of a Lewis acid, yielded the known 6-bromotryptamine (48) in fairly 
good yield.
176,177
 The tryptamine was used for a further reaction where it was protected with di-
tert-butyl dicarbonate in the presence of Et3N to yield tert-butyl-2-(6-bromo-1H-indol-3-
yl)ethylcarbamate (49). The compound was known as a glassy solid,
178
 but a melting point had 
not been reported. Because of the non-polar nature of the carbamate, it was relatively easy to 
purify by column chromatography. The Boc-protected tryptamine 49 was subjected to a 
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prenylation reaction to obtain the 2-substituted indole with freshly prepared prenyl 9-BBN
179
 in 
the presence of tert-butyl hypochlorite and Et3N, which yielded tert-butyl-2-(6-bromo-2-(1,1-
dimethylallyl)-1H-indol-3-yl)ethylcarbamate (50). This was one of the only reactions that was 
able to provide the 2-dimethylallyl substitution in the presence of 3- and 6-substitution on the 
indole nucleus (see below for other routes). Deprotection, along with conversion to an HCl salt, 
yielded 6-bromo-2-(1,1-dimethylallyl)tryptamine hydrochloride (40). 
 
Scheme 1. Synthesis of compound 40
a
 
 
a
Reagent: (a) 1-dimethylamino-2-nitroethylene, TFA, CH2Cl2, room temperature, 1 h; (b) 
NaBH4, BF3·Et2O, THF, reflux, 2 h; (c) di-tert-butyl dicarbonate, Et3N, DMF, room temperature, 
24 h; (d) (1) tert-butyl hypochlorite, Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN, THF, room 
temperature, 2 h; (3) NaOH, H2O2, 1 h; (e) HCl, EtOAc, 0 °C, 24 h, recrystallized from 
MeOH/EtOAc. 
 
Scheme 2 summarizes the various des-bromo analogs, 43-45, that were synthesized. o-Toludine 
(51) was treated with pivaloyl chloride in the presence of base to yield the corresponding amide 
  
57 
 
52
180
 which underwent cyclization in the presence of n-butyllithium to yield the known 2-tert-
butyl-1H-indole (55).
181
 This is a more convenient synthetic scheme for 2-substituted indoles 
though the drawback is that halogens are susceptible to lithium exchange so it cannot be used 
when a 6-bromo substituent is present. The Speeter-Anthony glyoxylamide reaction was 
performed on 2-tert-butyl-1H-indole (55), followed by LiAlH4 reduction and salt formation, to 
yield N-methyl-2-tert-butyltryptamine oxalate (43). A similar synthetic route was followed with 
2-methylbutanoyl chloride and acetyl chloride to yield 44 and 45, respectively. The synthesis of 
compound 44 and 45 was reported by German et al.
175
 (a postdoctoral fellow 2007-11 in Dr. 
Glennon’s Lab).  
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Scheme 2. Synthesis of compounds 43-45
a
 
 
a
Reagent: (a) trimethylacetyl chloride (for 43)/2-methylbutanoyl chloride (for 44)/acetyl chloride 
(for 45), Et3N, CH2Cl2; (b) n-butyllithium, THF; (c) (1) oxalyl chloride, Et2O, 0 °C; (2) 
methylamine, room temperature, overnight; (d) LiAlH4, THF, reflux; (e) oxalic acid, THF, Et2O, 
recrystallized from i-PrOH. 
 
Various synthetic routes were attempted for the synthesis of compounds 37 and 39. It was 
relatively difficult to incorporate the 6-bromo and 2-alkyl substituents while synthesizing the 
indole scaffold. All trials involved routes that can provide 6-bromo analogs with varying 2-
position alkyl substituents. Some of the attempts are shown in the following schemes (Scheme 3-
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7). The route shown in Scheme 3 was attempted based on the synthesis of 3-alkyl indoles.
180
 We 
tried to use a N-protected tryptamine, 61, reacting it with 2-iodobutane in the presence of zinc 
triflate, which assists in removal of the proton from the indole nucleus. No product (i.e., 62) was 
formed suggesting that 2-position alkylation is not possible even with the 3-position being 
blocked. 
  
Scheme 3. Attempt to achieve synthesis of 37 by alkylation of the N-protected tryptamine 61
a
 
 
a
Reagent: (a) di-tert-butyl dicarbonate, Et3N, THF; (b) zinc triflate, TBAB, DIPEA, 2-
iodobutane, toluene; (c) (1) oxalyl chloride, Et2O; (2) methylamine, THF, H2O; (3) 
BH3·S(CH3)2, THF; (4) salt formation. 
 
Scheme 4 represents a Fischer indole synthetic route for the synthesis of 2-substituted indoles. It 
is one of the oldest methods of indole synthesis and involves a rearrangement reaction of a 
Schiff’s base to give 2-substitued indoles. This route, however, is not favorable for obtaining 
ring-substituted indoles as intra-molecular ring closure can affect the final position of the ring 
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substituents. Attempts to perform intra-molecular ring closure of intermediate 64 were not 
successful and only starting material was recovered. We expected some sort of cyclization to 
occur but, with the recovery of starting material, we are unable to offer any possible explanation. 
 
Scheme 4. Fischer indole syntheses for the attempted synthesis of compound 37
a
 
 
a
Reagent: (a) 3-methylpentan-2-one, HOAc, MeOH; (b) 10% P2O5, CH3SO3H; (c) (1) oxalyl 
chloride, Et2O; (2) methylamine, THF, H2O; (d) BH3·S(CH3)2, THF; (4) salt formation. 
 
Another attempt to synthesize 39 was carried out by modifying the Leimgruber-Batcho indole 
synthesis as shown in Scheme 5. In this route the 2-nitrostyrene intermediate 70 should undergo 
hydrolysis to yield the phenyl ketone intermediate which can further undergo cyclization by 
reduction with Zn/HOAc. To introduce the 2-position alkyl group of 39, we subjected 69 to 
alkylation with pivaloyl chloride but the reaction was unsuccessful.
183
 A possible reason for the 
failure to synthesize 70 could be that a bulky substituent cannot be attached to the -styrene 
portion of 69.    
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Scheme 5. Modified Leimgruber-Batcho indole syntheses for the attempted preparation of 39
a
 
 
a
Reagent: (a) (1) NaNO2, HBr; (2) CuBr, HBr; (b) DMF.DMA, pyrrolidine, DMF; (c) 
trimethylacetyl chloride, Et3N; (d) (1) H2O, reflux; (2) Zn, HOAc; (e) (1) oxalyl chloride, Et2O; 
(2) methylamine, THF, H2O; (3) BH3·S(CH3)2, THF; (4) salt formation. 
 
Direct bromination was attempted to achieve regioselective bromination of the indole ring. Burm 
et al.
178
 reported the total synthesis of ()-arborescidine, a marine alkaloid in which 61 (see 
Scheme 4) was a key intermediate. Intermediate 61 was synthesized by direct bromination of the 
glyoxylamide, followed by reduction, N-protection and chromatographic separation of the 5- and 
6-bromo mixture.
178
 Scheme 6 summarizes the direct bromination route for the synthesis of 39. 
Bromination of 58 resulted in a mixture of 5- and 6-bromo compounds (73 and 72, respectively). 
Separation techniques, including flash column chromatography and preparative TLC, failed to 
separate the two isomers. A possible explanation could be because the 2-postion alkyl 
substitution makes the compounds quite lipophilic, resulting in very little difference in polarity 
of the compounds, making chromatographic separation nearly impossible.  
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Scheme 6. Direct bromination route for the attempted synthesis of 39
a
  
 
a
Reagent: (a) Br2, HOAc; (b) (1) oxalyl chloride, Et2O; (2) methylamine, THF, H2O; (3) 
BH3·S(CH3)2, THF; (4) salt formation.  
 
Scheme 7 shows an attempt to achieve the synthesis of 39 using a Grignard-based reaction for 
the cyclization. Pei at al.
184
 successfully achieved a synthetic route for the synthesis of 2-
substituted indoles with ring substitution by a [1,2]-aryl migration shift in -
chloroacetophenones. Intermediate 75 was synthesized using 3-bromoaniline (74) by reacting it 
with chloroacetonitrile in the presence of a Lewis acid, AlCl3 and BCl3. The substituted -
chloroacetophenone 75 was reacted with tert-butyl magnesium bromide to obtain 6-bromo-2-
tert-butyl-1H-indole, but here the reaction yielded total degradation indicated by numerous spots 
upon the TLC analysis with consumption of the starting material 75. The Grignard reagent route 
was successful in the synthesis of the 2-methylpropyl analog (65) (see Scheme 8). This suggests 
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that the tert-butyl Grignard reagent might be unstable in the presence of the aromatic halogens, 
especially bromine, which is very reactive with the Grignard reagent. There was loss of starting 
material and no product (i.e., 71) was formed; hence, finding modified routes for the synthesis of 
6-bromo-2-alkyl indoles were explored.  
 
Scheme 7. Grignard reagent route for the attempted synthesis of 39
a
 
 
a
Reagent: (a) chloroacetonitrile, AlCl3, BCl3, CH2Cl2; (b) tert-butyl magnesium bromide, Et2O; 
(c) ) (1) oxalyl chloride, Et2O; (2) methylamine, THF, H2O; (d) BH3·S(CH3)2, THF; (4) salt 
formation. 
 
We were finally successful in achieving the synthesis of 37 and 39 through a relatively long, but 
simple, route as shown in Scheme 8. This involved a Sonagashira coupling reaction to synthesize 
6-bromo-2-subsituted analogs. Scheme 8 summarizes the synthesis of N-methyl-6-bromo-2-tert-
butyltryptamine hydrochloride (39) and N-methyl-6-bromo-2-sec-butyltryptamine hydrochloride 
(37). Compound 37 was synthesized in collaboration with Dr. German.  
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2-Nitroaniline (76) was brominated with N-bromosuccinamide to yield 4-bromo-2-nitroaniline 
(77)
185
 which, on diazotization and reaction with KI and I2, yielded 4-bromo-2-nitroiodobenzene 
(78).
185,186
 This was further reduced with Fe and HCl to yield 5-bromo-2-iodoaniline (79).
187
 
Sonagashira coupling in the presence of the corresponding alkyne with ligand-based palladium 
catalysts was performed on 79 to yield 5-bromo-2-(3,3-dimethylbut-1-yn-1-yl)aniline (80). The 
corresponding alkyne was treated with ZnI2 to render cyclization to 6-bromo-2-tert-butyl-1H-
indole (71). Various Lewis acids can be used to perform the cyclization reaction, such as ZnBr2, 
ZnCl2, CuI, CuBr and many others.
188
 The synthesis of compound 37 was achieved via the 
Grignard reagent route where the corresponding indole was reacted with oxalyl chloride and 
methylamine via a Speeter-Anthony glyoxylamide reaction to yield N-methyl-6-bromo-2-tert-
butyl-1H-indol-3-glyoxylamide (72) and N-methyl-6-bromo-2-sec-butyl-1H-indol-3-yl-
glyoxylamide (66), which followed by reduction and formation of an HCl salt, yielded N-methyl-
6-bromo-2-tert-butyltryptamine hydrochloride (39) and N-methyl-6-bromo-2-sec-
butyltryptamine hydrochloride (37). The above routes have provided a versatile method for the 
synthesis of various 2-substituted indoles in the presence of a halogen in the indole nucleus. 
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Scheme 8. Synthesis of compounds 37 and 39
a
 
 
a
Reagents: (a) N-bromosuccinamide, EtOH, 40-50 °C, 5 h; (b) (1) BF3·Et2O, t-BuONO, THF, -
30 °C to room temperature, 1 h; (2) KI, I2, CH3CN, room temperature, 1 h; (3) Na2S2O3; (c) Fe, 
HOAc, EtOH, reflux, 1.5 h; (d) 3,3-dimethylbut-1-yne, CuI, PdCl2(PPh3)2, Et3N, THF, room 
temperature, 5 h; (e)  ZnI2, toluene, reflux, 41 h; (f) (1) oxalyl chloride, Et2O, reflux, overnight; 
(2) methylamine, THF, H2O, room temperature, 15 h; (g) (1) BH3·S(CH3)2, THF, reflux, 6 h; (2) 
HCl, Et2O, 0 °C, recrystallized from i-PrOH; (h) chloroacetonitrile, AlCl3, BCl3, CH2Cl2, 12 h 
reflux; (i) oxalyl chloride, Et2O, -5 °C, 30 min; (j) methylamine, THF, H2O, room temperature, 
overnight; (k) BH3·S(CH3)2, THF, reflux, overnight; (2) oxalic acid, CHCl3, 0 °C, 1.5 h, 
recrystallized from i-PrOH. 
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Compound 82, which is the des-bromo analog of 40, was also synthesized to compare the effect 
of the 6-bromo substituent with/without the N-methyl substituent. Compounds in Figure 12 will 
provide further evidence towards the importance of the 6-bromo and the N-methyl substituent of 
dFBr (32). 
 
Figure 12. Deconstruction of dFBr (32) at the 6-bromo and the N-methyl substituents. 
 
Scheme 9 summarizes the synthesis of compound 82. Compound 82 was synthesized by a 
relatively simple route from commercially available tryptamine (83) which was protected to 
obtain the Boc-protected tryptamine (84).
189
 Compound 84 was prenylated to yield tert-butyl-2-
(2-(1,1-dimethylallyl)-1H-indol-3-yl)ethylcarbamate (85), that, on deprotection, yielded 2-(1,1-
dimethylallyl)tryptamine hydrochloride (82) in fairly good yield. 
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Scheme 9. Synthesis of compound 82
a
 
 
a
Reagents: (a) di-tert-butyl dicarbonate, Et3N, DMF, room temperature, 20 h; (b) (1) tert-butyl 
hypochlorite, Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN, THF, room temperature, 3 h; (3) 
NaOH, H2O2, 1 h; (c) HCl, EtOAc, 0 °C, 24 h, recrystallized from i-PrOH/Et2O. 
  
 
C. Pharmacology 
Biological activities of the synthesized compounds were evaluated using two-electrode voltage 
clamp techniques employing Xenopus laevis oocytes with expressed human 42 nACh 
receptors in the absence or presence of 100 M ACh. A typical dose-response curve for the 
compounds tested on human α4β2 nACh receptors shows potentiation at lower concentrations 
and inhibitory activation at higher concentrations, but no effect in the absence of ACh. Table 3 
provides the biological results of the potentiation or antagonism (i.e., inhibition) of the action of 
ACh action at human 42 nACh receptors by dFBr (32) and its analogs. 
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Table 4. Effect of dFBr (32) and its deconstructed analogs on the action (potentiation or 
antagonism) of ACh action at the human 42 nACh receptors. 
Compound Potentiation Inhibition 
Half maximum 
potentiation 
concentration (EC50) 
(M) ( SEM) 
Half maximum 
inhibition 
concentration (IC50) 
(M) ( SEM) 
32 (dFBr) + + 0.33  0.52 150  0.20 
33 + + 7.59  3.50 12.6  3.20 
34 + + 0.14  0.69 NI
a
 
35 - + NP
b
 39.8  0.87 
36 - + NP 3.55  0.83 
37 + + 60. 5 (0.6-120) 40.7 (0.1-81) 
38 - + NP 72.4  0.79 
39   DA
c
 DA 
40 + + 0.51  0.58 NI 
41 + + 3.02  0.09 NI 
42 - - NP ND
d
 
43 + + 3.98  0.03 NI 
44 - + NP 16.6  0.28 
45   DA DA 
82   DA DA 
a
NI = Inhibition potency of the action of ACh could not be reliably determined. 
b
NP = No 
potentiation of the action of ACh. 
c
DA = Data unavailable. 
d
ND = Not determined.  = 95% 
confidence limits (CLs). n = 4. In some cases, data were provided as  SEM; in others, data were 
provided to us with 95% CLs.  
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D. Discussion 
The EC50 value obtained for dFBr (32) (0.33 M) (Table 4) in the current investigation is 
comparable to a previous report (EC50 = 0.12 M) from our laboratory, and the small difference 
might be the result of the large number of determinations carried out with 32 and experimental 
variation. Compounds 33-40 represent the first deconstructed analogs of dFBr (32) (Table 4; 
Figure 10). Comparing dFBr (32) with its des-bromo analog 33 (EC50 = 7.59 M), it is apparent 
that the 6-bromo substituent makes a substantial contribution to activity. Although removal of 
the 6-bromo substituent decreased potency by almost 20-fold, compound 33 is still active as a 
PAM at 42 nACh receptors. Thus, the 6-bromo substituent is optimal for potency but is not 
required for the PAM action of dFBr (32). Removal of the 6-bromo substituent improved the 
inhibitory action (IC50 = 12.6 M). It is notable that the removal of the 6-bromo group decreased 
the concentration range for the potentiation and the inhibition action at 42 nACh receptors 
(Table 4, 0.3 to 150 M for dFBr vs 7.6 to 12.6 M for 33, respectively). 
Next, the importance of the 2-position side chain of dFBr (32) was examined. Compounds 34, 
35, 36, and 38 were the initial analogs synthesized in our laboratory. Comparing dFBr (32) with 
34 (EC50 = 0.14 M), it is evident that chain unsaturation is not required for activity. It was 
found, however, that complete removal of the 2-position chain of dFBr (32), affording 35, 
resulted in no potentiation of the action of ACh. Compound 35 was, nevertheless, able to 
produce an inhibitory action at high concentrations (IC50 = 39.8 M). Evidently the 2-position 
substituent, or a portion thereof, is required for the potentiation of ACh action by dFBr at 42 
nACh receptors. Because compound 34 was twice as potent as its parent, dFBr (32), unsaturation 
of the side chain is not required for the action of ACh. Compound 36, retaining the propenyl side 
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chain was unable to potentiate the action of ACh, but produced relatively potent inhibition (IC50 
= 3.55 M). This indicates that at least one of the gem-dimethyl groups of dFBr (32), and not the 
unsaturation of the side chain, is important for the potentiating effect of the parent molecule, 32, 
as a PAM. Again, supportive of the notion that at least one of the gem-dimethyl groups is 
required for PAM activity, compound 38 lacked this action. Compound 37, the monomethyl 
counterpart of 34, is more than 400-fold less potent than 34 as a PAM. Hence, the gem-dimethyl 
groups seem to play a major role in PAM action.  
As in the case of compound 34, which is twice as potent as dFBr (32), compound 38, although an 
inhibitor, was almost 24-fold less potent compared to 36 in this regard suggesting a different 
mode of binding for the potentiation and antagonism at 42 nACh receptors.  
The N-des-methyl analog 40 (EC50 = 0.51 M) was half as potent as dFBr (32) (Table 4) as a 
PAM showing that the secondary amine of dFBr (32) is preferred over the primary amine of 40. 
Comparing compounds 32, 33, 40 and 82 it can be predicted that compound 82, which lacks the 
6-bromo and the N-methyl substituent, will be less potent than 33 and 40 although data have not 
yet been obtained for compound 82. It would appear that some steric bulk is tolerated at the 
terminal amine. Thus, most of the deconstructed analogs of dFBr (32) to be examined henceforth 
will retain the N-methyl group as seen in 32 (Figure 13). 
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Figure 13. Initial deconstruction of dFBr (32). Each arrow symbolizes a single structural change. 
Data are from Table 4. Certain analogs did not potentiate the effect of ACh at 42 ACh 
receptors at their highest concentration evaluated (i.e., 100 M). 
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Reconstruction. Up to this point, several structural features were found optimal for PAM action: 
a) an N-methyl amine, b) a 6-bromo substituent, and c) a 2-position substituent consisting of a 
quaternary carbon (Figure14).  
 
Figure 14. Deconstruction of dFBr (32) revealing the structural requirement for action. a) A 
secondary amine is optimal, b), a 6-bromo substituent is required for potency but not action, and 
c) a 2-position quaternary carbon is required for activity as a PAM at 42 nACh receptors. 
 
The next goal was a more detailed examination of 2-position substituents. Synthetically, to 
incorporate 2-position substituents with a 6-bromo group, is a challenge. Also, the des-bromo 
derivative 33 was active; thus, a relatively simpler route for the synthesis of various analogs of 
dFBr (32) which will help understand what portion of the 2-position substituent is required for 
the potentiation action of ACh was undertaken. The intent was to optimize the 2-position 
substituent for a 6-desbromo analog, and then to add a bromo group to the optimized 
compound(s). Compound 33 was further deconstructed to compounds 41-45 (Figure 15; Table 4) 
of which only compound 41 and 43 showed potentiation of the activity of ACh (41; EC50 = 3.02 
M and 43; EC50 = 3.98 M). Comparing compounds 32 and 33 with 34 and 41, respectively, it 
was observed that there is a similar trend where the saturated analogs, 34 and 41, are twice as 
potent as the parent molecules, 32 and 33, respectively. This information allows us to avoid the 
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unsaturation of dFBr which can prove to be a synthetic advantage for synthesizing simpler 
analogs. Compounds 42-44 (Table 4) provided information about the gem-dimethyl system of 
the 2-position substituent of dFBr (32). It was observed that the gem-dimethyl groups are 
important for the potentiation property of dFBr (32). Compound 44, which has a 2-methylpropyl 
side chain, was inactive as a PAM, but showed antagonist properties (IC50 = 16.6 M). 
Comparing compounds 42, having a 2-iso-propyl side chain, and 43 having a 2-tert-butyl side 
chain, it was seen that, although both the analogs possess a gem-dimethyl group, the presence of 
a quaternary carbon at the 2-position in 43 is what provides the potentiation property as a PAM 
at 42 nACh receptors. In simple terms it can be concluded that, for potentiation, the presence 
of a 2-position quaternary carbon atom is required whereas for the inhibitory/antagonistic effect, 
a propyl or a mono-substituted propyl substituent is tolerated (Figure 15). 
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Figure 15. Deconstruction of 33 to determine the role of the 2-position substituent on the PAM 
action of ACh at nACh receptors. Data are from Table 4. 
 
In the reconstruction process, we synthesized compound 39 which bears all the regional features 
shown in Figure 14. Although it was expected that the 2-tert-butyl compound 39 would be more 
potent than its des-bromo parent 43, data have not yet been obtained for this compound. 
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V. Results and discussion of elaboration of dFBr 
 
 
The elaboration step sought answers to several questions such as, for example: a) is a tertiary 
amine tolerated, b) is a quaternary amine tolerated (note: ACh is a quaternary amine) (Figure 
16), c) is the indolic N-H a contributor to action (Figure 16), d) what is the specific role of the 6-
bromo group, e) is the position of attachment of the bromo group important for activity (Figure 
17)? That is, the elaboration step introduced substituents not found in dFBr (32). 
 
A. Chemistry 
Several analogs of dFBr (32) were synthesized in collaboration with others in our laboratory 
concurrent with the present investigation. For example the synthesis of compounds 97-100 were 
synthesized in collaboration with Dr. German (a postdoctoral fellow in Dr. Glennon’s lab). 
Scheme 10 summarizes the synthesis of 86 and 87. Compound 40 was used as the starting 
material which was converted to its free base and subjected to Eschweiler-Clarke reaction with 
formic acid and formaldehyde to yield N,N-dimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine 
(101). The latter was converted to the oxalate salt to yield 86. Compound 101 was further 
methylated with iodomethane to yield N,N,N-trimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine 
methiodide (87) (Scheme 10). Direct quaternization of 40 resulted in the reaction not going to 
completion and yielded a mixture of mono and di-methylated side products under varying 
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conditions; from room temperature to reflux and varying equivalence of iodomethane; 3 to 10. 
Thus, a 2-step approach was adopted for the synthesis of 87. 
 
 
Figure 16. Elaborated analogs of dFBr (32) proposed for the synthesis and evaluation. For 
example compound 86, 87, 91 and 92 can provide information on the steric bulk tolerated on the 
amine, whereas compound 88 and 89 can provide information on the chain length while 
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compound 90 can provide information about the -substitution on the tryptamine side chain 
required for PAM action at the 42 nACh receptors. 
  
 
Figure 17. Elaborated analogs of dFBr (32) proposed for the synthesis and evaluation. For 
example, compounds 93-96 can provide information on the importance of indolic N-H, whereas 
compound 98 can provide information on the position of the bromo substituent and its 
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importance towards the activity. Compounds 99 and 100 on the other hand can provide 
information about the specific role of the 6-bromo substituent required for PAM action at the 
42 nACh receptors. 
 
Scheme 10. Synthesis of compounds 86 and 87
a
 
 
a
Reagents: (a) Formic acid, formaldehyde (37% v/v), H2O, reflux, 3 h; (b) Oxalic acid, CHCl3, 0 
°C, 1.5 h, recrystallized from i-PrOH/Et2O; (c) iodomethane, i-PrOH, 0 °C to room temperature, 
22 h, recrystallized from MeOH/i-PrOH. 
 
Synthesis of the homotryptamine analog (i.e., 89) and the 3-position des-methyl gramine side 
chain analog (i.e., 88) (Figure 16) was attempted. The instability of the des-methyl gramine 
analog 88 was a major issue, the product could not be isolated and, thus, the compound was not 
pursued any further. It was found that compound 86 (Scheme 10) was active (see discussion 
below) and thus, to see the effect of shortening of the tryptamine chain, compound 102 was 
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synthesized. Gramines (indole-3-yl-N,N-dimethylmethylamines) are stable and can be 
synthesized to obtain substitution on the indole nucleus. Similarly, to understand the role of 
extension of the tryptamine side chain, compound 103 was considered, which is a des-bromo 
analog of 89. This particular compound was considered based on the knowledge that the 6-
bromo substituent in dFBr (32) is required for potency, but not PAM action. Compound 104 was 
considered instead of 90 (Figure 16) based on the data that the primary amine (40) is only half as 
potent as dFBr (32) (see Table 3) and also because of the ease of synthesis of 104 compared to 
90.   
  
Compound 102 was synthesized by Dr. German. Scheme 11 summarizes the synthesis of 
compound 103. Indole-3-propionic acid (105) was treated with methyl chloroformate and then 
with methylamine hydrochloride to yield the known N-methyl-3-(1H-indol-3-yl)propanamide 
(106)
190
 which was further reduced with LiAlH4 to yield N-methyl-3-(1H-indol-3-
yl)propanamine (107).
191
 The amine was protected by di-tert-butyl dicarbonate in the presence of 
Et3N to yield tert-butyl-3-(indol-3-yl)propyl-N-methylcarbamate (108). Upon further treatment 
of 107 with freshly prepared prenyl-9-BBN in the presence of tert-butyl hypochlorite and Et3N, 
the reaction yielded tert-butyl-3-(2-(1,1-dimethylallyl)-1H-indol-3-yl)propyl-N-methylcarbamate 
(109), which was deprotected and converted to an oxalate salt to yield N-methyl-3-(2-(1,1-
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dimethylallyl)-indol-1H-yl)propanamine oxalate (103). Although homogeneous in thin-layer 
chromatographic analysis (Rf = 0.4 in CH2Cl2/MeOH/NH3 10:1:01), elemental analysis for 103 
was not within the permissible range of 0.4% (Anal. Calcd for (C17H24N2·C2H2O4) C, 65.87; H, 
7.56; N, 8.09. Found: C, 62.95; H, 7.12; N, 7.62). The oxalate salt can exist in different ratios 
with the free base (e.g., 1 mol of free base and 1 mol of oxalate or 1 mol of free base and 0.5 mol 
of oxalate). The 
1
H NMR spectrum didn’t indicate the presence of water in the sample. The MS 
of 103 revealed a molecular base peak of 257.15 (the same as the M+1 of the free base of 103). 
The mass peak of the oxalate ion will not be seen in the MS because the salt is ionic and at high 
temperature will be converted to CO2. Thus, on the basis of a constant melting point on repeated 
recrystallization with i-PrOH, the molecular base peak in the mass spectrum (all the hydrogen 
atoms in the molecular structure accounted for in the NMR spectrum) it was concluded that 103 
had been obtained. 
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Scheme 11. Synthesis of compound 103
a
 
 
a
Reagents: (a) (1) methyl chloroformate, Et3N, THF, 0 °C, 30 min; (2) methylamine HCl, 0 °C, 
1.5 h; (b) LiAlH4, dioxane, reflux, overnight; (c) di-tert-butyl dicarbonate, Et3N, CH2Cl2, room 
temperature, 19 h; (d) (1) tert-butyl hypochlorite, Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN, 
THF, room temperature, 2 h; (3) NaOH, H2O2, 1 h; (e) oxalic acid, Et2O, recrystallized from i-
PrOH. 
 
Scheme 12 summarizes the synthesis of compound 104. 6-Bromo-1H-indole-3-carboxaldehyde 
(110) underwent a Henry reaction in the presence of nitroethane and ammonium acetate as a 
weak base to yield 3-[(E)-2-nitroprop-1-en-1-yl]-6-bromo-1H-indole (111).
176
 Further reduction 
with NaBH4 in the presence of a Lewis acid yielded the corresponding -methyltryptamine 
(112), which was Boc-protected to yield tert-butyl-1-(6-bromo-1H-indol-3-yl)propyl-2-
carbamate (113). The 2-dimethylallyl substituent was introduced by a prenylation reaction to 
yield tert-butyl-1-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)propyl-2-carbamate (114) 
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which, on acidic deprotection, yielded 1-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)propan-
2-amine hydrochloride (104).  
 
Scheme 12. Synthesis of compound 104
a
 
 
a
Reagents: (a) Nitroethane, NH4Ac, reflux, 7 h; (b) NaBH4, BF3·Et2O, THF, reflux, 4 h; (c) di-
tert-butyl dicarbonate, Et3N, CH2Cl2, room temperature, 24 h; (d) (1) tert-butyl hypochlorite, 
Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN, THF, room temperature, 3 h; (3) NaOH, H2O2, 1 
h; (e) HCl, Et2O, 0 °C, 24 h, recrystallized from i-PrOH/Et2O. 
 
Scheme 13 summarizes the synthesis of compounds 91 and 92. The N-alkyl analogs of dFBr (32) 
were synthesized following a similar route where oxalyl chloride was reacted with 6-
bromoindole to yield the glyoxylyl chloride, which was further treated with the appropriate 
amine, iso-propylamine and benzylamine, respectively, to yield the corresponding glyoxylamides 
(115, 116) which, on reduction with borane dimethylsulfide complex, yielded the respective 
tryptamines (117, 118). Further treatment of 117 and 118 with di-tert-butyl dicarbonate in the 
presence of Et3N to yielded the Boc-protected tryptamines (119, 120) which were treated with 
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freshly prepared prenyl-9-BBN in the presence of tert-butyl hypochlorite and Et3N to yield the 
tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-isopropylcarbamate (121) 
and tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-benzylcarbamate (122), 
respectively. Compound 121 was deprotected and converted to an HCl salt to yield N-iso-propyl-
6-bromo-2-(1,1-dimethylallyl)tryptamine hydrochloride (91), while 122 was deprotected by 
using TFA and converted into a oxalate salt to yield N-benzyl-6-bromo-2-(1,1-
dimethylallyl)tryptamine hydrogen oxalate (92). It was observed that the bulkier N-alkyl 
substituent, benzyl group compared to the isopropyl group, lowered the yield of the various 
reactions involved in the reaction scheme. 
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Scheme 13. Synthesis of compounds 91 and 92
a
  
 
a
Reagents: Compound 91 (a) (1) oxalyl chloride, Et2O, -15 °C, 15 min, room temperature, 2 h; 
(2) iso-propylamine, room temperature, overnight; (b) BH3·S(CH3)2, THF, reflux, 5 h; (c) di-tert-
butyl dicarbonate, Et3N, DMF, room temperature, overnight; (d) (1) tert-butyl hypochlorite, 
Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN, THF, room temperature, 4 h; (3) NaOH, H2O2, 1 
h; (e) HCl, EtOAc, 0 °C, 24 h, recrystallized from MeOH. 
 
Compound 92 (a) (1) oxalyl chloride, Et2O, -10 °C, 5 min, room temperature, 2 h; (2) 
benzylamine, room temperature, 3 h; (b) BH3·S(CH3)2, THF, reflux, 6 h; (c) di-tert-butyl 
dicarbonate, Et3N, DMF, room temperature, 24 h; (d) (1) tert-butyl hypochlorite, Et3N, THF, -78 
°C, 45 min; (2) prenyl-9-BBN, THF, room temperature, 6 h; (3) NaOH, H2O2, 1 h; (f) (1) TFA, 
anhydrous CH2Cl2, room temperature 6 h; (2) oxalic acid, Et2O, recrystallized from i-PrOH. 
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Scheme 14 summarizes the synthesis of compounds 93 and 94 where oxalyl chloride was reacted 
with 6-bromoindole (46) to yield the glyoxylyl chloride, which was further treated with 
methylamine to yield N-methyl-6-bromo-1H-indol-3-glyoxylamide (123). This, on reduction 
with a borane dimethylsulfide complex, yielded N-methyl-6-bromotryptamine (35). Further 
treatment with di-tert-butyl dicarbonate in the presence of Et3N to yielded tert-butyl-2-(6-bromo-
1H-indol-3-yl)ethyl-N-methylcarbamate (61) which was treated with freshly prepared prenyl 9-
BBN
177
 in the presence of tert-butyl hypochlorite and Et3N to yield tert-butyl-2-(6-bromo-2-(1,1-
dimethylallyl)-1H-indol-3-yl)ethyl-N-methylcarbamate (124). This product was further 
methylated at the indole 1-position with iodomethane in the presence of NaH to yield tert-butyl-
2-(6-bromo-1-methyl-2-(1,1-dimethylallyl)-indol-3-yl)ethyl-N-methylcarbamate (125), which 
was deprotected and converted to an HCl salt to yield N-methyl-6-bromo-1-methyl-2-(1,1-
dimethylallyl)tryptamine hydrochloride (93). In a similar manner, 124 was alkylated with benzyl 
bromide in the presence of NaH to yield tert-butyl-2-(6-bromo-1-benzyl-2-(1,1-dimethylallyl)-
indol-3-yl)ethyl-N-methylcarbamate (126), which was deprotected by TFA and converted to an 
oxalate salt to yield N-methyl-6-bromo-1-benzyl-2-(1,1-dimethylallyl)tryptamine hydrogen 
oxalate (94).  
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Scheme 14. Synthesis of compound 93 and 94
a
 
 
a
Reagents: (a) (1) oxalyl chloride, Et2O, 0 °C, 2 h; (2) methylamine, room temperature, 2 h; (b) 
BH3·S(CH3)2, THF, reflux, 6 h; (c) di-tert-butyl dicarbonate, Et3N, DMF, room temperature, 24 
h; (d) (1) tert-butyl hypochlorite, Et3N, THF, -78 °C, 45 min; (2) prenyl-9-BBN, THF, room 
temperature, 2 h; (3) NaOH, H2O2, 1 h; (e) (1) NaH, DMF, 0 °C, 30 min; (2) CH3I, 1.5 h; (f) 
HCl, EtOAc, 0 °C, 7 h, recrystallized from MeOH; (g) (1) NaH, DMF, 0 °C, 45 min; (2) 
benzylbromide, room temperature, 5.5 h; (h) (1) TFA, CH2Cl2, 0 °C, 2.5 h; (2) oxalic acid, Et2O, 
recrystallized from i-PrOH. 
 
 
Various unsuccessful attempts were made to synthesize compound 95 (Figure 17). The problem 
reaction was the attachment of the 2-position dimethylallyl group in the presence of the 1-
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position substitution or vice versa. Various conditions were tried but none yielded the N-
methylethanamine side chain at the 1-position of the indole ring. While attempting the synthesis 
of 95, biological results for compound 86 were obtained (Table 4) which showed that the N,N-
dimethyl analog of 40 was active (see discussion); thus compound 127 was proposed. On similar 
lines, compound 96 was modified to its N,N-dimethyl analog, 129. Scheme 15 summarizes the 
synthesis of compound 127.  
 
5-Bromoindole (129) was brominated in presence of bromine to yield 3,5-dibromoindole 
(130),
192
 which was further treated with freshly prepared prenyl 9-BBN in the presence of Et3N 
to yield 5-bromo-2-(1,1-dimethylallyl)-1H-indole (131)
179,193
 Compound 131 was alkylated at 
the 1-position by N,N-dimethylaminoethyl chloride hydrochloride in the presence of NaH 
followed by salt formation to yield N,N-dimethyl-5-bromo-2-(1,1-dimethylallyl)isotryptamine 
hydrogen oxalate (127).  
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Scheme 15. Synthesis of compound 127
a
 
 
 
a
Reagent: (a) Br2, DMF, light protected, room temperature, 12 h; (b) prenyl-9-BBN, Et3N, THF, 
room temperature, 4 h; (c) (1) NaH, DMF, 0 °C, 30 min; (2) N,N-dimethylaminoethyl chloride 
hydrochloride, KtBuO, KI, reflux, 17 h; (3) oxalic acid, Et2O, recrystallized from MeOH/Et2O. 
 
Scheme 16 summarizes the unsuccessful attempt to synthesize the benzimidazole analog 128.  
Various unsuccessful attempts were made to attach the N,N-dimethylethanmine side chain to the 
5-bromo-2-(1,1-dimethtylallyl)-benzo[d]imidazole moiety. Scheme 16, however, provided a 
route for the synthesis of 5-bromo-2-(1,1-dimethtylallyl)-benzo[d]imidazole (136). The synthesis 
of the benzimidazole analog (136) was discontinued when it was found that the N-H of the 
indole was important towards the potency at the nACh receptors (see discussion below) 
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Scheme 16. Attempted synthesis of compound 130
a
 
  
a
Reagent: (a) LDE, THF, dimethyl sulphate, -78°C to 0°C, 1.5 h; (b) oxalyl chloride, CH2Cl2, 
DMF, room temperature, 16 h; (c) DCC, DMAP, CH2Cl2, reflux, 19 h; (d) Fe, HOAc, reflux, 7 h. 
 
 
Based on the results obtained for compound 102 (see discussion below) two more compounds; 
137 and 138, were synthesized to develop pairs of molecules in different classes of compounds 
(e.g., 33 and 137; 38 and 138).   
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Scheme 17 summarizes the synthesis of compound 137. The indole (139) was brominated in the 
presence of bromine to yield 3-bromoindole (140) which was further treated with freshly 
prepared prenyl-9-BBN in the presence of Et3N which undergoes a nucleophile substitution 
reaction where the 3-bromo substituent activates the 2-postion of the indole ring to yield 2-(1,1-
dimethylallyl)-1H-indole (141). Compound 141 was further treated with dimethylamine and 
formaldehyde in a Mannich fashion to yield the corresponding gramine that was converted to the 
oxalate salt to yield 2-(1,1-dimethylallyl)gramine oxalate (137).  
 
Scheme 17. Synthesis of compound 137
a
 
 
a
Reagents: (a) Liquid Br2, DMF, room temperature, 24 h; (b) prenyl-9-BBN, THF, Et3N room 
temperature, 5 h; (c) (1) dimethylamine, HCHO, room temperature, overnight; (2) oxalic acid, 
Et2O, recrystallized from i-PrOH. 
 
Scheme 18 summarizes the synthesis of compound 138. The synthetic route was similar to 
Scheme 8 which yielded compounds 37 and 39. Sonagashira coupling was performed in the 
presence of the corresponding alkyne and ligand-based palladium catalysts provided 5-bromo-2-
(1-pentynyl)aniline (142). The corresponding alkyne was treated with ZnI2 to effect cyclization 
to yield 6-bromo-2-propyl-1H-indole (143).  Compound 143 was treated with dimethylamine and 
formaldehyde in the presence of ZnI2 to undergo a Mannich reaction to yield the corresponding 
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gramine, which was converted to an oxalate salt to yield 6-bromo-2-propylgramine hydrogen 
oxalate (138).  
 
Scheme 18. Synthesis of compound 138
a
 
 
a
Reagents:  (a) 1-pentyne, CuI, PdCl2(PPh3)2, Et3N, THF, room temperature, overnight; (b) ZnI2, 
Toluene, reflux, 2.5 h; (c) (1) Formic acid, dimethylamine, ZnI2, EtOH, room temperature, 24 h; 
(2) oxalic acid, Et2O, recrystallized from i-PrOH.  
 
Based on the results obtained for compound 98 (see discussion below), compound 144 was 
prepared. Scheme 19 summarizes the synthesis of compound 144. Parsons; et al.
194
 in 2011, 
published a method to synthesize 5,6-dibromo indoles as an important building block for the 
synthesis of various alkaloids. We were able to replicate the two-step reaction where the 
commercially available methyl-1H-indole-3-carboxylate (145) was brominated using bromine 
and HOAc as the solvent to obtain methyl-5,6-dibromo-1H-indole-3-carboxylate (146) with a 
melting point matching the literature.
194
 This was one of the few reactions ever reported to 
synthesize a 5,6-dibrominated indoles. Decarboxylation was achieved by performing a 
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microwave-assisted reaction to obtain 5,6-dibromo-1H-indole (147).
194
 Oxalyl chloride was 
reacted with 5,6-dibromo-1H-indole to yield the glyoxylyl chloride, which was further treated 
with methylamine to yield N-methyl-5,6-bromo-1H-indol-3-glyoxylamide (148). This 
compound, upon reduction with a borane dimethylsulfide complex, yielded N-methyl-5,6-
dibromotryptamine (149). Further treatment with di-tert-butyl dicarbonate in the presence of 
Et3N yielded tert-butyl-2-(5,6-dibromo-1H-indol-3-yl)ethyl-N-methylcarbamate (150), which 
was treated with freshly prepared prenyl 9-BBN in the presence of tert-butyl hypochlorite and 
Et3N to yield tert-butyl-2-(5,6-dibromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-
methylcarbamate (151). Compound 151 was deprotected and converted to an HCl salt to yield N-
methyl-5,6-dibromo-2-(1,1-dimethylallyl)tryptamine hydrochloride (144). 
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Scheme 19. Synthesis of compound 144
a
 
 
 
a
Reagents: (a) Liquid Br2, HOAc, room temperature, 16 h; (b) KOH, MeOH, H2O, THF, MW 
100 W, 150 °C, 1 h; (c) (1) oxalyl chloride, Et2O, -5 °C 15 min, reflux 5 h; (2) methylamine, 
room temperature, overnight; (d) BH3·S(CH3)2, THF, reflux, 7 h; (e) di-tert-butyl dicarbonate, 
Et3N, DMF, room temperature, 24 h; (f) (1) tert-butyl hypochlorite, Et3N, THF, -78 °C, 1.5 h; (2) 
prenyl-9-BBN, THF, room temperature, 6 h; (3) NaOH, H2O2, 2 h; (g) HCl, EtOAc, 0 °C, 24 h, 
recrystallized from i-PrOH. 
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B. Pharmacology 
 
Function data for dFBr (32) analogs are provided in Table 5.  
 
 
Table 5. Effect of dFBr (32) and its elaborated analogs on the action (potentiation or 
antagonism) of ACh action at the human 42 nACh receptors. 
Compound Potentiation Inhibition 
Half maximum 
potentiation 
concentration (EC50) 
(M) ( SEM) 
Half maximum inhibition 
concentration (IC50) (M) 
( SEM) 
dFBr (32) + + 0.33  0.52 150  0.2 
86 + - 9.7 (2.3-17.1)
b
  146.5 (15.9-280)
b
 
87 - + - 2.48 (1.6-3.3)
b
 
91   DA
a
 DA 
92   DA DA 
93 + + 4.30  1.4 35.0  2.0  
94   DA DA 
97 + + 7.40  0.1 14.0  .8 
98 + + 0.90  0.5 32.0  0.6 
99 + - 2.40  0.2 25.0  21.0 
100 + - 0.90  0.1 19.5  0.9 
102 - + - 1.8  0.7 
103   DA DA 
104   DA DA 
127 + + 11.2  0.5 71.0  1.0 
137 - + - 17.9 (3.1-32.6)
b
  
138 - + - 17.8 (3.1-32.6)
b
 
144   DA DA 
a
DA = Data currently unavailable, 
b
95% confidence limits, n = 4. Note: where both potentiation 
and inhibition was observed, inhibitory potencies (IC50 values) are only estimates. 
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C. Discussion 
Compounds 86-100, 102-104, 127, 137, 138 and 144 represent elaborated analogs of dFBr (32) 
(Table 5; Figure 16 and 17); that is, they possess substituents uncommon to dFBr (32). 
Comparing dFBr (32) with 86 (Figure 18; EC50 = 9.7 M), it is evident that the N,N-dimethyl 
tertiary amine 86 is around 30-fold less potent than the secondary amine of dFBr (32). This 
suggests that either the tertiary amine or steric bulk at the terminal amine may cause the decrease 
in potency compared to dFBr (32). Interestingly with respect to effect, 86 enhanced the action of 
ACh at 42 nACh receptors by 300% (Figure 18). This is similar to what was found for dFBr 
(32) itself.
9
 Hence, N-methylation of dFBr (32) decreased its potency, but had no effect on its 
efficacy. 
 
 
Figure 18. Biphasic dose-response curve for compound 86 co-applied with 100 M ACh on 
human 42 nACh receptors. 
 
Compounds 91, which has an N-iso-propyl substituent, and 92, which is an N-benzyl analog, will 
help answer questions regarding the tolerance of steric bulk at the amine region of dFBr (32). 
Data have not yet been obtained for compounds 91 and 92.  
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The 42 nACh receptors are ion channel in nature with ACh being the endogenous ligand. ACh 
is a quaternary amine; thus, it was worthwhile to check the effect of a quaternary amine analog 
of dFBr (i.e., 87) on the activity of ACh at the 42 nACh receptors. It was found that 
compound 87 failed to potentiate the action of ACh, but was a relatively potent antagonist (Table 
5; IC50 = 2.5 M). 
 
Figure 19. Initial elaboration of dFBr (32). Data are from Table 5. Certain analogs did not 
potentiate the effect of ACh at nACh receptors, but blocked the effect of ACh. 
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Given its unusually high potency as an inhibitor, coupled with its quaternary nature, 87 might be 
a competitive antagonist. Its affinity at 42 nACh receptors remains to be measured. 
The gramine analog of dFBr (102) also showed no potentiation of action, but inhibited ACh 
action (Table 5, Figure 19; IC50 = 1.8 M). It might be proposed that the binding modes of dFBr 
(32) and 102 can be different and that 102 might be a member of an altogether different 
mechanistic class of compounds. Compound 102 was also further studied to see what 
substituents can be tolerated and yet retain the inhibition profile of the gramine analog of dFBr 
(32). The two series; 32 and 102 were studied to bring about a parallel structural change. A 
parallel change in structure should result in a parallel change in potency if the two series are 
behaving in the same manner. Figure 20 summarizes the compounds that were examined to 
rationally understand the effect of substituents on the action of ACh. It is rather interesting that 
gramine 102 is an antagonist that lacks the PAM action of dFBr (32). Apparently, the 6-bromo 
group is neither a requirement for PAM action (comparing 33 with 32) nor a requirement for 
blocking action (comparing 137 with 102) (Figure 20). But, whereas the gem-dimethyl groups 
appear required for PAM action of 32, they are not required for the blocking action (i.e., both 38 
and 138 behaved only as blockers with no action as PAMs). 
It might be concluded that shortening the tryptamine chain of dFBr-like compounds and not the 
presence of the N,N-dimethylamine accounts for the elimination of PAM action, because the 
N,N-dimethyl counterpart of dFBr (32), i.e., 86, retains such action. Likewise, comparing the 
des-bromo analog 33 with des-bromo gramine analog 137, it is apparent that the 6-bromo 
substituent is not required for potency as an inhibitor for dFBr-like compounds, whereas the lack 
of a 6-bromo substituent as in the des-bromogramine analog 137 decreases potency as an 
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inhibitor of ACh action. The tryptamine series and the gramine series appear to act very 
differently (i.e., some tryptamines lack PAM action, whereas all gramines examined lacked this 
action) and the SAR for their actions appear independent. Gramine analogs should be further 
explored to optimize this structurally diverse class of compounds behaving as blockers (potential 
NAMs?) at the 42 nACh receptors.  
 
 
Figure 20. Comparison of the two series of analogs; dFBr (32) and 102. Data for 32, 33, and 38 
are from Table 4; data for 102, 137, 138 are from Table 5. 
 
Comparing compounds 97, which has a piperidine substituent at the 3-position, 102, which is a 
gramine analog, and 103, which is a homotryptamine analog of dFBr (32), will help us 
understand the effect of changing tryptamine chain length. Comparing dFBr (32) with compound 
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97 (Table 5; EC50 = 7.4 M), it can be hypothesized that the 20-fold decrease in potency could 
be attributed to the slight elongation of the distance between the terminal amine and the indole 
nucleus (2-carbon length for dFBr vs the 2.5-carbon length for the piperidine moiety), or the -
substitution on the tryptamine chain. Thus, compound 103, which is the homotryptamine analog, 
and 104, which is a -methyl substituted analog, respectively, will be able to address each 
question individually to provide insight into the chain length and -substitution tolerance on the 
dFBr (32) and potency. 
It is known that the 6-bromo substituent of dFBr (32) makes a substantial contribution to activity. 
To further understand whether the effect of the 6-bromo substituent is due to a steric or 
electronic effect, compounds 99, which is a 6-methyl analog, and 100, which is a 6-
trifluoromethyl analog, were synthesized. Comparing 32, 99 and 100 (Figure 21) it is unclear 
whether an electronic or steric effect is predominant for activity. Additional compounds will be 
required to conduct a thorough QSAR study. 
Compound 98 in which the position of the bromo substituent was changed, did not substantially 
affect potency (Figure 21; Table 5; EC50 = 0.9 M). This suggests that there could be 
steric/electronic properties of the 5-position substituent that can be explored. The similarity in 
potency could be attributed to either steric or electronic properties of the bromo substituent. Also 
the 5- and 6-bromo compounds can be binding differently to produce their action as a PAM. 
Data for compound 144 will help answer the question of bulk tolerance at the 5- and 6-position 
of dFBr (32). It will also help understand if the 5- and 6-bromo analogs bind similarly at the 
receptor site. The 5-bromo analog 98 is an early example of exploration of the positions on the 
indolic ring that can be tolerated. Also with the 6-bromo and the 5-bromo analog being almost 
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equipotent (Table 5; 32; EC50 = 0.33 M, 98; EC50 = 0.87 M), by having both substituents in 
one compound (146), an increase in potency might be seen. Data for compound 144 has not yet 
been obtained. 
The importance of the N-H of the indole nucleus was addressed. Compound 93 (Table 5; EC50 = 
4.3 M), N1-methyl dFBr, was almost 13-fold less potent than dFBr (Table 5; 32; EC50 = 0.33 
M) suggesting that the N-H of the indole might be involved as a hydrogen-bond donor making 
an important hydrogen bond interaction with the amino acids in the receptor. This hypothesis 
was further strengthened when compound 127 (Table 5; EC50 = 11.2 M) was found to be almost 
34 times less potent than dFBr (32). However, the lower potency of compound 127 could also be 
due to the translocation of the indolic nitrogen atom and/or the presence of a substitution on the 
tertiary amine. However, the potency of 127 was similar to that of N-methyl dFBr (86; EC50 = 
9.7 M). The comparison of compounds 32, 93 and 127 helps us understand that a hydrogen 
bond donor might be important for the potency of dFBr (32) (Figure 21). 
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Figure 21. Elaborated analogs of dFBr (32). Data are from Table 5. Certain analogs did not 
potentiate the effect of ACh at ACh receptors. 
 
Radiolabelled dFBr 
Compound 40 was used as an intermediate and submitted for commercial tritiation to obtain 
[
3
H]dFBr (in Dr. Jonathan B. Cohen’s laboratory at Harvard Medical School).195 The tritiated 
dFBr (152) is the first radiolabelled positive allosteric modulator at 42 nACh receptors. All 
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the studies performed on dFBr (32) involved only the CNS 42 nACh receptors, while the 
peripheral muscle type receptor was not characterized. At the muscle type 42 ACh receptor, 
it was found that dFBr (32) does not activate nor potentiate the ACh response when expressed in 
Xenopus oocytes. Instead it was found to be a potent inhibitor (IC50 = 1 M). dFBr (32) was also 
found to reversibly inhibit the binding of [
3
H]phencyclidine (IC50 = 4 M) with higher affinity  
in the desensitized state than in the resting state ([
3
H]ACh, IC50 = 1 mM).
195
 Photolabeling 
studies performed with [
3
H]dFBr (152) highlight certain amino acids in the ion channel (M2 
helix): in the ACh binding orthosteric site on the -subunit (Tyr93, Tyr190 and Tyr198) as well 
to a site near the orthosteric ACh binding site on the  subunit (Tyr105, Tyr111 and Tyr117) in 
the presence and absence of ACh. This data shows dFBr as a potent inhibitor of muscle-type 
42 ACh receptor that acts as a channel blocker by binding in the channel pore. Studies are 
underway to identify possible binding site(s) for the PAM at 42 nACh receptor. 
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D. Antagonism of the ACh response 
In biological studies dFBr (32) produces a biphasic dose-response curve (Figure 8). The biphasic 
response provides information about the potentiation (EC50) as well as inhibition (IC50) of ACh’s 
effect. The biphasic dose-response curve has an overlay between the potentiation and inhibition 
profile and sometimes it is relatively difficult to define the two regions. Ideally, the biphasic 
dose-response curve should have a wide concentration range and a broad plateau to allow a 
definite demarcation of the potentiation and inhibition profile. Some analogs that were tested did 
not allow for an accurate estimation of the potentiation and inhibition profile. A more accurate 
IC50 value can be obtained for those compounds that only produced an antagonist effect. For 
purpose of establishing a preliminary SAR for the antagonistic action of dFBr (32), a high 
standard deviation was accepted and the IC50 values were compared. The aim of examining 
structural analogs of dFBr (32) was to determine similarities and differences for agonist vs 
antagonist SAR. Figure 22 summarizes dFBr (32) and its analogs. Comparing dFBr (32) with 37, 
which has a 2-methylpropyl substituent, and 36, with a 2-propenyl substituent, it is evident that 
the gem-dimethyl groups are not required for the antagonist action at 42 nACh receptors. In 
fact, compound 38 (lacking the methyl group of 37) was as potent as 37 as an antagonist. 
Removal of the 6-bromo group of dFBr (i.e., 33) resulted in almost a 12-fold increase in 
inhibitory action. The removal of the 6-bromo group of 37 (i.e., 44) seems to be tolerated and the 
resulting compound is 3-fold more potent than 37 as an inhibitor. N-Methyl dFBr (86) showed no 
change in potency compared to dFBr (32) while the gramine analog 102 was almost 80-fold 
more potent as an inhibitor. Thus, the gramine analog 102 attributes its relative potency as an 
antagonist to the shortening of the tryptamine side chain rather than to the N,N-dimethyl amine 
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found in 86. In the gramine series (compounds 102, 137 and 138), it can be concluded that the 
removal of the 6-bromo group is tolerated and is not required for action. Similarly the gem-
dimethyl groups are not essential for potency as an antagonist (comparing 137 and 138).  
 
Figure 22. Analogs of dFBr (32) comparing the inhibition of the ACh-induced response. Each 
arrow symbolizes a structural change. Data are from Tables 4 and 5. 
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As seen in Figure 22, comparing dFBr (32) and quaternary amine 87, it is seen that the 60-fold 
increase in potency of 87 is due to the quaternary amine, suggesting that the electronic nature of 
the amine is important towards the activity (inhibition), along with greater bulk at the amine 
region. An observation that needs to be further explored. The 1-methyl analog of dFBr (93) was 
shown to have a 10-fold decrease in PAM potency (Table 6; EC50 = 4.3 M), but an improved 
inhibition potency by almost 4-fold (Table 6; IC50 = 35 M). So it can be predicted that the steric 
bulk at the N1-position is not favored for potentiation but it is tolerated for inhibition of ACh 
action at 42 nACh receptors. Comparing dFBr (32) and the 1-methyl analog (93), it can also 
be concluded that the hydrogen bond donor property of the indolic N-H might be important for 
potentiation, while the hydrogen bond acceptor property of the substituted N1-position of the 
indole could be favoring the inhibition of the ACh-induced action at the 42 nACh receptors. 
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Table 6. Effect of dFBr (32) and its analogs on inhibition of ACh action at the human 42 
nACh receptors. 
Compound Potentiation Inhibition 
Half maximum 
potentiation 
concentration (EC50) 
(M) 
Half maximum 
inhibition concentration 
(IC50) (M) 
dFBr (32) + + 0.33  0.52* 150  0.2* 
86 + + 9.70 (2.3-17.1) 146.5 (15.9-280) 
87 - + NP
a
 2.48 (1.6-3.3) 
93 + + 4.30  1.4* 35.0  2.0* 
97 + + 7.40  0.1* 14.0  0.8* 
102 - + NP 1.8  0.7*  
137 - + NP 17.9 (3.1-32.6) 
138 - + NP 17.8 (3.1-32.6) 
a
NP = No potentiation of the action of ACh; * = SEM;  = 95% confidence limits;  n = 4. 
 
It can be concluded that the structural features required for potentiation action and inhibition 
action are not identical, as summarized in Table 7. Nevertheless, it is realized that the 
‘inhibitory’ effect is in need of further study. That is, the nature of ‘inhibition’ is unknown at this 
time. Several dramatic structural changes have been made (e.g., tryptamine vs quaternary amine 
vs gramine). Certain compounds might produce their inhibitory effect like dFBr (32), presumably 
by acting as a channel blocker; others might represent NAMs, or perhaps competitive antagonists 
that bind at the orthosteric site. This needs to be investigated. 
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Table 7. Summary of structural requirements for potentiation/inhibition of the ACh response at 
the 42 nACh receptors.  
Substituent Potentiators Inhibitors 
6-Bromo Required for potency but not 
action 
Not required for potency or 
action 
gem-Dimethyl Required for action Not required 
3-Position carbon chain 2-Carbon (tryptamine) 1-Carbon (gramine) 
N-Substituent Secondary amine optimal 
Quaternary amine might be 
optimal 
Secondary and tertiary amine 
are equipotent 
N1-Substitution 
Indolic NH required for 
activity 
Bulk tolerated at the indolic 
NH 
 
The results shown in Table 7 can be a good starting point to develop functionally different series 
of analogs as potentiators or inhibitors of the ACh response at the 42 nACh receptors. 
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VI. Conclusions 
 
 
des-Formylflustrabromine (dFBr, 32) has been identified as a positive allosteric modulator 
(PAM) at α4β2 nACh receptors that potentiates the actions of the neurotransmitter ACh. It was 
isolated in small quantities from a marine organism: Flustra foliacea. The present investigation 
was to identify what structural features of dFBr (32) are required for the action of dFBr as a 
PAM. The ‘deconstruction-reconstruction-elaboration’ approach also identified a possible 
pharmacophore for a positive allosteric modulator action at 42 nACh receptors.  
It is worth mentioning that the in vitro studies were performed on oocytes. The 
electrophysiological data obtained from the oocytes studies should be thoroughly examined and 
various factors such as temperature, experimental conditions, and functioning of the oocytes 
should be considered. Also the data obtained from electrophysiology should be used as a good 
starting point for performing in vivo studies which has a better correlation with how the drug 
behaves in humans.  
One of the aims of this study was to identify critical structural features of dFBr for potentiation 
of ACh at 42 nACh receptors. Figure 23 summarizes the structural features required for 
action/potency. The ‘deconstructed’ analogs of the 2-position showed that double bond 
saturation (i.e., 34) is tolerated. This provides a synthetic advantage for future dFBr (32) analogs. 
The gem-dimethyl groups are required along with a quaternary carbon at the 2-position (i.e., 39) 
for potency. The amine region was investigated and it was shown that the secondary amine of 
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dFBr (32) was optimal. The primary amine counterpart 40 was half as potent as the parent 
analog. The N,N-dimethyl tertiary amine analog 86 was almost 30 times less potent than dFBr 
(32). This might be attributed to the basicity of the amine or the steric bulk at the amine region. 
The quaternary amine 87 was studied to see if the quaternary amine and its cation- interaction 
similar to the interaction of ACh would have any effect. It was shown to be an antagonist, and 
was relatively potent. The antagonistic action of the analog can be because of a different mode of 
binding. The tryptamine side chain was examined and it was found that shortening of the chain 
abolishes potentiation of action of ACh, but the compound retains action as an antagonist. A 
possible explanation could be a different mode of binding. The development of the gramine 
analogs (i.e., 102, 137, and 138) provides some preliminary information on the structural 
requirements for their antagonist action (Figure 24). Additional gramine analogs should be 
explored for the antagonist action at 42 nACh receptors. 
 
  
110 
 
 
Figure 23. SAR for dFBr (32) at 42 nACh receptors. 
 
 
 
Figure 24. Preliminary SAR for antagonist action of dFBr (32) analogs at 42 nACh receptors. 
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The piperidine analog 97 was synthesized to examine a constrained side chain. The piperidine 
analog 97 possesses two features of interest; the distance of the amine from the indole nucleus, 
and branching of the 3-position tryptamine side chain. The secondary amines of dFBr (32) with 
i-propyl (i.e., 91) and benzyl (i.e., 92) substituents were synthesized to explore the region for 
steric bulk tolerance. The indolic N-H was investigated and it was seen that the hydrogen-bond 
donor is required at the receptor site, shown by the almost 10-fold decreased potency of 93 
compared to 32. The 1-methyl substitution of 93 provided information about the indolic N-H and 
steric bulk. Although a methyl substituent is not too bulky in volume, a benzyl substituent (i.e., 
94) was synthesized which might provide information about any region for bulk tolerance at the 
indolic N-H region. The isotryptamine analog 127 was similar in potency compared to N-methyl 
dFBr (86), which supports data for compound 93 suggesting that the N-H of the indole is optimal 
for potency. The 6-bromo substituent of dFBr (32) was investigated. Removal of the 6-bromo 
group was a major synthetic advantage for synthesis of 2-position substituted analogs of dFBr 
(32), although removal of the 6-bromo group reduced the activity by 20-fold; thus, the 6-bromo 
group is required for potency but not for action. The steric and electronic properties of the 6-
bromo substituent were further explored. The 6-methyl analog (i.e., 99) and the 6-trifluoromethyl 
analog (i.e., 100) explored the importance of the 6-bromo group, and comparing them, it is still 
unclear whether electronic or steric properties are important for the potentiation of the ACh-
induced response. Additional analogs are required for developing a QSAR for studying the 
electronic and steric effect for PAM action. The 5-position of dFBr (32), which is para- to the 
indolic N-H, was also examined and it was found that a 5-bromo substituent is tolerated; thus, 
compound 144 can possibly have a synergistic/additive effect towards the potency by having 5,6-
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dibromo substituents. Compound 152 will be a useful tool to perform binding experiments to 
understand the binding sites. In conclusion a pharmacophore of dFBr (32) was developed.  
 
Figure 25. Minimal structural features required for the PAM action of dFBr (32). This simplified 
structure might represent a pharmacophore for such action. 
 
There is growing interest in the discovery of PAMs which are selective for 4-, 2, or 2 
containing subunits, and one such compound; NS9283 (153) has been found to be selective for 
the 2- and 4- containing nACh receptors. Compound 153 is a potent PAM at the (2)3(2)2, 
(2)3(4)2, and (4)3(2)2 nACh receptors (EC50 = 1.3 M, EC50 = 1.7 M, EC50 = 3.3 M 
respectively).
196
 Attaining subunit selectivity and progressing towards subtype selectivity is the 
need of the hour for understanding the role of various subtypes of the nACh receptors. 
 
Binding experiments with tritiated dFBr will further help understand the binding of dFBr (32)-
like ligands at the 42 nACh receptors. Compound 152, being a radiolabeled ligand, can be 
used for high-throughput screening to identify other allosteric modulators for the 42 nACh 
receptors thus further helping in identification of possible new leads.  
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VII. Experimental 
 
 
A. Synthesis 
Melting points (mp) were measured on a Thomas-Hoover melting point apparatus using a glass 
capillary tube and are uncorrected. 
1
H NMR spectra were recorded on a Varian 400 MHz 
spectrometer using tetramethylsilane (TMS) as an internal standard. Peak positions are given in 
parts per million (). UHPLC-MS were recorded on a Perkin Elmer Flexar UHLPC with AxION 
2 Time of Flight (TOF) Mass Spectrometer and the molecular weight of the compounds was 
within 0.05% of calculated values. Elemental analysis was performed by Atlantic Microlab Inc. 
(Norcross, GA) for the elements indicated and the results are within 0.4% of calculated values. 
Infrared spectra were obtained on a Thermo Nicolet iS10 FT-IR.   Flash chromatography was 
performed on CombiFlash Companion/TS (Telodyne Isco Inc., Lincoln, NE) using packed silica 
gel (Silica Gel 230-400 mesh) columns (RediSep Rf Normal-phase Silica Flash Column, 
Teledyne Isco Inc., Lincoln, NE). All reactions were monitored by thin-layer chromatography 
(TLC) on silica gel GHLF plates (250 , 2.5 x 10 cm; Analtech Inc., Newark, DE). 
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N-Methyl-6-bromotryptamine (35). Compound 35 was prepared as described.
9
 Borane 
dimethylsulfide (10.1M in THF, 3.63 mL) was added in a dropwise manner at 60 °C to a stirred 
solution of N-methyl-6-bromo-1H-indol-3-gloxylamide (123) (3.4 g, 12 mmol) in anhydrous 
THF (35 mL). The reaction mixture was heated at reflux for 3 h, cooled to room temperature, 
quenched with HCl (2N, to pH 1), and extracted with EtOAc (2 x 30 mL). The aqueous portion 
was basified with NaOH (3M, to pH 8) and extracted with CH2Cl2 (3 x 40 mL). The combined 
organic portion was washed with H2O (2 x 50 mL), brine (50 mL), dried (Na2SO4), and 
evaporated under reduced pressure to yield 1.4 g (49%) of 35 as an off-white colored solid: mp 
108-110 °C (lit.
9
 mp 112-114 °C); 
1
H NMR (CDCl3) δ 2.38 (s, 3H, CH3), 2.85 (m, 4H, CH2), 
6.95-7.41 (m, 4H, Ar), 8.0 (s, 1H, indolic NH). 
 
N-Methyl-6-Bromo-2-sec-butyltryptamine Hydrogen Oxalate (37). Compound 37 was 
prepared using a literature procedure for a similar compound.
178
 Borane dimethylsulfide (10.1M 
in THF, 0.4 mL, 4.5 mmol) was added in a dropwise manner at 60 °C to a stirred solution of N-
methyl-6-bromo-2-sec-butyl-1H-indol-3-glyoxylamide (66) (0.5 g, 1.5 mmol) in anhydrous THF 
(15 mL). The reaction mixture was allowed to stir at reflux overnight, cooled to 0 °C, quenched 
with H2O (4 mL), acidified with HCl (2N, to pH 1), and heated at reflux for 30 min. The THF 
was evaporated under reduced pressure and the remaining aqueous portion was diluted with H2O 
(50 mL) and basified with NaOH (3M, to pH 14) and extracted with CH2Cl2 (2 x 20 mL). The 
combined organic portion was washed with H2O (2 x 15 mL), dried (Na2SO4), and solvent was 
evaporated under reduced pressure to yield 0.2 g (50%) of the free base of 37 as a yellow oil. 
Oxalic acid (0.1 g, 0.8 mmol) was added to the solution of free base of 37 in CHCl3 (3 mL) and 
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the reaction mixture was allowed to stir at room temperature for 30 min. The precipitate was 
collected by filtration to yield a white-colored solid which upon recrystallization from i-PrOH 
afforded 0.1 g (43%) of 37 as a white solid: mp 126-129 ºC;  
1
H NMR (DMSO-d6) δ 0.70 (t, 3H, 
CH3), 0.85-0.87 (m, 3H, CH3), 1.42-1.50 (m, 2H, CH2), 2.42 (s, 3H, CH3), 2.76-2.81 (m, 5H, 2 x 
CH2, CH), 6.92 (d, 1H, Ar), 7.24-7.28 (m, 2H, Ar), 10.78 (s, 1H, COOH). Anal. Calcd. 
(C15H21BrN2·C2H2O4·0.5H2O) C, 50.01;  H, 5.92; N, 6.86. Found: C,  49.90; H, 5.73;  N, 6.68. 
 
N-Methyl-6-Bromo-2-tert-butyltryptamine Hydrochloride (39). Compound 39 was prepared 
using a literature procedure for a similar compound.
178
 Borane dimethylsulfide (10.1M in THF, 
0.3 mL, 2.5 mmol) was added in a dropwise manner at 60 °C to a stirred solution of N-methyl-6-
bromo-2-tert-butyl-1H-indol-3-glyoxylamide (72) (0.3 g, 0.8 mmol) in anhydrous THF (15 mL). 
The reaction mixture was allowed to stir at reflux for 6 h, cooled to 0 °C, quenched with H2O (4 
mL), acidified with HCl (2N, to pH 1), and heated at reflux for 1 h. The THF was evaporated 
under reduced pressure and the remaining aqueous portion was diluted with H2O (50 mL) and 
extracted with Et2O (2 x 25 mL). The aqueous portion was basified with NaOH (3M, to pH 9) 
and extracted with CH2Cl2 (3 x 30 mL). The combined organic portion was washed with H2O (3 
x 70 mL), dried (Na2SO4), and solvent was evaporated under reduced pressure to yield 0.2 g 
(78%) of the free base of 39 as a yellow oil. The oil was dissolved in anhydrous Et2O (15 mL) 
and cooled to 0 °C. HCl/Et2O (10 mL) was added and the reaction mixture was allowed to stir 
overnight. The solvent was evaporated to yield a white solid which was recrystallized from i-
PrOH to yield 0.05 g (17%) of 39 as a white solid: mp 246-248 °C; 
1
H NMR (DMSO-d6) δ 1.44 
(s, 9H, (CH3)3), 2.61 (s, 3H, CH3), 2.94-2.98 (m, 2H, CH2), 3.16-3.19 (m, 2H, CH2), 7.09-7.12 
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(dd, J = 8.4, 1.7 Hz, 1H, Ar), 7.46 (d, J = 1.7 Hz, 1H, Ar), 7.52-7.54 (d, J = 8.4 Hz, 1H, Ar), 8.87 
(br s, 2H, NH2
+
 aliphatic), 10.76 (s, 1H, indolic NH). Anal. Calcd for (C15H21BrN2·HCl) C, 
52.11; H, 6.41; N, 8.10. Found: C, 52.28; H, 6.42; N, 8.01. 
 
6-Bromo-2-(1,1-dimethylallyl)tryptamine Hydrochloride (40). Gaseous HCl was bubbled into 
a solution of tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethylcarbamate (50) (90 
mg, 0.22 mmol) in anhydrous EtOAc (10 mL) at 0 °C. The reaction mixture was allowed to stir 
at room temperature for 24 h and the solvent was evaporated to yield a white solid which was 
recrystallized from EtOAc/MeOH to yield 25 mg (33%) of 40 as white crystals: mp 256-258 °C; 
1
H NMR (DMSO-d6) δ 1.49 (s, 6H, (CH3)2), 2.85 (t, 2H, CH2), 3.05 (t, 2H, CH2), 5.08 (m, 2H, 
CH), 6.14 (m, 1H, CH), 7.12 (dd, 1H, Ar), 7.50 (m, 2H, Ar), 7.98 (s, 3H, NH3
+ 
aliphatic), 10.76 
(s, 1H, indolic NH). Anal. Calcd for (C15H19BrN2∙HCl∙0.25H2O) C, 51.74; H, 5.93; N, 8.05. 
Found: C, 51.90; H, 5.87; N, 8.00. 
 
N-Methyl-2-tert-butyltryptamine Hydrogen Oxalate (43). Compound 43 was prepared using a 
literature procedure for a similar compound.
197
 Lithium aluminum hydride (0.3 g, 6.5 mmol) was 
suspended in dioxane (10 mL) and heated at reflux. A solution of N-methyl-2-tert-butyl-1H-
indol-3-glyoxylamide (58) (0.2 g, 0.7 mmol) was added, and the reaction mixture was allowed to 
reflux overnight. The reaction mixture was cooled to room temperature, diluted with THF (10 
mL) and quenched with MeOH (3 mL) and NaOH (3M, 3 mL). The reaction mixture was filtered 
and the filtrate was diluted with THF (15 mL) and further heated at reflux for 30 min, the organic 
solvent was evaporated under reduced pressure to yield a yellow oil. The residue was purified by 
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column chromatography (silica gel; CH2Cl2/MeOH 100:1 to 10:1) to afford 0.05 g (33%) of the 
free base as a yellow oil. A solution of the free base in anhydrous THF (2 mL) and anhydrous 
Et2O (5 mL) was cooled to 0 °C. Saturated oxalic acid solution in anhydrous Et2O (5 mL) was 
added and the reaction mixture was allowed to warm to room temperature and stirred overnight. 
The precipitate was collected by filtration to yield a white-colored solid which upon 
recrystallization from i-PrOH afford  0.03 g (56%) of 43 as white flakes: mp 194-195 °C; 
1
H 
NMR (DMSO-d6) δ 1.43 (s, 9H, (CH3)3), 2.64 (s, 3H, CH3), 2.94 (d, 2H, CH2), 3.15 (d, 2H, 
CH2), 6.96-7.51 (m, 4H, Ar), 10.55 (s, 1H, indolic NH). Anal. Calcd for 
(C18H30N2O·C2H2O4·C3H8O) C, 63.14; H, 8.49; N, 7.19. Found: C, 62.81; H, 8.46; N, 7.18. 
 
3-[(E)-2-Nitroethenyl]-6-bromo-1H-indole (47). Compound 47 was prepared as described.
176
 
In a 2-neck flask, 1-dimethylamino-2-nitroethylene (1.2 g, 10.2 mmol) was added to a solution of 
6-bromoindole (46) (2.0 g, 10.2 mmol) in anhydrous CH2Cl2 (10 mL) under a N2 atmosphere. 
Trifluoroacetic acid (1 mL) was added and the reaction mixture was allowed to stir at room 
temperature for 1 h, quenched carefully with a saturated aqueous solution of NaHCO3 and the 
residue was collected by filtration and dried to yield 2.4 g (88%) of 47 as a yellow solid: mp 193-
195 °C (decomp) (lit.
176
 mp not reported); 
1
H NMR (CDCl3) δ 7.37 (dd, J = 8.64, 1.56 Hz, 1H, 
Ar), 7.58 (m, 3H, Ar), 7.66 (d, J = 13.5 Hz, 1H, CH), 8.17 (d, J = 13.5 Hz, 1H, CH), 8.67 (s, 1H, 
indolic NH). 
 
6-Bromotryptamine (48). Compound 48 was prepared as described.
176
 To a round bottom flask 
cooled to 0 °C (ice bath), NaBH4 (0.8 g, 21 mmol) was added followed by addition of anhydrous 
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THF (18 mL) and BF3·Et2O (5.65 mL, 23 mmol). The ice bath was removed and the contents 
were allowed to stir at room temperature for 15 min. A solution of 3-[(E)-2-nitroethenyl]-6-
bromo-1H-indole (47) (1.0 g, 4 mmol) in anhydrous THF (11 mL) was added in a dropwise 
manner over 10 min, and the reaction mixture was heated at reflux for 2 h, cooled to room 
temperature and quenched with careful addition of ice. The mixture was acidified with HCl (2N, 
to pH 2) and heated at 80-85 °C for 2 h. After cooling, the acidic solution was extracted with 
Et2O (2 x 25 mL). The aqueous portion was basified with NaOH (3M, to pH 10) to liberate the 
amine. NaCl (10 g) was added and the product was extracted with Et2O (3 x 30 mL). The 
combined organic portion was washed with H2O (3 x 50 mL), brine (50 mL), dried (Na2SO4), 
and evaporated to dryness under reduced pressure to yield 0.33 g (40%) of 48 as a brown oil: 
1
H 
NMR (CDCl3) δ 2.81 (t, 2H, CH2), 2.95 (t, 2H, CH2), 6.93 (s, 1H, Ar), 7.14 (dd, J = 8.4, 1.6 Hz, 
1H, Ar), 7.39 (d, J = 8.4 Hz, 1H, Ar), 7.43 (s, J = 1.5 Hz, 1H, Ar),  8.2 (s, 1H, indolic NH). 
  
tert-Butyl-2-(6-bromo-1H-indol-3-yl)ethylcarbamate (49). Compound 49 was prepared as 
described.
9
 Di-tert-butyl dicarbonate (0.3 g, 1.3 mmol) and Et3N (0.2 mL, 1.3 mmol) were added 
to an anhydrous DMF (15 mL) solution of 6-bromotryptamine (48) (0.3 g, 1.3 mmol) and the 
reaction mixture was allowed to stir at room temperature for 24 h. The reaction mixture was 
quenched with ice-cold H2O (100 mL) and extracted with EtOAc (3 x 40 mL). The combined 
organic portion was washed with H2O (3 x 40 mL), brine (50 mL), dried (Na2SO4), and 
evaporated to dryness under reduced pressure to afford 0.26 g (60%) of 49 as a white foam 
which solidified on drying: mp 100-102 °C (lit.
178
 mp not reported); 
1
H NMR (CDCl3) δ 1.36 (s, 
9H, (CH3)3), 2.85 (t, 2H, CH2), 3.37 (t, 2H, CH2), 4.51 (s, 1H, NH aliphatic), 6.95 (s, 1H, Ar), 
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7.15 (dd, J = 8.5, 1.6 Hz, 1H, Ar), 7.39 (d, J = 8.4 Hz, 1H, Ar), 7.45 (s, J = 1.5 Hz, 1H, Ar), 7.94 
(s, 1H, indolic NH). 
 
tert-Butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethylcarbamate (50). Compound 
50 was prepared using a literature procedure for a similar compound.
198
  tert-Butyl hypochlorite 
(0.10 g, 0.9 mmol) was added to a solution of tert-butyl-2-(6-bromo-1H-indol-3-
yl)ethylcarbamate (49) (0.25 g, 0.7 mmol) and Et3N (0.90 g, 0.9 mmol)  in anhydrous THF (10 
mL) at -78 °C  and allowed to stir for 45 min. Freshly prepared prenyl 9-BBN
179
 (1.5 mmol) was 
added in a dropwise manner over 20 min while maintaining the temperature below -78 °C. The 
reaction mixture was allowed to warm to room temperature and stirred for an additional 2 h. 
NaOH (3M, 3 mL) and H2O2 (30% v/v, 3 mL) were added dropwise and stirring was continued 
for another 1 h at room temperature. The reaction mixture was diluted with Et2O (100 mL), the 
organic layer was separated and washed with H2O (3 x 30 mL), brine (40 mL) and dried 
(Na2SO4). The solvent was evaporated under reduced pressure to yield a crude residue which 
was purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 10:1) to afford 0.1 
g (33%) of 50 as a white foam: 
1
H NMR (CDCl3) δ 1.37 (s, 9H, (CH3)3), 1.48 (s, 6H, (CH3)2), 
2.93 (t, 2H, CH2), 3.29 (t, 2H, CH2), 5.08 (m, 2H, CH), 6.03 (m, 1H, CH), 7.10 (dd, 1H, Ar), 
7.35 (m, 2H, Ar), 7.78 (s, 1H, indolic NH). Compound 50 was used for the preparation of 
compound 40. 
 
2,2-Dimethyl-N-(o-tolyl)propionamide (52). Compound 52 was prepared as described.
180
 A 
solution of trimethylacetyl chloride (4.6 mL, 37 mmol) in anhydrous CH2Cl2 (10 mL) was added 
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to a solution of o-toludine (51) (4.01 mL, 37.3 mol) and Et3N (5.2 mL, 37.3 mol) in anhydrous 
CH2Cl (30 mL) which was previously cooled to 0 °C. The reaction mixture was allowed to warm 
to room temperature and stirred for 2 h. The reaction was quenched with H2O (50 mL). The 
organic layer was washed with H2O (3 x 50 mL), dried (Na2SO4) and evaporated to dryness 
under reduced pressure to yield a crude white solid which upon recrystallization from 
CH2Cl2/hexanes yielded 5.95 g (83%) of 52 as a white solid: mp 109-111 °C (lit.
180
 mp 109-111 
°C); 
1
H NMR (CDCl3) δ 1.36 (s, 9H, (CH3)3), 2.28 (s, 3H, CH3), 7.0-7.5 (m, 4H, Ar). 
 
2-tert-Butyl-1H-indole (55). Compound 55 was prepared as described.
181
 n-Butyllithium (1.6 M 
in hexane, 19.6 mL, 31 mmol) was added in a dropwise manner at 0 °C to a stirred solution of 
2,2-dimethyl-N-(o-tolyl)propionamide (52) (3 g, 16 mmol) in anhydrous THF (20 mL). The 
reaction mixture was allowed to stir at 0 °C for 1 h, at room temperature for 8 h and heated at 
reflux for 2 h. The reaction was cooled to room temperature, diluted with EtOAc (35 mL), and 
quenched with saturated NH4Cl (20 mL). The organic layer was separated, washed with H2O (2 
x 50 mL), dried (Na2SO4) and evaporated to dryness to yield a crude brown oil which on 
crystallization with MeOH/H2O yielded 2.0 g (74%) of 55 as a light brown solid: mp 73-75 °C 
(lit.
181
 mp 77 °C); 
1
H NMR (CDCl3) δ 1.46 (s, 9H, (CH3)3), 6.32 (s, 1H, CH), 7.15-7.61 (m, 4H, 
Ar), 7.99 (s, 1H, indolic NH).  
  
N-Methyl-2-tert-Butyl-1H-indol-3-glyoxylamide (58). Compound 58 was prepared using a 
literature procedure for a similar compound.
199
 A solution of 2-tert-butyl-1H-indole (55) (0.2 g, 1 
mmol) in anhydrous Et2O (10 mL) in a 2-neck flask was chilled to -5 °C and N2 was bubbled in 
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for 5 min. Oxalyl chloride (0.2 mL, 2 mmol) was added in a dropwise manner and the reaction 
mixture was allowed to stir at 0 °C for 6 h. The organic solvent was evaporated under reduced 
pressure and to the precipitate was added methylamine (40% in H2O, 5 mL) and the solution was 
allowed to stir at room temperature overnight. The precipitate was collected by filtration, washed 
with H2O (3 x 50 mL), dried and recrystallized from MeOH to yield 0.2 g (56%) of 58 as a 
brown solid: mp 190-191 °C; 
1
H NMR (CDCl3) δ 1.46 (s, 9H, (CH3)3), 3.1 (s, 3H, CH3), 6.77 (s, 
1H, NH aliphatic), 7.07-7.45 (m, 4H, Ar), 7.76 (s, 1H, indolic NH). Compound 58 was employed 
in synthesis of 43. 
 
tert-Butyl-2-(6-bromo-1H-indol-3-yl)ethyl-N-methylcarbamate (61). Compound 61 was 
prepared as described.
9
 Di-tert-butyl dicarbonate (0.9 g, 4 mmol) and Et3N (0.5 g, 4 mmol) were 
added to an anhydrous DMF (15 mL) solution of N-methyl-6-bromotryptamine (35) (1.0 g, 4 
mmol) and allowed to stir at room temperature for 24 h. The reaction mixture was quenched with 
H2O (40 mL) and extracted with EtOAc (3 x 40 mL). The combined organic portion was washed 
with H2O (3 x 40 mL), brine (50 mL), dried (Na2SO4) and evaporated to dryness to afford 1.3 g 
(94%) of 61 as a white foam: mp 124-126 °C (lit.
9
 mp 120-124 °C). The product was used 
without further purification in the attempted synthesis of 62. 
 
1-(3-Bromophenyl)-2-(3-methylpentan-2-ylidene)hydrazine (64). Compound 64 was prepared 
according to a literature procedure for a similar compound.
200
  To a solution of 3-methylpentan-
2-one (0.1 mL, 0.9 mmol) in MeOH (10 mL) was added 3-bromophenylhydrazine (63) (0.2 g, 
0.9 mmol) along with few drops of gl. HOAc and the reaction mixture was allowed to stir at 
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room temperature for 2 h. The solvent was removed under reduced pressure and the residue was 
dried to afford 0.23 g (95%) of 64 as a yellow-colored oil: 
1
H NMR (CDCl3)  0.54 (t, 3H, CH3), 
0.98 (d, 3H, CH3), 1.45-1.47 (m, 2H, CH2), 1.56-1.58 (m, 1H, CH), 2.04 (s, 3H, CH3), 6.69 (d, 
1H, Ar), 6.94-6.96 (m, 2H, Ar), 7.30 (m, 1H, Ar). The product was used without further 
purification in the attempted preparation of 65. 
 
6-Bromo-2-sec-butyl-1H-indole (65). Compound 64 was prepared according to a literature 
procedure for similar compound.
184
 A solution of sec-butyl magnesium chloride in THF (2.0 M, 
5 mL) was added in a dropwise manner to a solution of 1-(2-amino-4-bromophenyl)-2-
chloroethan-1-one (75) (1.0 g, 4.0 mmol) in anhydrous THF (20 mL) at -10 °C and allowed to  
stir in an ice bath for 15 min. The reaction mixture was allowed to warm to room temperature, 
and quenched with aqueous saturated NH4Cl (10 mL), extracted with MTBE (2 x 30 mL) and 
washed with brine (10 mL). The organic portion was combined, dried (Na2SO4) and the solvent 
was removed under reduced pressure. The oily residue was purified by column chromatography 
(silica gel) using hexanes/EtOAc (9:1) to afford 0.64 g (38%) of 65 as a yellow solid: mp 37-38 
°C; 
1
H NMR (CDCl3) δ 0.83 (t, 3H, CH3), 1.25 (d, 3H, CH3), 1.6-1.65 (m, 2H, CH2), 2.72-2.75 
(m, 1H, CH), 6.14 (s, 1H, ArH), 7.07 (d, J = 8.0 Hz, 1H, ArH), 7.29 (s, 1H, ArH), 7.35 (s, 1H, 
ArH), 7.78 (br s, 1H, indolic NH). 
 
N-Methyl-6-bromo-2-sec-butyl-1H-indol-3-glyoxylamide (66). Compound 66 was prepared 
using a literature procedure for a similar compound.
201
 A solution of 6-bromo-2-sec-butyl-1H-
indole-3-glyoxylchloride (81) (0.6 g, 1.9 mmol) in anhydrous THF (2 mL) was added to 
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methylamine (40% in H2O, 25 mL) cooled to °C. The reaction mixture was allowed to warm to 
room temperature and stirred overnight. The reaction mixture was diluted with H2O (100 mL) 
and the residue was collected by filtration, washed with H2O (3 x 50 mL) and dried to yield 0.5 g 
(82%) of 66 as a buff-colored solid: The compound was impure even after repeated attempts at 
crystallization with various solvents. Compound 66 was used without any further purification in 
the preparation of compound 37. 
  
4-Bromo-2-nitrotoluene (68). Compound 68 was prepared as described.
202
 A solution of 4-
methyl-3-nitroaniline (67) (10.0 g, 65.7 mmol) in H2O (25 mL) was added to conc. H2SO4 (25 
mL) in H2O (150 mL) in a flask. The mixture was heated until all the starting material was 
dissolved. On cooling the solid crystals were collected by filtration, washed with cold H2O (3 x 
50 mL) to give the sulfonic acid salt as dark-yellow crystals (A) which was dissolved in H2O (70 
mL) and HBr (62%, 17.5 mL) and the temperature was maintained at -5 °C. In a separate flask, a 
solution of NaNO2 (8.2 g, 118.3 mmol) in H2O (26 mL) was added slowly to the above solution 
while maintaining the temperature below 0 °C (B). In a 3-neck flask, CuBr (9.5 g, 65.7 mmol) 
was dissolved in HBr (62%, 12.5 mL) and the mixture was heated to reflux. To this heated 
solution, solution B was added slowly over 15 min and stirring was continued at reflux for 1.5 h. 
The reaction mixture was allowed to cool to room temperature and extracted with MTBE (3 x 50 
mL). The combined organic portion was washed with H2O (2 x 100 mL), 5% NH4OH (2 x 150 
mL), brine (150 mL), dried (MgSO4) and the solvent was removed under reduced pressure to 
afford 7.1 g (50%) of 68 as yellow, needle-shaped crystals: mp 42-44 °C (lit.
202
 mp 43-45 °C), 
1
H 
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NMR (CDCl3)  2.55 (s, 3H, CH3), 7.32 (d, J = 8.2 Hz, 1H, Ar), 7.72 (dd, J = 8.2, 1.9 Hz, 1H, 
Ar), 8.22 (d, J = 1.9 Hz, 1H, Ar).  
 
(E/Z)-1-(4-Bromo-2-nitrostyryl)pyrrolidine (69). Compound 69 was prepared as described.
203
 
A solution of 4-bromo-2-nitrotoluene (68) (1 g, 4.6 mmol), DMF-DMA (0.8 mL, 5.6 mmol) and 
pyrrolidine (0.5 mL, 5.6 mmol) in DMF (10 mL) was heated to 110 °C until the TLC analysis 
showed consumption of 68. The dark red solution was allowed to cool to room temperature, 
diluted with Et2O (30 mL) and washed with H2O (3 x 50 mL). The combined H2O portion was 
further extracted with Et2O (2 x 25 mL) and the combined organic portion was washed with H2O 
(3 x 50 mL), brine (50 mL), dried (Na2SO4) and the solvent was removed under reduced pressure 
to afford 1 g (70%) of 69 as a red-colored crystals: mp 61-63 °C (lit.
176
 mp not reported) 
1
H 
NMR (CDCl3)  1.92-1.96 (m, 4H, CH2), 3.32-3.36 (m, 4H, CH2), 5.80 (d, J = 13.4 Hz, 1H, CH), 
7.28 (d, J = 13.3 Hz, 1H, CH), 7.34 (d, J = 8.3 Hz, 1H, Ar), 7.58 (d, J = 1.8 Hz, 1H, Ar), 8.12 
(dd, J = 8.2, 1.9 Hz, 1H, Ar). Compound 69 was used in the attempted synthesis of 70.  
 
6-Bromo-2-tert-butyl-1H-indole (71). Compound 71 was prepared using a literature procedure 
for a similar compound.
188
 Zinc iodide (0.2 g, 0.6 mmol) was added in one portion to a solution 
of 5-bromo-2-(3,3-dimethylbut-1-yn-1-yl)aniline (80) (2.9 g, 11.5 mmol)  in anhydrous toluene 
(40 mL) and the reaction mixture was heated at reflux for 41 h. The reaction mixture was 
allowed to cool to room temperature and washed with H2O (3 x 50 mL). The aqueous portion 
was extracted with CH2Cl2 (3 x 50 mL) and the combined organic portion was washed with H2O 
(3 x 70 mL), dried (Na2SO4) and the solvent was evaporated under reduced pressure to yield a 
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crude product which upon recrystallization from hexanes afforded 1.5 g (51%) of 71 as buff-
colored flakes: mp 110-111 °C; 
1
H NMR (CDCl3) δ 1.39 (s, 9H, (CH3)3), 6.24 (s, 1H, Ar), 7.15-
7.18 (dd, J = 8.4, 1.2 Hz, 1H, Ar), 7.37-7.40 (d, J = 9 Hz, 1H, Ar), 7.46 (d, J = 1.2 Hz, 1H, Ar), 
7.94 (br s, 1H, indolic NH). 
  
N-Methyl-6-bromo-2-tert-butyl-1H-indol-3-glyoxylamide (72). Compound 72 was prepared 
using a literature procedure for a similar compound.
201
 A solution of 6-bromo-2-tert-butyl-1H-
indole (71) (1.3 g, 5 mmol) in anhydrous Et2O (25 mL) in a 2-neck flask was chilled to -5 °C and 
N2 was bubbled in for 5 min. Oxalyl chloride (0.9 mL, 10 mmol) was added in a dropwise 
manner and the reaction mixture was heated at reflux overnight. The Et2O was evaporated and 
the precipitate was dissolved in THF (5 mL) to which was added methylamine (40% in H2O, 25 
mL) and the solution was allowed to stir at room temperature for 15 h. The reaction mixture was 
diluted with H2O (100 mL) and the residue was collected by filtration, washed with H2O (3 x 50 
mL), hexanes (3 x 50 mL) and dried to yield 1.4 g (77%) of 72 as a buff-colored solid: mp 190-
193 °C (decomp); 
1
H NMR (CDCl3) δ 1.53 (s, 9H, (CH3)3), 3.04 (s, 3H, CH3), 6.85 (br s, 1H, 
NH), 7.28-7.29 (dd, J = 8.4, 1.4 Hz, 1H, Ar), 7.50 (d, J = 1.4 Hz, 1H, Ar), 7.54-7.57 (d, J = 8.4 
Hz, 1H, Ar), 8.66 (br s, 1H, indolic NH). Compound 72 was used in the preparation of 
compound 39.  
 
1-(2-Amino-4-bromophenyl)-2-chloroethan-1-one (75). Compound 75 was prepared according 
to a literature procedure for a similar compound.
184
 3-Bromoaniline (74) (5.0 g, 29 mmol) and 
chloroacetonitrile (4.6 mL, 73 mmol) were added sequentially to a mixture of AlCl3 (4.6 g, 35 
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mmol) and BCl3 solution (1.0 M in CH2Cl2, 35 mL, 35 mmol) in CH2Cl2 (30 mL) in an ice bath 
and the cloudy solution was allowed to stir for 5 h at room temperature and heated at reflux 
overnight. The reaction mixture was cooled in an ice bath, quenched with 2 N HCl 150 mL, 
heated at reflux for 20 min, allowed to cool to room temperature, and extracted with CH2Cl2 (3 x 
50 mL). The combined organic portion was washed with H2O (3 x 50 mL), brine (50 mL), dried 
(Na2SO4) and the solvent was removed under reduced pressure to afford 6.0 g (69%) of 75 as a 
yellow solid: mp 139-141 °C; 
1
H NMR (CDCl3)  4.54 (s, 2H, CH2), 6.28 (br s, 2H, NH2), 6.70 
(dd, J = 8.68, 1.84 Hz, 1H, Ar), 6.81 (d, J = 1.84 Hz ,1H, Ar), 7.40 (d, J = 8.68 Hz, 1H, Ar). The 
product was used without further purification in the attempted synthesis of 71. It was also used in 
the preparation of compound 65. 
 
4-Bromo-2-nitroaniline (77). Compound 77 was prepared as described.
185
 N-Bromosuccinimde 
(12.9 g, 72 mmol) was added slowly over 10 min to a solution of commercially available 2-
nitroaniline (77) (10.0 g, 72 mmol) in gl. HOAc (30 mL) and the solution was heated to 55 °C. 
The reaction mixture was allowed to stir at 40-50 °C for 5 h, upon which it was poured into ice-
water (100 mL). The product was collected by filtration, washed with cold H2O (3 x 50 mL), 
dried and recrystallized from EtOH to afford 12.4 g (79%) of 77 as orange, needle-shaped 
crystals: mp 110-111 °C (lit.
185
 mp 111-112 °C); 
1
H NMR (CDCl3) δ 6.01 (br s, 2H, NH2), 6.65 
(d, J = 8.9 Hz, 1H, Ar), 7.36 (dd, J = 8.8, 2.3 Hz, 1H, Ar), 8.20 (d, J = 2.3 Hz, 1H, Ar).  
 
4-Bromo-2-nitroiodobenzene (78). Compound 78 prepared as described.
186
 A solution of 4-
bromo-2-nitroaniline (77) (7.3 g, 34 mmol) in anhydrous THF (50 mL) was added in a dropwise 
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manner to BF3·Et2O (15.7 mL, 125 mmol) at -30 °C. The reaction mixture was allowed to stir for 
10 min and then a solution of t-BuONO (13.3 mL, 111 mmol) in anhydrous THF (40 mL) was 
added in a dropwise manner. The reaction mixture was allowed to warm to -10 °C, diluted with 
Et2O (100 mL), and stirring was continued at room temperature for 1 h until a pale-yellow solid 
precipitate was formed. The solid was collected by filtration and washed with Et2O (50 mL) to 
afford a pale-yellow solid, which was then slowly added to a mixture of KI (7.1 g, 43 mmol) and 
I2 (5.4 g, 21 mmol) in MeCN (100 mL). The reaction mixture was allowed to stir at room 
temperature for 1 h. A saturated aqueous solution of Na2S2O3 (250 mL) was added and the 
reaction mixture was extracted with CH2Cl2 (2 x 90 mL). The combined organic portion was 
washed with H2O (2 x 100 mL), dried (Na2SO4) and the solvent was removed under reduced 
pressure to afford 9.3 g (84%) of 78 as a yellow powder: mp 86-88 °C ( lit.
186
 mp 87-89 °C ); 
1
H 
NMR (CDCl3) δ  7.40 (dd, J = 8.4, 2.2 Hz, 1H, Ar), 7.89 (d, J = 8.4 Hz, 1H, Ar), 8.0 (d, J = 2.2 
Hz, 1H, Ar).  
  
5-Bromo-2-iodoaniline (79). Compound 79 was prepared as described.
187
 A mixture of 4-
bromo-2-nitroiodobenzene (78) (8.4 g, 26 mmol), Fe powder (6.1 g, 110 mmol) in gl. HOAc (45 
mL) and absolute EtOH (40 mL) was heated at reflux for 1.5 h. The reaction mixture was 
allowed to cool to room temperature and a saturated aqueous solution of NaHCO3 (200 mL) was 
added. The mixture was extracted with Et2O (4 x 50 mL) and the combined organic portion was 
washed with H2O (3 x 100 mL), brine (100 mL), dried (Na2SO4) and the solvent was evaporated 
under reduced pressure to yield a crude residue. The crude product was purified by column 
chromatography (silica gel; hexanes/EtOAc; 100:1 to 100:5) to afford 4.6 g (60%) of 79 as a 
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cream-colored solid: mp 54-55 °C (lit.
187
 mp 55 °C);
 1
H NMR (CDCl3) δ 4.14 (br s, 2H, NH2), 
6.60 (dd, J = 8.4, 2.2 Hz, 1H, Ar), 6.88 (d, J = 2.2 Hz, 1H, Ar), 7.45 (d, J = 8.4 Hz, 1H, Ar).  
 
5-Bromo-2-(3,3-dimethylbut-1-yn-1-yl)aniline (80). Compound 80 was prepared using a 
literature procedure for a similar compound.
204
 A mixture of 5-bromo-2-iodoaniline (79) (4.0 g, 
13.4 mmol), CuI (0.1 g, 0.7 mmol) and PdCl2(PPh3)2 (0.5 g, 0.7 mmol) was suspended in 
anhydrous THF (50 mL). Et3N (5.6 mL, 40.3 mmol) and 3,3-dimethylbut-1-yne (2.2 mL, 17.5 
mmol) were added successively and the reaction mixture was allowed to stir at room temperature 
for 5 h. The reaction mixture was diluted with Et2O (100 mL), filtered through Celite, and the 
organic portion was washed sequentially with H2O (3 x 100 mL), a saturated aqueous solution of 
NH4Cl (50 mL), brine (50 mL), dried (Na2SO4) and the solvent was evaporated under reduced 
pressure to yield a crude residue. The crude product was purified by column chromatography 
(silica gel; hexanes/EtOAc 100:1 to 75:1) to afford 2.9 g (86%) of 80 as a light-yellow oil: 
1
H 
NMR (CDCl3) δ 1.34 (s, 9H, (CH3)3), 4.19 (br s, 2H, NH2), 6.75-6.79 (dd, J = 8.4, 1.9 Hz, 1H, 
Ar), 6.84 (d, J = 1.9 Hz, 1H, Ar), 7.06-7.08 (d, J = 8.1 Hz, 1H, Ar). Compound 80 was used in 
the preparation of compound 71. 
 
6-Bromo-2-sec-butyl-1H-indol-3-glyoxylchloride (81). Compound 81 was prepared using a 
literature procedure for a similar compound.
201
 A solution of 6-bromo-2-sec-butyl-1H-indole 
(65) (0.5 g, 1.98 mmol) in anhydrous Et2O (20 mL) in a 2-neck flask was chilled to -5 °C and N2 
was bubbled in for 5 min. Oxalyl chloride (0.2 mL, 2.40 mmol) was added in a dropwise manner 
and allowed to stir for 30 min at 0 °C. The Et2O was evaporated and the residue was washed 
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with Et2O (2 x 5 mL) to remove excess oxalyl chloride to afford 0.6 g (94%) of 81 as a yellow 
colored oil. The product was used without any further purification for the synthesis of compound 
66. 
 
2-(1,1-Dimethylallyl)tryptamine Hydrochloride (82). Gaseous HCl was bubbled into a 
solution of tert-butyl-2-(2-(1,1-dimethylallyl)-1H-indol-3-yl)ethylcarbamate (85) (0.4 g) in 
anhydrous Et2O (20 mL) at 0 °C. The reaction mixture was allowed to stir for 24 h and the 
solvent was evaporated to yield a purple solid which was recrystallized from i-PrOH/Et2O to 
yield 0.1 g (28%) of 82 as brown crystals: mp 231-232 °C; 
1
H NMR (DMSO-d6) δ 1.50 (s, 6H, 
CH3), 2.86 (t, 2H, CH2), 3.07 (t, 2H, CH2), 5.06-5.11 (m, 2H, CH2), 6.12-6.18 (m, 1H, CH), 
6.95-7.06 (m, 2H, Ar), 7.34 (d, J = 7.9 Hz, 1H, Ar), 7.51 (d, J = 7.8 Hz, 1H, Ar), 8.05 (br s, 3H, 
NH3
+
 aliphatic), 10.59 (br s, 1H, indolic NH). Anal. Calcd for (C15H20N2·HCl) C, 68.04; H, 7.99; 
N, 10.58. Found: C, 67.89; H, 7.99; N, 10.46. 
 
tert-Butyl-2-(1H-indol-3-yl)ethylcarbamate (84). Compound 84 was prepared as described.
189
 
Triethylamine (0.9 g, 8.5 mmol) and di-tert-butyl dicarbonate (1.9 g, 8.5 mmol) were added to a 
solution of tryptamine (83) (1.4 g, 8.5 mmol) in anhydrous DMF (30 mL) and allowed to stir for 
20 h at room temperature. The reaction mixture was quenched with ice and H2O (80 mL) and 
extracted with EtOAc (3 x 40 mL). The combined organic portion was washed with H2O (3 x 40 
mL), brine (50 mL), dried (Na2SO4) and the solvent was removed under reduced pressure to 
yield a crude oil. The crude product was purified by column chromatography (silica gel; 
hexanes/EtOAc; 100:1 to 4:1) to afford 2.0 g (91%) of 84  as a white solid: mp 92-94 °C (lit.
189
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mp 96 °C); 
1
H NMR (CDCl3) δ 1.37 (s, 9H, CH3), 2.96 (t, 2H, CH2), 3.32 (m, 2H, CH2), 4.55 (br 
s, 1H, NH aliphatic), 6.98-7.08 (m, 3H, Ar), 7.21 (d, J = 8.0 Hz, 1H, Ar), 7.48 (d, J = 7.8 Hz, 1H, 
Ar), 7.79 (br s, 1H, indolic NH). 
 
tert-Butyl-2-(2-(1,1-dimethylallyl)-1H-indol-3-yl)ethylcarbamate (85). Compound 85 was 
prepared using a literature procedure for a similar compound.
198
 tert-Butyl hypochlorite (0.5 g, 
4.6 mmol) was added to a solution of tert-butyl-2-(1H-indol-3-yl)ethylcarbamate (84) (1.0 g, 3.8 
mmol) and Et3N (0.5 g, 4.6 mmol)  in anhydrous THF (25 mL) at -78 °C  and the solution was 
allowed to stir for 45 min. Freshly prepared prenyl 9-BBN
179
 (7.7 mmol) was added in a 
dropwise manner over 15 min while maintaining the temperature at -55 °C. The reaction mixture 
was allowed to warm to room temperature and was stirred for an additional 3 h. Sodium 
hydroxide (3M, 10 mL) and H2O2 (30% v/v, 10 mL) were added in a dropwise manner and the 
reaction mixture was allowed to stir for 1 h at room temperature. The reaction was diluted with 
Et2O (100 mL), the organic layer was separated and washed with H2O (3 x 60 mL), brine (80 
mL) and dried (Na2SO4). The solvent was evaporated under reduced pressure to yield a crude 
residue which was purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 5:1) 
to afford 0.5 g (36%) of 85  as a white foam: 
1
H NMR (CDCl3) δ 1.37 (s, 9H, CH3), 1.47 (s, 6H, 
CH3), 2.96 (t, 2H, CH2), 3.32 (m, 2H, CH2), 4.53 (br s, 1H, NH aliphatic), 5.06-5.11 (m, 2H, 
CH2), 6.01-6.08 (m, 1H, CH), 6.98-7.08 (m, 2H, Ar), 7.21 (d, J = 8.0 Hz, 1H, Ar), 7.48 (d, J = 
7.8 Hz, 1H, Ar), 7.79 (br s, 1H, indolic NH). Compound 85 was used in the preparation of 
compound 82. 
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N,N-Dimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine Hydrogen Oxalate (86). A solution 
of N,N-dimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine (101) (0.05 g) in anhydrous CHCl3 (3 
mL) was allowed to stir at 0 °C for 1.5 h. The precipitate was collected by filtration and the 
white solid obtained was recrystallized from i-PrOH/Et2O to yield 0.02 g (36%) of 86 as a white 
crystals: mp 172-173 °C; NMR (DMSO-d6) δ 1.58 (s, 6H, (CH3)2), 2.73 (s, 6H, N(CH3)2), 4.39 
(m, 4H CH2), 5.25-5.29 (m, 2H, CH2), 6.31-6.38 (m, 1H, CH),  7.25 (dd, J  = 8.4, 1H, Ar), 7.59 
(d, J  = 1.6 Hz, 1H, Ar), 7.70 (d, J = 8.4, 1.5 Hz, 1H, Ar), 11.27 (s, 1H, COOH). Anal. Calcd for 
(C17H23BrN2·C2H2O4) C, 53.40; H, 6.36; N, 6.55. Found: C, 53.39; H, 6.06; N, 6.50.  
 
N,N,N-Trimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine Methiodide (87). A solution of 
N,N-dimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine (101) (0.05g, 0.2 mmol) in anhydrous i-
PrOH (4 mL) was cooled to 0 °C (ice-bath). Iodomethane (0.06 g, 0.5 mmol) was added and the 
reaction mixture was allowed to stir for 22 h at room temperature under a N2 atmosphere. The 
precipitate was collected by filtration and washed with anhydrous Et2O (3 x 15 mL), air dried 
and crystallized from MeOH/i-PrOH to afford 0.02 g (30%) of 87 as yellow crystals: mp 208-
210 °C; 
1
H NMR (CD3CN) δ 1.54 (s, 6H, (CH3)2), 3.15 (s, 9H, N(CH3)3), 3.22-3.38 (m, 4H 
CH2), 5.25 (m, 2H, CH2), 6.22 (m, 1H, CH),  7.22 (dd, J  = 8.4, 1.7 Hz, 1H, Ar), 7.46 (d, J  = 8.5 
Hz, 1H, Ar), 7.59 (d, J = 1.5 Hz, 1H, Ar), 9.35 (br s, 1H, indolic NH). Anal. Calcd for 
(C18H26BrIN2·C3H8O) C, 46.94; H, 6.38; N, 5.21. Found: C, 46.73; H, 6.29; N, 5.25. 
 
N-iso-Propyl-6-bromo-2-(1,1-dimethylallyl)tryptamine Hydrochloride (91). HCl gas was 
bubbled into a 0 °C solution of tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-
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N-iso-propylcarbamate (121) (0.4 g) in dry anhydrous EtOAc (10 mL). The reaction mixture was 
allowed to stir for 24 h and the solvent was evaporated to yield a white solid which was 
recrystallized from MeOH to yield  0.1g, (29%) of 91 as white crystals: mp 295-299 °C; 
1
HNMR 
(DMSO-d6) δ  1.25 (d, 6H, CH3), 1.50 (s, 6H, CH3), 2.88-2.92 (m, 2H, CH2), 3.09-3.14 (t, 2H, 
CH2), 5.09-5.13 (d, 2H CH2), 6.12-6.19 (m, 1H, CH), 7.11-7.14 (d, J = 8.4, 1.8 Hz, 1H, Ar), 7.49 
(d, J = 1.7 Hz, 1H, Ar), 7.53-7.55 (d, J = 8.4 Hz, 1H, Ar), 8.86 (br s, 2H, NH2
+
 aliphatic), 10.78 
(s, IH, indolic NH). Anal. Calcd for (C18H25BrN2·HCl) C, 56.04; H, 6.79; N, 7.26. Found: C, 
56.02; H, 6.75; N, 7.32. 
 
N-Benzyl-6-bromo-2-(1,1-dimethylallyl)tryptamine Hydrogen  Oxalate (92). Trifluoroacetic 
acid (0.05 mL) was added into a 0 °C solution of tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-
1H-indol-3-yl)ethyl-N-benzylcarbamate (122) (0.05 g) in anhydrous CH2Cl2 (5 mL), and the 
reaction mixture was allowed to stir for 6 h at room temperature. The reaction was quenched 
with H2O (25 mL) and the organic portion was separated. The aqueous portion was further 
extracted with CH2Cl2 (2 x 15 mL) and the combined organic portion was washed with NaOH 
(3M, 3 x 25 mL), H2O (3 x 50 mL), dried (Na2SO4) and evaporated under reduced pressure to 
yield a yellow oil. The free base was dissolved in anhydrous Et2O (15 mL) and converted to the 
oxalate salt by addition of saturated oxalic acid solution in Et2O (4 ml). The precipitate was 
collected by filtration, dried and recrystallized from i-PrOH to yield 0.02g (51%) of 92 as a white 
powder: mp 244-245 °C; 
1
HNMR (DMSO-d6) δ  1.47 (s, 6H, (CH3)2), 2.99 (br s, 2H, CH2), 3.07 
(br s, 2H, CH2), 4.15 (s, 2H, CH2), 4.99-5.04 (d, 2H CH2), 6.03-6.10 (m, 1H, CH), 7.09 (d, J = 
8.6 Hz, 1H, Ar), 7.38-7.50 (m, 7H, Ar), 10.72 (s, IH, indolic NH). Anal. Calcd 
  
133 
 
(C22H25BrN2·C2H2O4) C, 59.14; H, 5.58; N, 5.75. Found: C, 56.02; H, 6.75; N, 7.32. UHPLC-
MS; [M
+
1] calculated for C22H25BrN2 397.1, found 397.1.  
 
N-Methyl-6-bromo-1-methyl-2-(1,1-dimethylallyl)tryptamine Hydrochloride (93). Gaseous 
HCl was bubbled into a 0 °C solution of tert-butyl-2-(6-bromo-1-methyl-2-(1,1-dimethylallyl)-
indol-3-yl)ethyl-N-methylcarbamate (125) (100 mg) in anhydrous EtOAc (10 mL). The reaction 
mixture was allowed to stir at room temperature for 7 h and the solvent was evaporated under 
reduced pressure to yield a white solid which was recrystallized from MeOH to yield 35 mg 
(41%) of 93 as white crystals: mp 251-252 °C; 
1
H NMR (DMSO-d6) δ 1.52 (s, 6H, (CH3)2), 2.53 
(s, 3H NHCH3), 2.87 (t, 2H, CH2), 3.2 (t, 2H, CH2), 3.6 (s, 3H, NCH3), 4. 88 (d, 1H CH2), 5.05 
(d, 1H, CH2), 6.15 (m, 1H, CH), 7.12 (d. 1H, Ar), 7.54 (m, 2H, Ar), 8.78 (s, 2H, NH2
+
 aliphatic). 
Anal. Calcd for (C17H23BrN2·HCl) C, 54.93; H, 6.51; N, 7.54. Found: C, 55.21; H, 6.70; N, 7.27. 
 
N-Methyl-6-bromo-1-benzyl-2-(1,1-dimethylallyl)tryptamine Hydrogen Oxalate (94). 
Gaseous HCl was bubbled into a 0 °C solution of tert-butyl-2-(6-bromo-1-benzyl-2-(1,1-
dimethylallyl)-indol-3-yl)ethyl-N-methylcarbamate (126) (100 mg) in anhydrous EtOAc (10 
mL). The reaction mixture was allowed to stir at room temperature for 7 h and the solvent was 
evaporated under reduced pressure to yield a sticky yellow solid which was converted to an 
oxalate salt which upon recrystallization from i-PrOH yielded 50 mg (60%) of 94 as a yellow 
solid: mp 184-186 °C; 
1
H NMR (DMSO-d6) δ 1.52 (s, 6H, (CH3)2), 2.53 (s, 3H NHCH3), 2.87 (t, 
2H, CH2), 3.2 (t, 2H, CH2), 3.6 (s, 3H, NCH3), 4. 88 (d, 1H CH2), 5.05 (d, 1H, CH2), 6.15 (m, 
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1H, CH), 7.12 (d. 1H, Ar), 7.54 (m, 2H, Ar), 8.78 (s, 2H, NH2
+
 aliphatic). UHPLC-MS; [M
+
1] 
calculated for C23H27BrN2 410.13, found 410.13. 
 
N,N-Dimethyl-6-bromo-2-(1,1-dimethylallyl)tryptamine (101). Compound 101 was prepared 
using a literature procedure for a similar compound.
205
 An aqueous mixture (3N NaOH to pH 10) 
of 6-bromo-2-(1,1-dimethylallyl)tryptamine hydrochloride (40) (0.06 g, 0.2 mmol) was extracted 
with CH2Cl2 (3 x 10 mL). The combined organic portion was washed with H2O (3 x 15 mL), 
brine (30 mL), dried (Na2SO4) and the solvent was evaporated under reduced pressure to yield 6-
bromo-2-(1,1-dimethylallyl)tryptamine (40, free base). Formic acid (0.04 g, 0.8 mmol), 
formaldehyde (37%, 0.02 g, 0.5 mmol) and H2O (3 mL) were added and the reaction mixture 
was heated at reflux for 3 h. The reaction mixture was allowed to cool to room temperature, H2O 
(5 mL) was added, and the reaction mixture was basified with NaOH (3M, to pH 10). The 
aqueous portion was extracted with EtOAc (3 x 20 mL) and the combined organic portion was 
washed with H2O (3 x 40 mL), brine (50 mL), dried (Na2SO4) and the solvent was removed 
under reduced pressure to yield 0.05g (91%) of 101 as a crude product which was used for 
further reaction without purification in the preparation of compound 86 and 87. 
 
N-Methyl-3-(2-(1,1-dimethylallyl)-1H-indol-3-yl)propanamine Hydrogen Oxalate (103). 
Gaseous HCl was bubbled into a solution of tert-butyl-3-(2-(1,1-dimethylallyl)-1H-indol-3-
yl)propyl-N-methylcarbamate (109) (0.1 g, 0.3 mmol) in anhydrous EtOAc (10 mL) at 0 °C. The 
reaction mixture was allowed to stir at room temperature overnight. The solvent was evaporated 
under reduced pressure to yield a brown solid which was converted to the oxalate salt and 
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recrystallized from i-PrOH to yield 0.03 g (28%) of 103 as a yellow solid: mp 135-138 °C; 
1
H 
NMR (DMSO-d6) δ 1.49 (s, 6H, (CH3)2), 1.83 (m, 2H, CH2), 2.55 (s, 3H, CH3), 2.76 (t, 2H, 
CH2), 2.94 (t, 2H, CH2), 5.09 (m, 2H, CH2), 6.16 (m, 1H, CH), 6.95 (t, 1H, Ar), 7.21 (t, 1H, Ar), 
7.32 (d, J = 8.0 Hz, 1H, Ar), 7.44 (d, J = 7.8 Hz, 1H, Ar), 10.47 (s, 1H, COOH). Anal. Calcd for 
(C17H24N2·C2H2O4) C, 63.04; H, 7.18; N, 7.50. Found: C, 65.87; H, 7.56; N, 8.09; UHPLC-MS; 
[M
+
1] calculated for C17H24N2 257.15, found 257.15. 
 
1-(6-Bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)propan-2-amine Hydrochloride (104). 
Gaseous HCl was bubbled into a solution of tert-butyl-1-(6-bromo-2-(1,1-dimethylallyl)-1H-
indol-3-yl)propyl-2-carbamate (114) (300 mg, 0.2 mmol) in anhydrous Et2O (20 mL) at 0 °C. 
The reaction mixture was allowed to stir at room temperature for 24 h and the solvent was 
evaporated to yield a white solid which was recrystallized from i-PrOH/Et2O to yield 60 mg 
(27%) of 104 as white crystals: mp 229-230 °C; 
1
H NMR (DMSO-d6) δ 1.09 (d, 3H, CH3), 1.51 
(d, 6H, (CH3)2), 2.95-3.14 (m, 2H, CH2), 3.43 (m, 1H, CH), 5.08-5.15 (m, 2H, CH), 6.14-6.21 
(m, 1H, CH), 7.14 (dd, 1H, Ar), 7.51 (m, 2H, Ar), 8.07 (br s, 3H, NH3
+
 aliphatic), 10.86 (br s, 
1H, indolic NH). Anal. Calcd for (C16H21BrN2·HCl) C, 53.72; H, 6.20; N, 7.83. Found: C, 53.55; 
H, 6.25; N, 7.82.  
 
N-Methyl-3-(1H-indol-3-yl)propanamide (106). Compound 106 was prepared as described.
190
 
Indole-3-propionic acid (105) (1 g, 5.3 mmol) and Et3N (2.1 g, 21.1 mmol) were dissolved in 
anhydrous THF (40 mL). The solution was cooled to 0 °C in an ice bath to which was added 
methyl chloroformate (0.5 mL, 6.3 mmol) in a dropwise manner over 10 min. Stirring was 
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continued at 0 °C for an additional 30 min. Methylamine hydrochloride (5.5 g, 81.4 mmol) was 
added and the reaction was allowed to stir further at 0 °C for 90 min upon which the precipitate 
was removed by filtration and the filtrate was evaporated under reduced pressure to yield a crude 
yellow oil. The crude product was purified by column chromatography (silica gel; 
hexanes/EtOAc; 100:1 to 5:1) to afford 0.8 g (76%) of 106 as a cream-colored solid: mp 99-100 
°C (lit.
190
 mp 99-101 °C); 
1
H NMR (CDCl3) δ 2.49 (t, 2H, CH2), 2.66 (d, 3H, CH3), 3.05 (t, 2H, 
CH2), 6.94 (s, 1H, Ar), 7.03-7.06 (dt, 1H, Ar), 7.10-7.14 (dt, 1H, Ar), 7.28 (d, J = 8.0 Hz, 1H, 
Ar), 7.52 (d, J = 7.6 Hz, 1H, Ar), 7.95 (br s, 1H, indolic NH). 
 
N-Methyl-(1H-indol-3-yl)propanamine (107). Compound 107 was prepared as described.
191
 
Lithium aluminum hydride (1.1 g, 27.7 mmol) was suspended in anhydrous dioxane (12 mL) and 
a solution of 3-(1H-indol-3-yl)-N-methylpropanamide (106) (0.2 g, 0.65 mmol) was added, and 
the reaction mixture was heated at reflux overnight. The reaction mixture was allowed to cool to 
room temperature and diluted with Et2O (50 mL), H2O (1 mL), NaOH (15%, 1 mL) and EtOH (2 
mL). The reaction mixture was further stirred at room temperature for 2 h and dried (Na2SO4). 
The organic portion was evaporated under reduced pressure to afford 0.5 g (67%) of 107 as a 
yellow oil which was used without purification for the next step. 
  
tert-Butyl-3-(1H-indol-3-yl)propyl-N-methylcarbamate (108). Compound 108 was prepared 
using a literature procedure for a similar compound.
9
 Triethylamine (0.4 mL, 2.6 mmol) and di-
tert-butyl dicarbonate (0.6 g, 2.6 mmol) were added to a CH2Cl2 (15 mL) solution of indol-3-yl-
N-methylpropanamine (107) (0.5 g, 2.6 mmol) and allowed to stir at room temperature for 19 h. 
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The reaction mixture was quenched with H2O (50 mL) and extracted with CH2Cl2 (2 x 30 mL). 
The combined organic portion was washed with H2O (3 x 50 mL), dried (Na2SO4) and 
evaporated under reduced pressure to obtain a yellow oil. The crude product was purified by 
column chromatography (silica gel; hexanes/EtOAc; 100:1 to 25:1) to afford 0.4 g (58%) of 108 
as a white foam: 
1
H NMR (CDCl3) δ 1.37 (s, 9H, (CH3)3), 1.83-1.90 (m, 2H, CH2), 2.68 (t, 2H, 
CH2), 2.78 (s, 3H, CH3), 3.24 (m, 2H, CH2), 6.93 (s, 1H, Ar), 7.01-7.03 (dt, 1H, Ar), 7.09-7.13 
(dt, 1H, Ar), 7.28 (d, J = 8.0 Hz, 1H, Ar), 7.52 (d, J = 7.8 Hz, 1H, Ar), 7.86 (br s, 1H, indolic 
NH). 
 
tert-Butyl-3-(2-(1,1-dimethylallyl)-1H-indol-3-yl)propyl-N-methylcarbamate (109). 
Compound 109 was prepared using a literature procedure for a similar compound.
198
 tert-Butyl 
hypochlorite (0.2 g, 1.7 mmol) was added to a solution of tert-butyl-3-(indol-3-yl)propyl-N-
methylcarbamate (108) (0.4 g, 1.4 mmol) and Et3N (0.2 g, 1.7 mmol)  in THF (15 mL) at -78 °C  
and allowed to stir for 45 min. Freshly prepared prenyl-9-BBN
179
 (2.8 mmol) was added in a 
dropwise manner over 10 min while maintaining temperature at -78 °C. The reaction mixture 
was allowed to warm to room temperature and stirred for additional 2 h. Sodium hydroxide (3M, 
5 mL) and H2O2 (30% v/v, 5 mL) were added in a dropwise manner and the solution was stirred 
for 1 h and diluted with Et2O (100 mL). The organic layer was washed with H2O (3 x 60 mL), 
brine (80 mL), dried (Na2SO4), and evaporated under reduced pressure to yield a yellow oil 
which was subjected to purification by column chromatography (silica gel; hexanes/EtOAc; 
100:1 to 25:1) to afford 0.2 g (40%) of 109 as a glassy solid: mp 116-118 °C; 
1
H NMR (CDCl3) 
δ 1.38 (s, 9H, (CH3)3), 1.45 (m, 8H, CH2, CH3), 2.72 (t, 2H, CH2), 2.81 (s, 3H, CH3), 3.25 (m, 
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2H, CH2), 5.05-5.10 (m, 2H, CH2), 6.01-6.08 (m, 1H, CH), 6.97-7.06 m, 2H, Ar), 7.20 (d, J = 7.8 
Hz, 1H, Ar), 7.41 (d, J = 7.6 Hz, 1H, Ar), 7.74 (br s, 1H, indolic NH). Compound 109 was used 
in the preparation of compound 103. 
 
3-[(E)-2-Nitroprop-1-en-1-yl]-6-bromo-1H-indole (111). Compound 111 was prepared as 
described.
176
 Ammonium acetate (1.2 g, 15 mmol) was added to a solution of 6-bromo-1H-
indole-3-carboxaldehyde (110) (4.0 g, 17.9 mmol) in nitroethane (25 mL) in a 2-neck flask under 
an N2 atmosphere and the solution was then allowed to stir at reflux for 7 h. The reaction mixture 
was allowed to cool to room temperature and the precipitate was collected by filtration, washed 
with H2O (30 mL), nitroethane (2 x 15 mL) and dried to yield 3.7 g (74%) of 111 as a yellow 
solid: mp 219-220 °C (lit.
176
 mp not reported); 
1
H NMR (CDCl3) δ 2.53 (d, 3H, CH3), 7.39-7.42 
(dd, J = 8.48, 1.68 Hz, 1H, Ar), 7.54 (d, J = 2.8 Hz, 1H, Ar), 7.63 (d, J = 1.4 Hz, 1H, CH), 7.68 
(d, J = 8.52 Hz, 1H, Ar), 8.43 (s, 1H, Ar), 8.65 (br s, 1H, indolic NH). 
 
1-(6-Bromo-1H-indol-3-yl)propan-2-amine (112). Compound 112 was prepared using a 
literature procedure for a similar compound.
176
 Sodium borohydride (2.8 g, 73 mmol) was added 
to a solution of anhydrous THF (40 mL) and BF3·Et2O (10 mL, 79 mmol) at 0 °C, and the 
resulting suspension was stirred for 15 min while maintaining the temperature at 0 °C. 3-[(E)-2-
Nitroprop-1-en-1-yl)-6-bromo-1H-indole (111) (3.7 g, 13 mmol) was then added, and the 
reaction mixture was allowed to stir at reflux for 4 h, cooled in an ice bath and quenched by the 
careful addition of H2O (2 mL). The mixture was acidified with HCl (2N, to pH 1) and heated at 
reflux for a further 2 h. After cooling, the acidic solution was extracted with Et2O (2 x 25 mL). 
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The aqueous portion was basified with NaOH (3M, to pH 10) and extracted with Et2O (3 x 50 
mL). The combined organic portion was washed with H2O (3 x 100 mL), brine (50 mL), dried 
(Na2SO4), and the solvent was evaporated under reduced pressure to yield 1.5 g (44%) of 112 as 
a white foam which was used for next step without purification.  
  
tert-Butyl-1-(6-bromo-1H-indol-3-yl)propyl-2-carbamate (113). Compound 113 was prepared 
using a literature procedure for a similar compound.
9
 Di-tert-butyl dicarbonate (1.3 g, 5.8 mmol) 
and Et3N (0.6 g, 5.8 mmol) were added to a solution of 1-(6-bromo-1H-indol-3-yl)propan-2-
amine (112) (1.5 g, 1.3 mmol) in anhydrous DMF (20 mL) and the reaction mixture was allowed 
to stir for 24 h. The reaction mixture was poured into H2O with ice (100 mL) and extracted with 
EtOAc (3 x 40 mL). The combined organic portion was washed with H2O (3 x 40 mL), brine (50 
mL), dried (Na2SO4), and evaporated under reduced pressure to yield the crude product. The 
crude residue was purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 3:1) 
to afford 1.5 g (75%) of 113  as a white foam: 
1
H NMR (CDCl3) δ 1.04 (d, 3H, CH3), 1.36 (s, 
9H, (CH3)3), 2.72-2.89 (m, 2H, CH2), 3.92 (m, 1H, CH), 4.34 (s, 1H, NH aliphatic), 6.93 (s, J = 
2.1 Hz, 1H, Ar), 7.14 (dd, J = 8.4, 1.6 Hz, 1H, Ar), 7.43 (m, 2H, Ar), 7.95 (s, 1H, indolic NH). 
  
tert-Butyl-1-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)propyl-2-carbamate (114). 
Compound 114 was prepared using a literature procedure for a similar compound.
198
 tert-Butyl 
hypochlorite (0.4 g, 3.3 mmol) was added to a solution of tert-butyl-3-(6-bromo-1H-indol-3-
yl)propyl-2-carbamate (113) (0.9 g, 2.5 mmol) and Et3N (0.3 g, 3.3 mmol)  in anhydrous THF 
(30 mL) at -78 °C  and the solution was allowed to stir for 45 min. Freshly prepared prenyl-9-
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BBN
179
 (5.1 mmol) was added in a dropwise manner over 20 min while maintaining the 
temperature at -55 °C. The reaction mixture was allowed to warm to room temperature and was 
stirred for an additional 3 h. Aqueous NaOH (3M, 7 mL) and H2O2 (30% v/v, 7 mL) were added 
in a dropwise manner and stirring was continued for another 1 h. The reaction mixture was 
diluted with Et2O (100 mL), the organic layer was separated and washed with H2O (3 x 100 mL), 
brine (80 mL), dried (Na2SO4) and evaporated under reduced pressure to yield a crude residue 
which was purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 100:8) to 
afford 0.5 g (45%) of 114 as a white foam: 
1
H NMR (CDCl3) δ 1.09 (d, 3H, CH3), 1.36 (s, 9H, 
(CH3)3), 1.51 (d, 6H, (CH3)2), 2.95-3.14 (m, 2H, CH2), 3.43 (m, 1H, CH), 4.34 (s, 1H, NH 
aliphatic), 5.08-5.15 (m, 2H, CH), 6.14-6.21 (m, 1H, CH), 7.14 (dd, 1H, Ar), 7.51 (m, 2H, Ar), 
7.95 (s, 1H, indolic NH). Compound 114 was employed in the preparation of compound 104. 
  
N-iso-Propyl-6-bromo-1H-indol-3-glyoxylamide (115). Compound 115 was prepared using a 
literature procedure for a similar compound.
201,206
 In a 2-neck flask a solution of 6-bromoindole 
(46) (4.0 g, 20.4 mmol) in anhydrous Et2O (25 mL) was chilled to -15 
o
C and N2 was bubbled for 
5 min. Oxalyl chloride (3.6 mL, 40.8 mol) was added in a dropwise manner with continued 
stirring for 2 h, after which the precipitate was collected by filtration, washed with Et2O (2 x 25 
mL) and dried over vacuum. The solid was dissolved in THF (10 mL) and cooled to 0 °C. iso-
Propylamine (3 mL) was added in a dropwise manner and the reaction mixture was allowed to 
stir at room temperature overnight. The organic portion was evaporated and the residue was 
washed with H2O (100 mL), Et2O (3 x 35 mL) to afford 2.7 g (69%) of 115 as a white solid: mp 
268-269 °C; 
1
H NMR (DMSO-d6) δ 1.16-1.18 (d, 6H, CH3), 4.00-4.06 (sep, 1H, CH),  7.40-7.42 
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(dd, J = 8.4, 1.8 Hz, 1H, Ar), 7.44 (d, J = 1.8 Hz, 1H, Ar), 8.14-8.16 (d, J = 8.5 Hz, 1H, Ar), 
8.53-8.55 (d, J = 8.2 Hz, 1H, Ar), 8.74 (s, 1H, NH aliphatic), 12.27 (br s, 1H, indolic NH). 
 
N-Benzyl-6-bromo-1H-indol-3-glyoxylamide (116). Compound 116 was prepared using a 
literature procedure for a similar compound.
201,206
 In a 2-neck flask a solution of 6-bromoindole 
(46) (1.7 g, 8.7 mmol) in anhydrous Et2O (25 mL) was chilled to -10 °C and N2 was bubbled for 
5 min. Oxalyl chloride (1.5 mL, 17.4 mmol) was added in a dropwise manner and the stirring 
was continued for 2 h. The glyoxyl chloride formed was collected by filtration, washed with 
Et2O (2 x 25 mL), dried under reduced pressure, dissolved in anhydrous THF (18 mL), and the 
solution cooled to 0 °C. Benzylamine (1.4 mL, 13.1 mmol) was added in a dropwise manner and 
the reaction was allowed to stir at room temperature for 3 h. The precipitate was collected by 
filtration and washed with H2O (100 mL). The crude product was recrystallized from MeOH to 
afford 1.6 g (51%) of 116 as buff-colored, needle-shaped crystals: mp 232-233 °C; 
1
H NMR 
(DMSO-d6) δ 4.42-4.44 (d, 2H, CH2), 7.26-7.28 (m, 1H, Ar), 7.33-7.35 (m, 4H, Ar), 7.40-7.43 
(dd, J = 8.5, 1.8 Hz, 1H, Ar), 8.16-8.18 (d, J = 8.4 Hz, 1H, Ar), 8.78 (s, 1H, Ar), 9.30-9.33 (t, 
1H, NH aliphatic), 12.30 (br s, 1H, indolic NH). 
 
N-iso-Propyl-6-bromotryptamine (117). Compound 117 was prepared using a literature 
procedure for a similar compound.
178
 Borane dimethylsulfide (10.1M in THF, 1.4 mL) was 
added in a dropwise manner at 60 °C to a stirred solution of N-iso-propyl-6-bromo-1H-indol-3-
glyoxylamide (115) (1.5 g, 4.9 mol) in dry THF (35 mL). The reaction mixture was heated at 
reflux for 5 h, cooled to room temperature and quenched with HCl (2N, to pH 1). The THF was 
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evaporated under reduced pressure and the remaining aqueous portion was diluted with H2O 
(100 mL), basified with NaOH (3M, to pH 9) and extracted with CH2Cl2 (3 x 50 mL). The 
combined organic portions were washed with H2O (2 x 50 mL), dried (Na2SO4), and solvent was 
evaporated under reduced pressure to yield 1.2 g (89%) of 117 as a yellow foam: 
1
H NMR 
(CDCl3) δ 1.07-1.09 (d, 6H, CH3), 2.86-2.90 (m, 2H, CH2), 3.21-3.23 (t, 2H, CH2), 6.91 (s, 1H, 
Ar), 7.13-7.15 (d, 1H, Ar), 7.43 (s, 2H, Ar), 8.01 (s, IH, indolic NH). Compound 117 was used 
without further purification in the synthesis of compound 119. 
 
N-Benzyl-6-bromotryptamine (118). Compound 118 was prepared using a literature procedure 
for a similar compound.
178
 Borane dimethylsulfide (10.1M in THF, 1.3 mL) was added in a 
dropwise manner at 60 °C to a stirred solution of N-benzyl-6-bromo-1H-indol-3-glyoxylamide 
(116) (1.5 g, 4.2 mmol) in anhydrous THF (35 mL). The reaction mixture was heated at reflux 
for 5.5 h, cooled to room temperature and quenched with HCl (2N, to pH 1). The organic solvent 
was evaporated under reduced pressure and the remaining aqueous mixture was diluted with H2O 
(100 mL), basified with NaOH (3M, to pH 9) and extracted with CH2Cl2 (3 x 50 mL). The 
combined organic portion was washed with H2O (2 x 50 mL), dried (Na2SO4), and solvent was 
evaporated under reduced pressure to yield 1.4 g (61%) of 118 as a yellow foam. Compound 118 
was used without further purification for synthesis of compound 120. 
 
 tert-Butyl-2-(6-bromo-1H-indol-3-yl)ethyl-N-iso-propylcarbamate (119). Compound 119 
was prepared using a literature procedure for a similar compound.
9
 Triethylamine (0.60 mL, 4.3 
mmol) and di-tert-butyl dicarbonate (0.93 g, 4.3 mmol) were added to a CH2Cl2 (20 mL) solution 
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of N-iso-propyl-6-bromotryptamine (117) (1.20 g, 4.3 mmol) and allowed to stir overnight. The 
reaction mixture was diluted with CH2Cl2 (30 mL) and washed with H2O (3 x 40 mL), dried 
(Na2SO4), and evaporated to yield a crude residue. The residue was purified by column 
chromatography (silica gel; hexanes/EtOAc; 100:1 to 100:24) to afford 1.04 g (64%) of 119 as 
white foam: 
1
H NMR (CDCl3) δ 1.07-1.09 (d, 6H, CH3), 1.43 (s, 9H, CH3), 2.86-2.90 (m, 2H, 
CH2), 3.21-3.23 (t, 2H, CH2), 4.04-4.06 (sep, 1H, CH), 6.91 (s, 1H, Ar), 7.13-7.15 (d, 1H, Ar), 
7.43 (s, 2H, Ar), 8.01 (s, IH, indolic NH). 
 
tert-Butyl-2-(6-bromo-1H-indol-3-yl)ethyl-N-benzylcarbamate (120). Compound 120 was 
prepared using a literature procedure for a similar compound.
9
 Triethylamine (0.3 g, 2.6 mmol) 
and di-tert-butyl dicarbonate (0.6 g, 2.6 mmol) were added to an anhydrous CH2Cl2 (15 mL) 
solution of N-benzyl-6-bromotryptamine (118) (0.8 g, 2.6 mmol) and allowed to stir at room 
temperature for 24 h. The reaction mixture was diluted with CH2Cl2 (30 mL) and washed with 
H2O (3 x 40 mL), dried (Na2SO4), and evaporated to yield a crude residue. The residue was 
purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 100:24) to afford 0.6 g 
(50%) of 120 as a white foam: 
1
H NMR (CDCl3) δ 1.38 (s, 9H, (CH3)3), 2.83 (br s, 2H, CH2), 
3.36 (br s, 2H, CH2), 4.31 (s, 2H, CH2), 6.84 (br s, 1H, Ar), 7.10-7.30 (m, 8H, Ar), 7.91 (br s, IH, 
indolic NH). 
 
tert-Butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-iso-propyl carbamate 
(121). Compound 121 was prepared using a literature procedure for a similar compound.
198
 tert-
Butyl hypochlorite (0.24 g, 2.2 mmol) was added to a solution of tert-butyl-2-(6-bromo-1H-
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indol-3-yl)ethyl-N-iso-propylcarbamate (119) (0.70 g, 1.8 mmol) and Et3N (0.22 g, 2.2 mmol)  in 
THF (15 mL) at -65 
o
C  and allowed to stir for 45 min. Freshly prepared prenyl 9-BBN
179
 (3.7 
mmol) was added in a dropwise manner over 30 min while maintaining the temperature at -50 
o
C. The reaction mixture was allowed to warm to room temperature and stirred for an additional 
4 h. Sodium hydroxide (3M, 7 mL) and H2O2 (30%, 7 mL) were added in a dropwise manner and 
stirring was continued for 1 h. The reaction mixture was diluted with Et2O (50 mL), and the 
organic layer was washed with H2O (3 x 60 mL), brine (80 mL), dried (Na2SO4), and evaporated 
to yield a crude residue. The residue was purified by column chromatography (silica gel; 
hexanes/EtOAc; 100:1 to 10:1) to afford 0.5 g (62%) of 121  as a white foam: 
1
HNMR (CDCl3) δ 
1.25 (d, 6H, CH3), 1.43 (s, 9H, CH3), 1.50 (s, 6H, CH3), 2.86-2.90 (m, 2H, CH2), 3.21-3.23 (t, 
2H, CH2), 5.09-5.13 (d, 2H CH2), 6.12-6.19 (m, 1H, CH), 7.13-7.15 (d, J = 8.4, 1.8 Hz, 1H, Ar), 
7.43 (s, 2H, Ar), 8.01 (s, IH, indolic NH). Compound 121 was used in preparation of 91. 
 
tert-Butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-benzylcarbamate (122). 
Compound 122 was prepared using a literature procedure for a similar compound.
198
 tert-Butyl 
hypochlorite (0.09 g, 0.8 mmol) was added to a solution of tert-butyl-2-(6-bromo-1H-indol-3-
yl)ethyl-N-benzylcarbamate (120) (0.30 g, 0.7 mmol) and Et3N (0.08 g, 0.8 mmol) in anhydrous 
THF (10 mL) at -65 °C and allowed to stir for 45 min. Freshly prepared prenyl 9-BBN
179
 (1.4 
mmol) was added in a dropwise manner over 10 min while maintaining the temperature at -50 
°C. The reaction mixture was allowed to warm to room temperature and stirred for an additional 
5.5 h. Sodium hydroxide (3M, 3 mL) and H2O2 (30%, 3 mL) were added in a dropwise manner 
and stirring was continued for 1 h. The reaction mixture was diluted with Et2O (50 mL), and the 
  
145 
 
organic layer was washed with H2O (3 x 30 mL), brine (50 mL), dried (Na2SO4), and evaporated 
to yield a crude residue. The residue was purified by column chromatography (silica gel; 
hexanes/EtOAc; 100:1 to 10:1) to afford 0.06 g (17%) of 122  as a white foam: 
1
H NMR 
(CDCl3) δ 1.37 (s, 9H, (CH3)3), 1.43 (s, 6H, (CH3)2), 2.84 (br s, 2H, CH2), 3.36 (br s, 2H, CH2), 
4.31 (s, 2H, CH2), 4.99-5.03 (d, 2H CH2), 6.02-6.08 (m, 1H, CH), 6.84 (d, J = 8.4 Hz, 1H, Ar), 
7.10-7.30 (m, 7H, Ar), 7.43 (s, 2H, Ar), 8.01 (s, IH, indolic NH). This compound was employed 
in the preparation of compound 92. 
 
N-Methyl-6-bromo-1H-indol-3-glyoxylamide (123). Compound 123 was prepared as 
described.
201
 In a 2-neck flask a solution of 6-bromoindole (46) (4.0 g, 20 mmol) in anhydrous 
Et2O (20 mL) was chilled to -5 °C and N2 was bubbled for 5 min. Oxalyl chloride (3.6 mL, 41 
mmol) was added in a dropwise manner with continued stirring and the reaction was stirred at 0 
°C for 2 h, after which the solvent was evaporated, the residue was washed with cold Et2O (25 
mL) and dried under vacuum. The solid was added to cold aqueous methylamine (40%, 35 mL)  
and was allowed to stir at room temperature for 2 h after which the precipitate was collected by 
filtration to yield a brown solid which, upon recrystallization from MeOH, yielded 4.3 g (73%) 
of 123 as a white solid: mp 252-253 °C (lit.
9
 mp 249-252 °C); 
1
H NMR (DMSO-d6) δ 2.75 (s, 
3H, CH3), 7.4 (d, J = 8.48 Hz, 1H, Ar), 7.73 (s, 1H, Ar), 8.15 (d, J = 8.48 Hz, 1H, Ar), 8.68 (s, 
1H, NH aliphatic), 8.79 (s, 1H, Ar), 12.26 (s, 1H, indolic NH). Compound 123 was used in the 
preparation of compound 35. 
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tert-Butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-methylcarbamate (124). 
Compound 124 was prepared as described.
198
 tert-Butyl hypochlorite (0.5 g, 4.1 mmol) was 
added to a solution of tert-butyl-2-(6-bromo-1H-indol-3-yl)ethyl-N-methylcarbamate (61) (1.2 g, 
3.4 mmol) and Et3N (0.4 g, 4.1 mmol)  in anhydrous THF (15 mL) at -78 °C  and allowed to stir 
for 45 min. Freshly prepared prenyl 9-BBN
179
 (6.8 mmol) was added in a dropwise manner over 
30 min while maintaining the temperature at -78 °C. The reaction mixture was allowed to warm 
to room temperature and stirred for 2 h. Sodium hydroxide (3M, 5 mL) and H2O2 (30% v/v, 5 
mL) were added in a dropwise manner and stirring was continued for 1 h. The reaction mixture 
was diluted with Et2O (100 mL), and the organic layer was washed with H2O (3 x 60 mL), brine 
(80 mL), dried (Na2SO4), and evaporated to yield a crude residue which was purified by column 
chromatography (silica gel; hexanes/EtOAc 100:1 to 10:1) to afford 0.4 g (27%) of 124 as a 
white foam: 
1
H NMR (CDCl3) δ 1.40 (s, 9H, (CH3)3), 1.54 (s, 6H, (CH3)2), 2.78 (t, 3H, CH3), 
2.92 (t, 2H, CH2), 3.32 (t, 2H, CH2), 5.09 (m, 2H, CH2), 6.03 (m, 1H, CH), 7.10-7.35 (m, 3H, 
Ar), 7.77 (s, 1H, indolic NH). 
  
tert-Butyl-2-(6-bromo-1-methyl-2-(1,1-dimethylallyl)-indol-3-yl)ethyl-N-methyl carbamate 
(125). Compound 125 was prepared according to a literature procedure for a similar 
compound.
207,208
 In a dry, round-bottom flask NaH (60% oil dispersion) (0.04 g, 0.9 mmol) was 
allowed to stir with anhydrous toluene at 0 °C (ice bath) for 10 min. After removal of the 
toluene, a solution of tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-
methylcarbamate (124) (0.3 g, 0.7 mmol) in anhydrous DMF (5 mL) was added and stirring 
continued at 0 °C (ice bath) for 30 min. Iodomethane (0.15 g, 1.1 mmol) was added to the cold 
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solution and the reaction mixture was allowed to stir at room temperature for 1.5 h. The reaction 
was quenched with H2O (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic 
portions were washed with H2O (3 x 25 mL) and brine (40 mL), dried (Na2SO4) and evaporated 
to dryness under reduced pressure to yield a crude, yellow-colored oil which was purified by 
column chromatography (silica gel; hexanes/EtOAc 100:1 to 10:1) to afford 0.2 g (79%) of 125 
as a light-yellow oil: 
1
H NMR (CDCl3) δ 1.41 (s, 9H, (CH3)3), 1.56 (s, 6H, (CH3)2), 1.97-2.11 
(m, 2H, CH2), 2.51 (br s, 5H, NCH3, CH2), 5.18-5.26 (m, 2H, CH2), 6.28-6.35 (m, 1H, CH), 6.77 
(d, 2H, ArCH2), 7.13-7.18 (m. 7H, Ar), 7.72 (s, 1H, Ar). The product was used in the preparation 
of compound 93. 
 
tert-Butyl-2-(6-bromo-1-benzyl-2-(1,1-dimethylallyl)-indol-3-yl)ethyl-N-methyl carbamate 
(126). Compound 126 was prepared according to a literature procedure for a similar 
compound.
207,208
 In a dry, round-bottom flask NaH (60% oil dispersion) (0.02 g, 0.6 mmol) was 
allowed to stir with anhydrous toluene at 0 °C (ice bath) for 10 min. After removal of the 
toluene, a solution of tert-butyl-2-(6-bromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-
methylcarbamate (124) (0.2 g, 0.5 mmol) in anhydrous DMF (2 mL) was added and stirring 
continued at 0 °C (ice bath) for 45 min. Benzyl bromide (0.09 g, 0.6 mmol) was added to the 
cold solution and the reaction mixture was allowed to stir at room temperature for 5.5 h. The 
reaction was quenched with H2O (30 mL) and extracted with EtOAc (3 x 20 mL). The combined 
organic portions were washed with H2O (3 x 25 mL) and brine (40 mL), dried (Na2SO4) and 
evaporated to dryness under reduced pressure to yield a crude, yellow-colored oil which was 
purified by column chromatography (silica gel; hexanes/EtOAc 100:1 to 100:5) to afford 0.13 g 
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(55%) of 126 as a white foam: 
1
H NMR (CDCl3) δ 1.31 (s, 9H, (CH3)3), 1.47 (s, 6H, (CH3)2), 
1.97-2.11 (m, 2H, CH2), 2.51 (br s, 5H, NCH3, CH2), 5.18-5.26 (m, 2H, CH2), 6.28-6.35 (m, 1H, 
CH), 6.7 (s, 2H, CH2), 7.1-7.2 (m, 7H, Ar), 7.37 (s, 1H, Ar). Compound 126 was used in the 
preparation of compound 94. 
 
N,N-Dimethyl-5-bromo-2-(1,1-dimethylallyl)isotryptamine Hydrogen Oxalate (127). 
Compound 127 was prepared according to a literature procedure for a similar compound.
207,208
 In 
a dry, round-bottom flask NaH (60% oil dispersion) (0.06 g, 1.4 mmol) was allowed to stir with 
anhydrous toluene in an ice bath for 10 min. After removal of the toluene, a solution of 5-bromo-
2-(1,1-dimethylallyl)-1H-indole (131) (0.15 g, 0.6 mmol) in anhydrous DMF (5 mL) was added 
and stirring continued in an ice bath (0 °C) for another 20 min. In a separate beaker a solution of 
N,N-dimethylaminoethyl chloride hydrochloride (0.2 g, 1.1 mmol), KtBuO (0.2 g, 1.4 mmol) and 
KI (0.08 g, 0.6 mmol) in cold anhydrous DMF (3 mL) was then added to the round-bottom flask 
and the reaction mixture was heated at reflux for 17 h. The reaction mixture was quenched with 
H2O (20 mL) and extracted with EtOAc (2 x 25 mL) and CH2Cl2 (2 x 25 mL). The combined 
organic portions were washed with H2O (2 x 50 mL), brine (50 mL), dried (Na2SO4) and 
evaporated to dryness to yield 0.1 g (63%) of free base as a brown-colored oil. Saturated oxalic 
acid solution in anhydrous Et2O (5 mL) was added to a solution of the free base (0.1 g) in 
anhydrous Et2O (5 mL) at 0 °C and allowed to stir overnight. The precipitate formed was 
collected by filtration and recrystallized from MeOH/Et2O to afford 0.04 g (32%) of 127 as white 
flakes: mp 185-188 °C [The compound was prepared as previously described by D. Kim 
(postdoctoral fellow in Dr. Glennons lab) as JSK-087 (mp 191-194 °C)]; 
1
H NMR (DMSO-d6) δ 
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1.49 (s, 6H, (CH3)2), 2.69 (s, 6H N(CH3)2), 3.03 (t, 2H, CH2), 4.42 (t, 2H, CH2), 5.17 (m, 2H, 
CH2), 6.09 (m, 1H, CH),  6.37 (s,1H, CH), 7.25 (d, 1H, J = 8.7 Hz, Ar), 7.43 (s, 1H, J = 8.7 Hz, 
Ar), 7.70 (d, 1H, Ar). 
  
3,5-Dibromo-1H-indole (130). Compound 130 prepared as described.
192
 A solution of liquid Br2 
(0.2 mL, 4 mmol) in anhydrous DMF (5 mL) was added in a dropwise manner to a solution of 5-
bromoindole (129) (1.0 g, 4 mmol) in anhydrous DMF (5 mL). The light-protected mixture was 
allowed to stir at room temperature for 12 h and then poured into water and ice (100 mL) 
containing NH4OH (2 mL) and saturated aqueous NaS2O3 (0.3 mL). The product was collected 
by filtration and was washed with water, dried under reduced pressure to yield 0.6 g (41%) of 
130 as a brown solid: mp 90-92 °C (decomp) (lit.
192
 mp 94 °C); 
1
H NMR (DMSOd6) δ 7.41 (dd, 
1H, Ar), 7.29 (dd, 1H, Ar), 7.62 (s, 1H, Ar), 7.53 (s, 1H, Ar), 11.69 (br s, 1H, indolic NH). 
 
5-Bromo-2-(1,1-dimethylallyl)-1H-indole (131). Compound 131 was prepared as described.
193
 
3,5-Dibromo-1H-indole (130) (0.5 g, 1.8 mmol) was added in one portion to a freshly prepared 
prenyl 9-BBN
177
 (5.4 mmol) and Et3N (0.9 mL, 6.3 mmol) in anhydrous THF (10 mL) at room 
temperature. The reaction mixture was allowed to stir at room temperature for 4 h and then 
quenched with a saturated solution of NaHCO3 (20 mL). The organic layer was separated and the 
aqueous portion was extracted with Et2O (2 x 20 mL). The combined organic portion was 
washed with H2O (2 x 30 mL), brine (30 mL), dried (Na2SO4) evaporated to dryness under 
reduced pressure to yield a crude, dark-yellow oil. The residue was purified by column 
chromatography (silica gel; hexanes/EtOAc 100:1 to 30:1) to afford 0.3 g (78%) of 131 as a 
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yellow oil: 
1
H NMR (CDCl3) δ 1.47 (s, 6H, CH3), 5.10 (m, 2H, CH2), 6.01 (m, 1H, CH), 6.24 (s, 
1H, Ar), 7.20 (dd, 2H, Ar), 7.89 (br s, 1H, indolic NH). Compound 131 was used in the 
preparation of 127. 
 
2,2-Dimethylbut-3-enoic acid (133). Compound 133 was prepared as described.
209
 n-
Butyllithium (2.5 M in hexane, 4.6 mL, 11.5 mmol) was added to a 3-neck flask and the solvent 
was evaporated to dryness under N2. Anhydrous THF (5 mL) was added and the resulting 
solution was cooled to -78 °C. Diethylamine (1.1 mL, 10.9 mmol) was added and the solution 
was stirred for 15 min at 0 °C and cooled to -78 °C after which a solution of 2-methylbut-2-enoic 
acid (132) (0.5 g, 4.9 mmol) in THF (3 mL) was added over 5 min with continuous stirring and 
stirred additionally for 0.5 h at 0 °C. The solution was cooled again to -78 °C and dimethyl 
sulfate (0.5 mL, 4.9 mmol) in THF (5 mL) was added over 5 min and stirring was continued for 
0.5 h at the temperature, and then for additional 1.5 h at room temperature. The reaction mixture 
was quenched with H2O (10 mL) and the mixture was washed with Et2O (3 x 15 mL). The 
aqueous portion was acidified with conc. HCl (to pH 1) and extracted with EtOAc (3 x 10 mL). 
The combined organic portion was washed with H2O (3 x 25 mL), brine (30 mL), dried (Na2SO4) 
and evaporated to dryness to afford 0.35 g (61%) of 133 as a colorless oil: bp 184-187 °C (lit.
209
 
bp not reported); 
1
H NMR (CDCl3) δ 1.27 (s, 6H, (CH3)2), 5.03-5.11 (m, 2H, CH2), 5.95-6.02 
(m, 1H, CH), 6.93 (s, 1H, COOH). 
 
2,2-Dimethylbut-3-enoyl chloride (134). Compound 134 was prepared as described.
210
 Oxalyl 
chloride (0.3 mL, 2.9 mmol) was added dropwise to a solution of 2,2-dimethylbut-3-enoic acid 
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(133) (0.3 g, 2.6 mmol) in anhydrous CH2Cl2 (5 mL) and few drops of DMF at 0 °C and stirred 
for 16 h at room temperature. On completion the reaction mixture was evaporated to dryness 
under reduced pressure to afford 0.3 g (90%) of 134 as a colorless oil. The material was used 
without further purification for synthesis of compound 135. 
 
N-(4-Bromo-2-nitrophenyl)-2,2-dimethylbut-3-enamide (135). Compound 135 was prepared 
according to a literature procedure for a similar compound.
211
 A solution of 2-butyl-2-methylbut-
3-enoyl chloride (134) (0.3 g, 2.4 mmol) in CH2Cl2 (30 mL) was cooled to 0 °C to which DMAP 
(0.1 g, 0.8 mmol), 4-bromo-2-nitroaniline (77) (0.3 g, 1.5 mmol) and DCC (0.3 g, 1.5 mmol) was 
added sequentially, stirred for 10 min at 0 °C and heated at reflux for 19 h. The reaction mixture 
was allowed to cool to room temperature and washed with HCl (2M, 3 x 30 mL), saturated 
NaHCO3 (40 mL), brine (40 mL), dried (Na2SO4) and the solvent was removed under reduced 
pressure to yield a crude,  yellow oil. The residue was purified by column chromatography (silica 
gel; hexanes/EtOAc; 100:1 to 100:15) to afford 0.2 g (52%) of 135 as a yellow solid: mp 98-99 
°C; 
1
H NMR (CDCl3)  1.35 (s, 6H, (CH3)2), 5.33-5.37 (m, 2H, CH2), 5.98-6.06 (m, 1H, CH), 
7.65 (dd, J = 9.1, 2.4 Hz, 1H, Ar), 8.28 (d, J = 2.4 Hz, 1H, Ar), 8.68 (d, J = 9.1 Hz, 1H, Ar), 
10.51 (br s, 1H, NH). ); IR (Diamond): 1698 cm
-1
 (C=O). 
 
5-Bromo-2-(1,1-dimethtylallyl)-benzo[d]imidazole (136). Compound 136 was prepared 
according to a literature procedure for a similar compound.
212
 Iron (0.07 g, 1.3 mmol) was added 
to a solution of N-(4-bromo-2-nitrophenyl)-2,2-dimethylbut-3-enamide (135) (0.2 g, 0.6 mmol) 
in gl. HOAc (4 mL) and the reaction mixture was heated at reflux for 5 h. The reaction mixture 
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was allowed to cool to room temperature and diluted with H2O (25 mL). The aqueous mixture 
was washed with EtOAc (2 x 25 mL) and basified with NaOH (3M, to pH 8). The basified 
aqueous portion was extracted with EtOAc (3 x 30 mL), and the combined organic portions were 
washed with H2O (2 x 30 mL), brine (30 mL), dried (Na2SO4) and the solvent was removed 
under reduced pressure to yield 0.15 g (86%) of 136 as a cream-colored solid: mp 231-233 °C; 
1
H NMR (CDCl3)  1.52 (s, 6H, (CH3)2), 5.15-5.20 (m, 2H, CH2), 6.04-6.11 (m, 1H, CH), 7.44 
(d, J = 1.8 Hz, 1H, Ar), 7.55 (dd, J = 8.5, 1.8 Hz, 1H, Ar), 7.82 (d, J = 8.6 Hz, 1H, Ar), 8.73 (br 
s, 1H, NH).  
 
2-(1,1-Dimethylallyl)gramine Hydrogen Oxalate (137). Compound 137 was prepared 
following a literature procedure for a similar compound.
213
 Dimethylamine (40%, 0.1 mL, 0.8 
mmol) and HCHO (37%, 0.7 mL, 0.8 mmol) were added to a solution of 2-(1,1-dimethylallyl)-
1H-indole (141) (0.10 g, 0.5 mmol) in gl. HOAc (3 mL) maintained at 5 °C. When the vapors 
ceased, MeOH (4 mL) was added to make a clear solution and the reaction mixture was allowed 
to stir overnight at room temperature. The organic solvent was removed by evaporation under 
reduced pressure and the solution was basified with NaOH (3M, to pH 10). The aqueous portion 
was extracted with Et2O (3 x 30 mL) and the combined organic portion was washed with H2O (3 
x 50 mL), brine (50 mL), dried (Na2SO4) and the solvent was removed under reduced pressure to 
yield the gramine as a free base which was converted to an oxalate salt by addition of a saturated 
oxalic acid solution in anhydrous Et2O (5 mL) to a solution of crude 2-(1,1-
dimethylallyl)gramine in anhydrous Et2O (5 mL) at 0 °C. The precipitate was collected by 
filtration, dried and recrystallized from i-PrOH to afford 0.04 g (22%) of 137 as white crystals: 
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mp 155-158 °C; 
1
H NMR (DMSO-d6) δ 1.54 (s, 6H, (CH3)2), 2.72 (s, 6H, N(CH3)2), 4.39 (s, 2H, 
CH2), 5.22 (m, 2H, CH2), 6.33 (m, 1H, CH), 7.04-7.68 (m, 4H, Ar), 11.13 (br s, 1H, COOH). 
Anal. Calcd for (C16H22N2·C2H2O4·0.5 H2O) C, 63.33; H, 7.38; N, 8.21. Found: C, 63.09; H, 
7.40; N, 8.42. 
 
6-Bromo-2-propylgramine Hydrogen Oxalate (138). Compound 138 was prepared following a 
literature procedure for a similar compound.
213
 Dimethylamine (40% in H2O, 0.12 mL, 1.0 
mmol), formaldehyde (37%, 0.07 mL, 0.9 mmol) and zinc iodide (0.30 g, 1.0 mmol) were added 
to a solution of 6-bromo-2-propyl-1H-indole (143) (0.15 g, 0.6 mmol) in absolute EtOH (20 mL) 
and allowed to stir at room temperature for 24 h. The organic solvent was evaporated under 
reduced pressure, and the aqueous portion was extracted with CH2Cl2 (2 x 40 mL). The 
combined organic portions were washed with H2O (3 x 50 mL), dried (Na2SO4) and evaporated 
under reduced pressure to yield the free base as a yellow oil. Saturated oxalic acid solution in 
anhydrous Et2O (5 mL) was added to a solution of crude 6-bromo-2-propylgramine (0.1 g) in 
anhydrous Et2O (5 mL) at 0 °C and allowed to stir overnight. The precipitate formed was 
collected by filtration and recrystallized from i-PrOH to afford 0.05 g (21%) of 138 as white 
crystals: mp 181-183 °C; 
1
H NMR (DMSO-d6) δ 0.93 (s, 3H, CH3), 1.69 (m, 2H, CH2), 2.74 (s, 
6H, CH3), 2.79 (t, 2H, CH2), 4.39 (s, 2H, CH2), 7.20 (dd, J = 8.4, 1.8 Hz, 1H, Ar), 7.50 (d, J = 
1.6 Hz, 1H, Ar), 7.65 (d, J = 8.4 Hz, 1H, Ar), 9.17 (br s, 1H, indolic NH), 11.47 (s, 1H, COOH). 
Anal. Calcd for (C14H19BrN2·C2H2O4) C, 49.88; H, 5.49; N, 7.27. Found: C, 49.85; H, 5.44; N, 
7.26. 
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3-Bromo-1H-indole (140). Compound 140 was prepared as described.
192,214
 A solution of liquid 
Br2 (0.7 mL, 14 mmol) in anhydrous DMF (20 mL) was added in a dropwise manner to a 
solution of indole (139) (2.0 g, 17 mmol) in anhydrous DMF (20 mL). The light-protected 
mixture was allowed to stir at room temperature for 24 h and then poured into water and ice (100 
mL) containing NH4OH (2 mL) and a saturated aqueous solution of Na2S2O3 (0.5 mL). The 
aqueous portion was extracted with EtOAc (3 x 40 mL). The combined organic portion was 
washed with 5% aqueous LiCl (3 x 40 mL), brine (50 mL), dried (Na2SO4) and the solvent was 
removed under reduced pressure to yield a crude product which upon recrystallization from 
petroleum ether/Et2O yield 1.6 g (48%) of 140 as an off-white solid:  mp 66-67 °C (decomp) 
(lit.
214
 mp 65 °C). 
 
2-(1,1-Dimethylallyl)-1H-indole (141). Compound 141 was prepared as described.
215
 3-Bromo-
1H-indole (140) (0.3 g, 1.3 mmol) was added in one portion to freshly prepared prenyl 9-BBN
177
 
(3.8 mmol) and Et3N (0.6 mL, 4.5 mmol) in anhydrous THF (10 mL) at room temperature. The 
reaction mixture was allowed to stir at room temperature for 5 h and then quenched with 
saturated NaHCO3 (20 mL). The organic layer was separated and the aqueous portion was 
extracted with Et2O (3 x 40 mL). The combined organic portion was washed with H2O (2 x 30 
mL), brine (30 mL), dried (Na2SO4) and the solvent was removed under reduced pressure to 
yield a crude, yellow oil. The residue was purified by column chromatography (silica gel; 
hexanes/EtOAc; 50:1 to 10:1) to afford 0.2 g (85%) of 141 as a yellow oil: 
1
H NMR (CDCl3) δ 
1.41 (s, 6H, (CH3)2), 5.05 (m, 2H, CH2), 5.97 (m, 1H, CH), 6.24 (s, 1H, Ar), 6.97-7.48 (m, 4H, 
Ar), 7.8 (br s, 1H, indolic NH). Compound 141 was used in the preparation of compound 137. 
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5-Bromo-2-(1-pentynyl)aniline (142). Compound 142 was prepared following a literature 
procedure for a similar compound.
204
 A mixture of 5-bromo-2-iodoaniline (79) (1.0 g, 3.4 
mmol), CuI (0.03 g, 0.2 mmol) and PdCl2(PPh3)2 (0.12 g, 0.2 mmol) were suspended in 
anhydrous THF (30 mL). Et3N (1.4 mL, 10.1 mmol) and 1-pentyne (0.4 mL, 4.4 mmol) were 
added successively and the reaction mixture was allowed to stir at room temperature overnight. 
The reaction mixture was diluted with Et2O (100 mL), filtered through Celite, and the organic 
portion was washed sequentially with H2O (3 x 100 mL), a saturated aqueous solution of NH4Cl 
(50 mL), brine (50 mL), dried (Na2SO4) and the solvent was evaporated under reduced pressure 
to yield a crude residue. The crude product was purified by column chromatography (silica gel; 
hexanes/EtOAc 100:1 to 75:1) to afford 1.4 g (88%) of 142 as a light-yellow oil: 
1
H NMR 
(CDCl3) δ 0.98 (t, 3H, CH3), 1.57 (m, 2H, CH2), 2.36 (t, 2H, CH2), 4.14 (br s, 2H, NH2), 6.70 
(dd, J = 8.2, 1.9 Hz, 1H, Ar), 6.76 (d, J = 1.9 Hz, 1H, Ar), 7.01 (d, J = 8.2 Hz, 1H, Ar). 
 
 6-Bromo-2-propyl-1H-indole (143). Compound 143 was prepared following a literature 
procedure for a similar compound.
188
 Zinc iodide (0.9 g, 0.3 mmol) was added in one portion to a 
solution of 5-bromo-2-(1-pentynyl)aniline (142) (1.4 g, 5.9 mmol)  in anhydrous toluene (20 mL) 
and the reaction mixture was heated at reflux for 3 h. The reaction mixture was allowed to cool 
to room temperature, quenched with H2O (100 mL) and extracted with CH2Cl2 (3 X 50 mL). The 
combined organic portion was washed with H2O (3 x 70 mL), dried (Na2SO4) and the solvent 
was evaporated under reduced pressure to afford a crude product which after recrystallization 
from hexanes yielded 1.2 g (87%) of 143 as yellow crystals: mp 85-86 °C; 
1
H NMR (CDCl3) δ 
  
156 
 
0.93 (t, 3H, CH3), 1.67 (m, 2H, CH2), 2.64 (t, 2H, CH2), 6.14 (s, 1H, Ar), 7.09 (dd, J = 8.4, 1.7 
Hz, 1H, Ar), 7.29 (d, J = 8.4 Hz, 1H, Ar), 7.36 (s, 1H, Ar), 7.77 (br s, 1H, indolic NH). 
Compound 143 was employed in preparation of compound 138. 
 
N-Methyl-5,6-Dibromo-2-(1,1-dimethylallyl)tryptamine Hydrochloride (144). Gaseous HCl 
was bubbled through a solution of tert-butyl-2-(5,6-dibromo-2-(1,1-dimethylallyl)-1H-indol-3-
yl)ethyl-N-methylcarbamate (151) (280 mg) in dry anhydrous EtOAc (10 mL) at 0 °C. The 
reaction mixture was allowed to stir for 24 h and the solvent was evaporated to yield a white 
solid which upon recrystallization from i-PrOH, yielded 60 mg (25%) of 144 as white crystals: 
mp 238-239 °C; 
1
H NMR (DMSO-d6) δ  1.52 (s, 6H, CH3), 2.62 (s, 3H NH(CH3), 2.95 (t, 2H, 
CH2), 3.09 (t, 2H, CH2), 5.10-5.16 (m, 2H, CH2), 6.12-6.19 (m, 1H, CH), 7.71 (s, 1H, Ar), 8.03 
(s, 1H, Ar), 8.81 (br s, 1H, NH
+
 aliphatic), 10.98 (s, 1H, indolic NH). Anal. Calcd for 
(C16H20Br2N2·HCl) C, 44.01; H, 4.85; N, 6.35. Found: C, 43.99; H, 4.74; N, 6.35.  
 
Methyl-5,6-dibromo-1H-indolyl-3-carboxylate (146). Compound 146 was prepared as 
described.
194
 Liquid Br2 (3.9 mL, 75 mmol) was added to a suspension of commercially available 
methyl-1H-indolyl-3-carboxylate (145) (6 g, 34 mmol) in HOAc (45 mL) and the reaction 
mixture was allowed to stir at room temperature for 16 h. The reaction mixture was filtered and 
the precipitate was collected and washed with EtOH (2 x 50 mL) and petroleum ether (50 mL), 
and dried in air to yield 7.7 g (68%) of 146 as a grey powder: mp 246-252 °C (lit.
194 
 mp 237-242 
°C); 
1
H NMR (CDCl3) δ 3.85 (s, 3H, CH3), 7.65 (s, 1H, Ar), 7.83 (s, 1H, Ar), 8.39 (s, 1H, Ar), 
8.45 (br s, 1H, indolic NH). 
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5,6-Dibromo-1H-indole (147). Compound 146 was prepared as described.
194
 Methyl-5,6-
dibromo-1H-indolyl-3-carboxylate (146) (5 g, 15 mmol), KOH (3 g, 54 mmol), MeOH (9 mL), 
THF (9 mL) and H2O (4 mL) was added to a 50 mL glass tube. The solution was microwave 
(100 W, 150 °C, 1 h) irradiated. The reaction mixture was diluted with CH2Cl2 (50 mL) and the 
organic phase was separated and washed with H2O (2 x 50 mL), and dried (Na2SO4) to obtain a 
crude brown solid which, on recrystallization with toluene/hexanes, yielded 3.2 g (68%) of 147 
as buff-colored flakes: mp 150-152 °C (lit.
192
 mp 150-151°C); 
1
H NMR (CDCl3) δ 6.41 (m, 1H, 
Ar), 7.14 (t, 1H, Ar), 7.63 (s, 1H, Ar), 7.84 (s, 1H, Ar), 8.09 (br s, 1H, indolic NH). 
  
N-Methyl-5,6-dibromo-1H-indol-3-glyoxylamide (148). Compound 148 was prepared 
according to a literature procedure for a similar compound.
201
 A solution of 5,6-dibromo-1H-
indole (147) (1.8 g, 6.6 mmol) in anhydrous Et2O (20 mL) in a 2-neck flask was chilled to -5 °C 
and N2 was bubbled in for 5 min. Oxalyl chloride (1.2 mL, 13.1 mmol) was added in a dropwise 
manner and the reaction mixture was heated at reflux for 5 h. The reaction mixture was filtered 
and the precipitate was washed with cold Et2O (2 x 10 mL) and air dried. The solid was added to 
cold methylamine (40% in H2O, 25 mL) and the solution was allowed to stir at room temperature 
overnight. The reaction mixture was diluted with H2O (100 mL) and the residue was collected by 
filtration and air dried to yield 1.8 g (76%) of 148 as a buff-colored solid: mp 263-264 °C 
(decomp); 
1
H NMR (DMSOd6) δ 2.75 (s, 3H, CH3), 7.14 (s, 1H, Ar), 7.63 (s, 1H, Ar), 7.84 (s, 
1H, Ar), 8.09 (br s, 1H, indolic NH). 
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N-Methyl-5,6-Dibromotryptamine (149). Borane dimethylsulfide (10.1M in THF, 1.4 mL, 14 
mmol) was added in a dropwise manner at 60 °C to a stirred solution of N-methyl-5,6-dibromo-
1H-indol-3-glyoxylamide (148) (1.7 g, 5 mmol) in dry THF (35 mL). The reaction mixture was 
allowed to stir at reflux for 7 h, cooled to 0 °C, quenched with H2O (4 mL), acidified with HCl 
(2N, to pH 1), and heated at reflux for 1 h. The THF was evaporated under reduced pressure and 
the remaining aqueous portion was diluted with H2O (100 mL), basified with NaOH (3M, to pH 
9) and extracted with CH2Cl2 (3 x 50 mL). The combined organic portions were washed with 
H2O (2 x 50 mL), dried (Na2SO4), and solvent was evaporated under reduced pressure to yield 
1.5 g (96%) of 149 as a white solid: mp 107-111 °C; 
1
H NMR (CDCl3) δ 2.30 (s, 3H, NHCH3), 
2.71 (t, 2H, CH2), 2.76 (t, 2H, CH2), 7.25 (s, 1H, Ar), 7.73 (s, 1H, Ar), 7.91 (s, 1H, Ar), 11.09 (br 
s, 1H, indolic NH). The material was used without further purification for synthesis of compound 
150.  
 
tert-Butyl-2-(5,6-dibromo-1H-indol-3-yl)ethyl-N-methylcarbamate (150). Compound 150 
was prepared based on a literature procedure for similar compound.
9
 Triethylamine (0.5 g, 4.5 
mmol) and di-tert-butyl dicarbonate (1.0 g, 4.5 mmol) were added to a solution of 5,6-dibromo-
1H-indol-3-yl-N-methylethanamine (149) (1.5 g, 4.5 mmol) in DMF (20 mL) and the solution 
was allowed to stir at room temperature for 24 h. The reaction mixture was quenched with H2O 
(40 mL) and extracted with EtOAc (3 x 40 mL). The combined organic portions were washed 
with H2O (3 x 40 mL), brine (50 mL), dried (Na2SO4) and the solvent was evaporated under 
reduced pressure to yield a crude residue. The residue was purified by column chromatography 
(silica gel; hexanes/EtOAc; 100:1 to 3:1) to afford 1.2 g (60%) of 150  as a white foam: 
1
H NMR 
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(CDCl3) δ 1.40 (s, 9H, CH3), 2.84 (s, 3H, NHCH3), 2.91 (t, 2H, CH2), 3.48 (t, 2H, CH2), 7.01 (s, 
1H, Ar), 7.66 (s, 1H, Ar), 7.87 (s, 1H, Ar), 8.07 (br s, 1H, indolic NH). 
 
tert-Butyl-2-(5,6-dibromo-2-(1,1-dimethylallyl)-1H-indol-3-yl)ethyl-N-methylcarbamate 
(151). Compound 151 was prepared based on a literature procedure of a similar compound.
198
 
tert-Butyl hypochlorite (0.3 g, 3.0 mmol) was added to a solution of tert-butyl-2-(5,6-dibromo-
1H-indol-3-yl)ethyl-N-methylcarbamate (150) (1.0 g, 2.3 mmol) and Et3N (0.3 g, 3 mmol)  in 
THF (25 mL) at -78 
o
C  and the solution was allowed to stir for 90 min. Freshly prepared prenyl 
9-BBN
179
 (4.6 mmol) was added in a dropwise manner over 20 min while maintaining the 
temperature at -55 
o
C. The reaction mixture was allowed to warm to room temperature and 
stirred for an additional 6 h. Sodium hydroxide (3M, 10 mL) and H2O2 (30%, 10 mL) were 
added in a dropwise manner, and reaction mixture was stirred for an additional 2 h, and then 
diluted with Et2O (100 mL). The organic layer was washed with H2O (3 x 60 mL), brine (80 
mL), dried (Na2SO4), and evaporated under reduced pressure to yield a crude residue. The 
residue was purified by column chromatography (silica gel; hexanes/EtOAc; 100:1 to 10:1) to 
afford 0.4 g (33%) of 151  as a white foam: mp 55-57 °C; 
1
H NMR (CDCl3) δ 1.44 (s, 9H, CH3), 
2.71-2.90 (m, 5H, CH2, CH3), 3.29 (m, 2H, CH2), 5.07-5.12 (m, 2H, CH2), 5.99-6.06 (m, 1H, 
CH), 7.49 (s, 1H, Ar), 7.72 (s, 1H, Ar), 7.82 (br s, 1H, indolic NH). Compound 151 was 
employed in the preparation of compound 144. 
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B. Electrophysiology 
The electrophysiological studies were performed in Dr. Shulte’s lab at the University of Alaska 
(Fairbanks). The cDNA sequences for the human 4 (NCBI Reference Sequence: 
NM_000744.5) and 2 (NCBI Reference Sequence: NM_000748.2) nACh receptors were used 
for the synthesis of the cDNA for for each of the subunits (performed in Burlingame, CA). The 
cDNA for the 2 subunit was inserted in the pcDNA3.1/Zero (+) expression vector and the 4 
subunit was inserted in the pcDNA3.1/hygromyocin expression vector (both the vectors obtained 
from Invitrogen, Carlsbad, CA). Ovarian lobes from the Xenopus laevis frogs were obtained by 
surgically removing and washing twice with Barth’s buffer (Ca2+ free) (82.5 mM NaCl/2.5 mM 
KCl/1 mM MgCl2/5 mM HEPES, pH 7.4). The oocytes were then shaken with collagenase (1.5 
mg/mL, Sigma Type II obtained from Sigma-Aldrich) for 1 h at 20-25 °C. Stage IV oocytes were 
selected for the microinjection and injected with 50 nL of the appropriate ratios of the synthetic 
cRNA transcripts of 4 and 2 subunits (prepared using mMESSAGE mMACHINE High Yield 
Capped RNA Transcription Kit obtained from Ambion, TX) at a concentration of 0.2 ng/mL. 
Later the injected oocytes were incubated at 19 °C for 24-72 h before being used for the voltage 
clamp experiments. The incubated oocytes were used for recordings were obtained using an 
automated two-electrode voltage-clamp system incorporating an OC-725C oocyte amplifier 
(obtained from Warner Instruments, CT) which was coupled to a computerized data acquisition 
system; Datapac 2000 (obtained from RUN technologies) and an autoinjection system (Gilson) 
for the injection of solution of test compounds. The electrodes used for recording and the one 
providing the current (with a resistance of 1-4 M) were filled with 3 M KCl solution. The 
oocytes were held in a vertical flow chamber of 200 L volume and perfused with ND-96 buffer 
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(96 mM NaCl/ 2 mM KCl/ 1.8 mM CaCl2/ 1 mM MgCl2/5 mM HEPES; pH 7.4) at a rate of 20 
mL/min. The test compound solution (using ND-96 buffer) were injected into the chamber (20 
mL/min) using the autoinjection system. The test compounds were applied alone or co-applied 
with 100 M (EC75) of ACh.
9 
All assays were performed at least in triplicate. The EC50 values 
were calculated by fitting the dose-response curve by non-linear cruve fitting. Built-in algorithms 
of GraphPad prism (San Diego, CA) was used for the calculation. For IC50 determination dose-
response curve data were fit to a single-site competition model. For compounds with the biphasic 
dose-response curve the data were fit to a hormetic model which generates the EC50 and IC50 
simultaneously. Data was expressed in  SEM or 95% confidence limits. All statistical 
differences were tested using student’s t-test with the P values (P  0.05 representing significant 
statistical difference).
9,167,216
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